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ABSTRACT 
 
Bacterial infection is a feature of long-term peritoneal dialysis (PD) and a cause of loss of 
peritoneal function and treatment failure. Understanding how local inflammation is initiated and 
peritoneal host defence mechanisms are activated in PD patients is key to reducing the 
detrimental consequences of peritonitis. The capacity of human peritoneal mesothelial cells 
(HPMC) to ingest bacteria has been described, and the ability of the Toll-like family of innate 
immune receptors (TLR) to trigger inflammatory responses to pathogens has been 
demonstrated. However, the pathogen recognition ability, the potential role of TLRs, the specific 
role in the early inflammatory response, and the regulation of HPMC’ putative ability for 
pathogen recognition have not been fully investigated. To address these issues, the present 
study aimed at characterising TLR expression and responses in HPMC and evaluating the 
capacity of modulators of pro-inflammatory responses, namely soluble TLR2 (sTLR2) and the 
IL-6/sIL-6R complex, to regulate TLR-mediated HPMC and peritoneal responses in vitro and in 
vivo. HPMC were found to respond to an array of bacterial pathogens via expression and 
function of a specific set of TLRs. HPMC responses were susceptible to modulation by sTLR2 
and sIL-6R, resulting in inhibition of TLR2-driven HPMC responses. In vivo, sTLR2 and IL-6/sIL-
6R reduced neutrophil influx partly by inhibiting NF-κB activation in stromal cells of the 
peritoneum. IL-6 signalling counteracted TLR2-mediated responses by reducing peritoneal 
leukocyte recruitment and chemokine production. Notably, following the establishment of a 
mouse model of peritoneal bacterial infection, IL-6 signalling was confirmed to be beneficial to 
bacterial clearance. The results of this thesis confirm and extend the knowledge of the pivotal 
role that HPMC play in peritoneal responses to infection. The capacity of sTLR2 and IL-6/sIL-6R 
to modulate peritoneal responses demonstrated in this study may inform the design of new 
therapeutic strategies to reduce PD-associated peritonitis and thus improve treatment 
outcomes. 
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Chapter I 
INTRODUCTION 
 2 
1.1 Renal replacement therapy 
1.1.1 Renal failure 
End-stage renal disease (ESRD) is a condition in which a patient’s kidneys have stopped 
functioning and renal replacement therapy (RRT) is required. There are two major forms of RRT 
available following kidney failure: renal transplant or dialysis. Kidney transplant is the best 
possible option available for some patients, but there are not enough donor kidneys for all 
patients and not always suitable recipients. About 23% of ESRD patients have a renal 
transplant (Grassmann et al., 2005), leaving the remaining patients relying on dialysis therapy. 
1.1.2 Peritoneal dialysis vs. haemodialysis 
There are mainly two types of dialysis therapies: haemodialysis (HD), the most common dialysis 
method, and peritoneal dialysis (PD). The latter is the method used for about 11% of patients 
worldwide (Jain et al., 2012), with a higher rate in some countries such as the UK, where 16.8% 
of RRT consists of PD (Byrne et al.).  
HD takes place at the hospital or at home, where the patient’s blood is pumped and passed 
through an artificial kidney to be filtered.  
PD, for which the internal lining of the abdomen acts as the artificial kidney, is carried out at 
home. Dialysis fluid is instilled into the peritoneal cavity via a catheter surgically installed in the 
cavity (Fig 1.1). An exchange of water and solutes takes place across the peritoneum between 
the capillary blood and the dialysate (see detailed description of the technique below, section 
1.1.4.). PD potentially offers several advantages over HD, including a better preservation of the 
residual renal function (RRF) (Jansen et al., 2002) and a lower cost. RRF is an important 
parameter when considering the success of the dialysis process, and PD appears to have a 
survival advantage in the first 2 to 4 years (Saxena and West, 2006; Sinnakirouchenan and 
Holley, 2011). This technique also allows a greater flexibility for the patient, who can continue to 
work and travel and have less dietary restrictions, therefore contributing to a better quality of life 
(Saxena and West, 2006). Most patients stay only a few years on PD. The main causes of PD 
treatment failure are peritonitis, the structural and functional changes of the peritoneal 
membrane and the loss of RRF (Saxena and West, 2006). Globally, there is a 6 to 7% annual 
increase in ESRD patients, with an increase in both HD and PD quite variable depending on the 
country (Grassmann et al., 2005). In the UK, the prevalence of patients on RRT has increased 
by about 4% over the last two decades (Byrne et al., 2010), with HD increasing while PD 
decreases. It is essential to give the best possible choice for the patient as well as providing a 
cost effective treatment.  
 
 
 
Figure 1.1. Schematic representation of fluid exchange during PD. 
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1.1.3 History of peritoneal dialysis 
It was in 1923 that the first description of a saline solution being infused into the peritoneal 
cavity of a woman, whose condition then improved, was published (Ganter, 1923). Over the 
next 50 years, this method was developed and refined in patients as well as animals (Boen, 
1988). Initially known as equilibrium peritoneal dialysis technique, Continuous Ambulatory 
Peritoneal Dialysis (CAPD) was introduced in 1976 by Popovitch (Popovich et al., 1978). It 
marked the transition from using PD only for acute renal failure to chronic renal failure (Krediet, 
2007).  
1.1.4 Peritoneal dialysis 
1.1.4.1 The technique 
When the peritoneal membrane is bathed in fluid, waste products can diffuse from the capillary 
blood vessels into the fluid. Thereby, blood toxins such us urea, creatinine, phosphates, among 
other molecules, can be removed as they diffuse into the dialysate. Excess body water is also 
removed during PD by ultrafiltration. This is achieved by adding an osmotically active agent, 
typically glucose, to the PD fluid to make it hypertonic compared to blood. During peritoneal 
dialysis, 2-3 litres of dialysis fluid is infused into the peritoneal cavity where it remains for 
several hours, whilst waste products diffuse into it, and it is then drained out. This process, 
repeated several times a day, can effectively replace some of the excretory functions of the 
kidney. 
 
1.1.4.2 Peritoneal dialysis modalities 
Over the years, different types of PD schedules have been established, with procedures being 
manual or automated, continuous or intermittent (Saxena and West, 2006). CAPD is the most 
common regimen, and is usually the manual performance of 3 exchanges during the day and an 
overnight long dwell. An alternate procedure with shorter and more frequent dwells, termed 
Automated Peritoneal Dialysis, uses a mechanised cycler which infuses and drains peritoneal 
dialysate at night for faster fluid exchanges (Ryckelynck et al., 2005). The choice of regimen will 
depend on the peritoneal membrane transport kinetics. 
1.1.5 Complications and treatment failure 
Despite presenting advantages over HD, including improved well-being due to continuous 
removal of waste products, PD has long-term complications such as inflammation, infection, 
vasculopathy and fibrosis within the peritoneal membrane (de Lima et al., 2013). 
 
1.1.5.1 Inflammation 
Even in the absence of infection, an inflammatory status is a feature of chronic kidney disease, 
even at early stages. Although it may pre-exist the treatment, it often worsens due to uremia, 
the presence of waste products, as well as mechanical stress and the existence of 
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comorbidities. Macrophages and cytokines have been found in the peritoneal cavity of PD 
patients, indicating a state of chronic inflammation (de Lima et al., 2013).  
 
1.1.5.2 Infection 
Microbial-induced peritonitis remains a leading complication of PD, occurring at a variable rate 
depending on centers and countries. Immediate consequences can be hospitalisation, transfer 
to HD and increased mortality, while longer-term problems include membrane failure and 
cardiovascular morbidity (Lam et al., 2007). Patients usually present with abdominal pain and 
“cloudy” dialysis fluid. The diagnosis is subsequently confirmed by the finding of > 100 white 
blood cells/mm3 of dialysate (with at least 50% of neutrophils). The most common pathogenic 
organisms involved in peritonitis in PD patients are skin commensals such as Gram-positive 
Staphylococci. In particular, Staphylococcus epidermidis and Staphylococcus aureus are found 
in 30-50% of peritoneal infections (Szeto et al., 2005). Over the past decade, however, a 
growing feature of this mode of treatment is the clinically more severe infections with Gram-
negative organisms, resulting in increased rate of treatment failure and poor patient outcomes 
(Szeto and Chow, 2007). The wide spectrum of organisms responsible for PD-associated 
infections is summarised in Table 1.1. 
 
Other detrimental factors impairing PD, such as bioincompatible PD solutions (described in 
section 1.2.2.2) affect the peritoneal membrane, which functions as a permeability barrier 
across which diffusion and ultrafiltration occur. The maintenance of this function is critical to the 
technique success.  
 
1.2 The peritoneal cavity and peritoneum 
1.2.1 Structure of the peritoneal cavity 
The abdominal or peritoneal cavity is the space circumscribed by the peritoneal membrane or 
peritoneum. It comprises the digestive system (stomach and intestines) as well as the liver, 
pancreas, spleen, kidneys and bladder. It also includes the peritoneal reflections which are the 
peritoneal ligaments, mesenteries and omenta, fatty tissue that connects the spleen, stomach, 
pancreas and colon (Healy and Reznek, 2000). A thin layer of serous fluid (up to 100 ml) 
maintains the surface of the peritoneum moist and smooth, protecting it from frictional damage 
(Raftery et al., 1989). The following is a brief description of the different parts of the peritoneal 
cavity and their main roles. 
 
1.2.1.1 Visceral-Parietal 
The peritoneum can be divided into the parietal peritoneum lining the abdominal wall and the 
visceral peritoneum around the abdominal organs (Healy and Reznek, 2000). In PD, it is mainly 
 
 
 
 
 
 
 
 
 
 
   Table 1.1 Organisms associated with PD infections 
Organisms                                                              Frequency  
     Gram-positive bacteria 
         Staphylococcus epidermidis   50-90% 
         Staphylococcus aureus   30-40% 
         Streptococcus viridians   5-10% 
         Streptococcus fecalis   5-10% 
    Gram-negative bacteria 
         Escherichia coli    5-10% 
         Klebsiella/Enterobacter spp.   5% 
         Pseudomonas spp.    < 10% 
         Acinetobacter spp.    < 5% 
         Mycobacterium spp.    < 5% 
         Other     < 5% 
    Fungi 
         Candida spp. Other Fungi   1-10% 
Culture negative                                                   5-20 (up to 30) % 
    Adapted from (Munib 2006, Akoh 2012) 
 
 5 
the parietal peritoneum which is effectively involved in the exchanges of water and solutes 
(Saxena and West, 2006). 
 
1.2.1.2 Mesentery adipose tissue  
There are four mesenteries adipose tissue in the peritoneal cavity (small bowel mesentery, 
transverse mesocolon, sigmoid mesocolon and mesoappendix), which are folds of peritoneum 
connecting various organs to each other or to the abdominal wall (Healy and Reznek, 2000). 
Clusters of lymphocytes, able to proliferate and secrete an array of cytokines in response to 
stimulation, have recently been observed in both mouse and human mesentery (Moro et al., 
2010). 
 
1.2.1.3 Omenta and milky spots 
Among the two omenta, the lesser and greater omentum, the latter is the largest peritoneal fold 
and plays an important role in immunity (Healy and Reznek, 2000). It has been referred to as 
the “abdominal policeman”. Within the greater omentum, anatomist Ranvier described in 1874 
small white aggregates of cells of lymphoid origin that he named milky spots (Broche and 
Tellado, 2001). In a resting state, milky spots are mainly composed of macrophages and B1 
lymphocytes as well as few T lymphocytes (Rangel-Moreno et al., 2009). Following expression 
of various adhesion molecules (ICAM-1, VCAM-1) on the peritoneal membrane, the leukocytes 
can migrate from the bloodstream through the milky spots into the peritoneal cavity. This 
phenomenon occurs in both resting and stimulated conditions, providing the supply of peritoneal 
macrophages to the cavity (Cui et al., 2002). Rapidly following the start of PD, the number and 
size of milky spots increase (Beelen et al., 2005). 
 
1.2.1.4 Immunocompetent resident cells 
Resident peritoneal macrophages constitute the main leukocyte cell population in the cavity (70-
90%), which also contains B and T lymphocytes (5-10%). The presence of small proportions of 
natural killer (NK) cells and dendritic cells (DC) has also been reported (Broche and Tellado, 
2001; Sammour et al., 2010). In addition, mesothelial cells greatly contribute to host defence. 
Their role as well as the role of the different immunocompetent cells of the peritoneal cavity, 
including fibroblasts and adipocytes, will be described in section 1.4. 
1.2.2 The peritoneal membrane 
The peritoneum has been studied since antiquity, as the first mention of lymph vessels 
(lacteals-milk, white fluid) in the peritoneum is from Erasistratus, a Greek physician who died in 
280 BC (Robinson, 1897). Most of the research was done from the 16th century by various 
European anatomists and surgeons. Notably, Bichat (1771-1808) first established that the 
peritoneum had a structure (anatomy) and function (physiology) and called it a serous 
membrane (Robinson, 1897). In 1897, Robinson writes that the function of the peritoneum is “to 
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regulate fluid for nutrient and mechanical purposes. Its anatomical utility is chiefly mechanical, 
ie. to allow limited action, to facilitate motion, to economise friction and conduct vessels and 
nerves to viscera” (Robinson, 1897). There has been a renewed interest in the study of the 
peritoneum since the introduction of PD as a treatment of ESRD. 
 
1.2.2.1 Anatomy of the peritoneal membrane 
The name peritoneum comes from the Greek periteino, which means to stretch around (Arnold 
and Bryce, 2010). The peritoneum, which is the largest serous membrane of the body, has a 
surface area equal to that of the skin with 1-2 m2. It consists of two layers, the mesothelium and 
the tunica propria. 
1) mesothelium: a simple squamous epithelium resting on a basal lamina (basement membrane 
or sub-mesothelial compact zone). 
2) tunica propria: a layer of vascular loose connective tissue formed by a complex network of 
extracellular matrix (ECM), which consists of macromolecules of collagen, elastin and 
fibronectin as well as hydrated gel made of different glycosaminoglycans (Hyaluronan (HA), 
sulphated proteoglycans). Some large and small blood vessels are found in a deeper loosen 
adipose layer. Draining lymphatics are mainly in the interstitium of the sub-diaphragmatic 
peritoneal membrane, whereas the extracellular fluid is found throughout the ECM. Fibroblasts, 
macrophages and mast cells are also present (Nagy and Jackman, 1998; Raftery et al., 1989) 
(Fig 1.2). 
 
1.2.2.2 Loss of peritoneal membrane function with time on PD 
This is one of the main causes of treatment failure. Although the precise biological mechanisms 
responsible for the changes are still not well defined, it is generally assumed that alterations in 
peritoneal function are related to structural changes in the membrane. These changes include 
loss or degeneration of the mesotelium, increase in the thickness of the sub-mesothelial 
compact zone and various vascular changes, such as small vessel atherosclerosis (Williams et 
al., 2002; Williams et al., 2003b). These modifications in membrane structure are generally 
described as fibrosis. Studies showed that over time on PD, the membrane thickness increases 
from an average of 50-100 µm up to 700-1000 µm (Williams et al., 2002; Williams et al., 2003a; 
Williams et al., 2003b). These changes are associated with a loss of ultrafiltration and decrease 
of solute clearance. Encapsulating peritoneal sclerosis is a serious complication, characterised 
by gross fibrotic changes leading to bowel obstruction, whose frequency increases with time on 
PD (Lambie et al., 2010). Although multi-factorial, membrane fibrosis is mainly thought to be 
due to exposure to bioincompatible PD solutions and to recurrent infections. 
 
a. Bioincompatible PD solutions 
     The precise etiology is still speculative, but studies suggested that the continuous exposure 
to dialysis fluids is associated with membrane fibrosis. These fluids have a detrimental effect 
due to their low pH (which prevents the caramelisation of glucose during sterilisation), the high 
Figure 1.2. Structure of the peritoneal membrane.  
Cross section of the peritoneal membrane shown schematically (A), and following transmission electron microscopy 
(B, C). The mesothelium is covered with microvilli. Tissue macrophage and peritoneal fibroblast are indicated. ECM, 
extracellular matrix.  
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Tissue 
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concentration of glucose, glucose degradation products (GDP) and lactate. These fluids are 
referred to as “bioincompatible”. Glucose is a potent activator of human peritoneal mesothelial 
cells (HPMC), inducing production of fibronectin and Transforming Growth Factor β (TGFβ), 
both drivers of fibrosis (Ha et al., 2001). PD fluids may also contribute to membrane damage via 
the presence of GDP and the formation of advanced glycation end products (AGE) (Honda et 
al., 1999). In vitro studies show that certain GDP inhibit mesothelial wound healing (Morgan et 
al., 2003), whilst in vivo mouse studies suggest that they contribute to angiogenesis and 
fibrosis. Glucose, AGE and lactate have also been implicated in cellular pathways involved in 
fibrosis (Saxena, 2008; ter Wee et al., 2003). Upon experimental PD and exposure to PD fluids, 
mast cells were found to accumulate in the omentum in proximity of blood vessels and produce 
angiogenic and profibrotic factors, suggesting a role in omental tissue remodelling in long-term 
PD (Zareie et al., 2006). To prevent these adverse effects, new PD fluids have been developed 
with a physiological pH, a bicarbonate buffer and low GDP content. Despite being less 
cytotoxic, a beneficial effect for patient outcomes remains to be demonstrated. 
 
b.  Peritonitis 
     A correlation between the peritoneal membrane thickness and the number of peritonitis 
episodes has been demonstrated, as well as the increased TGFβ production by HPMC 
following pro-inflammatory cytokines secretion (Kang et al., 1999). In addition, the degree of 
associated peritoneal inflammation has been shown to influence the changes in peritoneal 
kinetics (Davies et al., 1996). With time on CAPD, the accumulation of AGE was also shown to 
be increased with the number of peritonitis episodes (Park et al., 2000), which might in turn 
have a detrimental effect on the membrane. Furthermore, following exposure to bioincompatible 
solutions, the inflammatory response has been shown to be impaired, with a lower viability of 
leukocytes and mesothelial cells, a defect in cytokines and chemokines secretion, decreased 
phagocytosis, respiratory burst and bacterial killing, increasing the detrimental effect of infection 
(Mackenzie et al., 2003; Mortier et al., 2004). Notably, treatment of a mesothelial cell line with 
glucose-based solutions decreased Toll-like receptor 2 (TLR2) and TLR4 expression and 
tumour necrosis factor α (TNFα) and interleukin 1β (IL-1β) secretion following stimulation with 
TLR ligands (Wu et al., 2010), potentially impairing the peritoneal response to bacterial 
peritonitis. 
Of note, infection has a profound effect on its own by impairing the physiological properties of 
the membrane, and by contributing to fibrosis. 
 
The combination of inflammation and angiogenesis occurring in the sub-mesothelial compact 
zone simultaneously to fibrosis, results in an impaired exchange of solutes and water between 
dialysis solution and blood, leading to ultrafiltration failure, in particular in long-term PD patients. 
The mesothelial cells lining the peritoneal membrane greatly contribute to these events because 
of their versatile roles. 
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1.3 Mesothelial cells 
1.3.1 Mesothelium anatomy 
The monolayer of cells covering the surface of the peritoneum originates from the mesoderm 
and looks like an epithelium, therefore was named mesothelium by Minot (Minot, 1880). It 
extends over several regions, including the abdominal cavity (peritoneum), the chest cavity 
(pleura), and pericardium (heart) (Mutsaers, 2004). Stomata are 4-10 µm openings between 
mesothelial cells, located on the mesothelium lining of the diaphragm as well as the omental, 
mesenteric and pelvic peritoneum (Yao et al., 2003). They represent an important channel of 
communication between the peritoneal cavity and the lymphatic system (Sammour et al., 2010). 
1.3.2 Mesothelial cells 
1.3.2.1 Morphology 
Mesothelial cells constitute one of the most numerous cell types of the peritoneal cavity, with 
about 1 x 109 cells (Nagy and Jackman, 1998). They show a predominantly flattened and 
squamous aspect, but can also appear cuboidal in specific areas (Fig 1.3) - notably around 
milky spots - and each type has a different metabolic state. The cuboidal mesothelial cells are 
more active, with a cytoplasm rich in mitochondria, rough endoplasmic reticulum, Golgi 
apparatus and microtubules (Mutsaers, 2002; Yao et al., 2003). 
 
HPMC are between 0.5 µm to 2 µm thick and about 30 µm in diameter, with the cytoplasm 
raised over the nucleus region and a thinner surrounding region, where HPMC are in contact 
with each other to form a continuous sheet (Mutsaers, 2004; Raftery et al., 1989). The integrity 
of the mesothelium is provided in part by the overlapping of cells, but mainly by a number of 
cell-cell and cell-matrix interactions. Adherens junctions and desmosomes form anchoring 
junctions to attach HPMC to each other or to the basement membrane; gap junctions allow 
chemical and electrical signals between HPMC (Mutsaers, 2004; Nagy and Jackman, 1998). 
The apical, luminal, surface is covered with microvilli, which can increase the cell surface area 
up to 40 m2. Microvilli can adapt to the physiological conditions by increasing their length and 
number (Raftery et al., 1989; Yung and Chan, 2009). Cilia, up to five times longer than 
microvilli, can also be observed on the apical surface, which in addition to a protective role as 
part of the peritoneal barrier might play a role in the cells’ polarity and adhesion, as well as in 
matrix proteins synthesis (van der Wal and Jeekel, 2007). 
 
1.3.2.2 Typical features of HPMC 
HPMC express specific mesenchymal intermediate filaments such as vimentin and desmin, but 
also cytokeratin 6, 8 and 18, which are characteristic of epithelial cells (Broche and Tellado, 
2001; Mutsaers, 2004). Constitutive expression of ICAM-1, VCAM-1 and Platelet Endothelial 
Cell Adhesion Molecule 1 (PECAM-1) is also characteristic of HPMC (Broche and Tellado, 
Figure 1.3. Mesothelial cells 
Confluent monolayer of HPMC showing polygonal 
shape and typical “cobblestone” appearance 
(magnification x250).  
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2001; Nagy and Jackman, 1998). The mesothelium has the ability to slowly regenerate itself in 
resting conditions (0.16-0.5% of cells), but can greatly increase to 30-80% in case of injury, at 
the edge of the wound (Mutsaers, 2004). Cancer Antigen 125, a detection marker of ovarian 
cancer, is highly expressed in HPMC and characteristic of their integrity (Visser et al., 1995a). 
 
It is now well documented that the mesothelium performs diverse functions, both physiological 
and in disease. 
1.3.3 Physiological functions of the mesothelium 
1.3.3.1 Protection barrier 
Initially, the function of the peritoneal membrane was considered to be mainly passive. By 
trapping some fluid and creating a slippery surface, the peritoneum creates a smooth 
environment for the movement of organs. The network of ECM and hydrated gel of 
glycosaminoglycans produced by HPMC - in particular hyaluronan (HA) which is one of the 
main constituent - in conjunction with the microvilli and cilia, forms a protective barrier against 
physical damage and invading organisms (Mutsaers, 2004; Raftery et al., 1989; Yung and 
Chan, 2009). 
Beside their primary function of providing a non-adhesive, frictionless, protective barrier, HPMC 
are also capable of producing and secreting a variety of macromolecules and peptides that 
contribute to the structural and functional integrity of the underlying basement membrane. 
 
1.3.3.2 Transport and communication 
The mesothelium is actively involved in the passage of soluble substances and cells across the 
membrane through the action of microvilli, gap junctions, pinocytic vesicles and stomata 
(Mutsaers, 2004). The aqueous phase of the interstitium allows the transport of water, nutrients 
electrolytes, hormones, waste metabolites and gases between the cells within the ECM and the 
blood capillaries (Nagy and Jackman, 1998). A prominent rough endoplasmic reticulum with 
numerous intra-cytoplasmic lipid inclusions reflect the active role of the mesothelial cells in 
intercellular communication and secretion of protein and lipid mediators to their environment 
(Broche and Tellado, 2001). 
 
1.3.3.3 Peritoneal clearance 
The stomata can increase their number and their size up to 20 µm during inflammation, and 
eliminate contaminants into the lymphatic vessels lying underneath. The microvilli can also 
increase their size and number in response to peritoneal insult. It only takes a few minutes for 
this process to start clearing contaminants, showing the capacity of the mesothelium to adapt in 
order to improve the peritoneal clearance (Mutsaers, 2004; Yao et al., 2003).  
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1.3.3.4 Procoagulant and fibrinolytic activities  
HPMC are involved in the coagulation cascade through the expression of tissue factor (an 
activator of coagulation), leading to fibrin deposit (Nagy and Jackman, 1998; van der Wal and 
Jeekel, 2007). Fibrin deposit and clearance is a constant process in the serosal cavities. HPMC 
play a role in the fibrinolytic process of the peritoneal cavity through their capacity to express 
both tissue plasminogen activator and urokinase type plasminogen activator and inhibitors (type 
1 and type 2 plasminogen activator inhibitors, PAI-1 and PAI-2). Tissue plasminogen activator 
and urokinase type plasminogen activator can activate the plasmin-mediated fibrinolytic 
cascade. In normal conditions, the mesothelium has a fibrinolytic activity, to prevent the 
formation of fibrous adhesions between peritoneal surfaces. When injury or inflammation 
occurs, the balance between activators and inhibitors of the fibrinolytic process can be modified 
by various stimuli (cytokines, growth factors), and the fibrinolytic activity is altered or abolished 
to allow repair (Mutsaers, 2004; Nagy and Jackman, 1998; Sammour et al., 2010). 
During peritonitis, coagulation takes place in parallel with a decrease in the fibrinolytic activity, 
leading to the deposit of fibrin and formation of peritoneal adhesions and sclerotic thickening. In 
PD patients, these events can lead to a loss of efficiency of the peritoneal membrane as a filter, 
resulting in treatment failure (Nagy and Jackman, 1998). 
 
1.3.3.5 Tissue repair and extracellular matrix remodelling 
HPMC synthesise a number of ECM molecules (collagen I, III & IV, elastin, fibronectin, laminin, 
HA, dermatan and chondroitin sulfates), and can organise them into complex structures 
(Mutsaers, 2004). In turn, this ability is balanced by the action of matrix metalloproteinases 
(MMP) and their inhibitors (TIMP), some of which are expressed by HPMC (MMP-2, MMP-3, 
MMP-9, TIMP-1, TIMP-2 and TIMP-3) (Martin et al., 2000). Through their ability to secrete these 
different categories of molecules, HPMC participate in the ECM turnover and regulation. The 
balance between these processes is influenced by the production of cytokines and growth 
factors. The resulting sub-mesothelial ECM forms gels with pores of different sizes and charge 
densities, controlling the traffic of macromolecules and cells across the membrane (Nagy and 
Jackman, 1998). A controlled deposition of ECM is part of the normal peritoneal membrane 
repair, whereas its excessive accumulation results in adhesion formation and fibrosis (Mutsaers, 
2004; Nagy and Jackman, 1998). Notably, HPMC play an important role in fibrosis via their 
secretion of TGFβ following injury or infection (Mutsaers, 2004; Nagy and Jackman, 1998). 
 
1.3.3.6 Epithelial-to-mesenchymal transition 
HPMC have the ability to modify their phenotype in what is called epithelial-to-mesenchymal 
transition, where reduced intercellular adhesions and increased motility occur. It is an essential 
and reversible process in embryogenesis and wound healing, characterised by the loss of 
epithelial markers such as E-cadherin and up-regulation of mesenchymal ones. Several 
molecules (growth factors and in particular TGFβ and intermediates of its signalling pathway) 
regulate this complex process. There is increasing evidence of this phenomenon occurring 
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during PD, with an involvement in fibrosis as well as angiogenesis. Episodes of peritonitis and 
bioincompatible PD fluids seem to affect this process, with a detrimental effect on the peritoneal 
membrane function (Devuyst et al., 2010; Lai and Leung, 2010a; Mutsaers, 2004; Yung and 
Chan, 2009). 
 
The specific roles of mesothelial cells in inflammation will be described in the following section. 
 
1.4 Peritoneal immunity 
The peritoneal cavity is home to a variety of cell types with immune properties as listed 
previously in section 1.2.1.4. The characteristics of these cell types and roles are described 
below as well as their interaction with some specific components of the peritoneal inflammatory 
response. 
1.4.1 Immunocompetent cells of the peritoneal cavity  
1.4.1.1 Role of the mesothelium in inflammation 
The mesothelium plays a role in various diseases including endometriosis, gastric and ovarian 
cancer and mesothelioma by being involved in ECM remodelling, fibrosis and epithelial-to-
mesenchymal transition (Izzi et al., 2012; Tsukada et al., 2012; Young et al., 2013), but the 
focus here will be on its specific role in microbial-induced inflammation. 
 
a. Ingestion of bacteria 
     Being the most numerous cells in the peritoneal cavity, HPMC are exposed more frequently 
to microorganisms invading the cavity than resident peritoneal macrophages, whose numbers 
are low in the uninfected cavity (104-105 macrophages/ml) (Topley and Williams, 1994). HPMC 
are able to ingest, digest and kill some bacteria, although not equally among all strains. 
Staphylococci ingestion and digestion induce CXCL8 secretion, which triggers neutrophil 
recruitment, whereas Escherichia coli ingestion leads to a less efficient digestion, no chemokine 
secretion, disintegration of the cells and extracellular proliferation (Visser et al., 1996). This 
might partly explain why peritonitis caused by Gram-negative bacteria have worse outcomes. 
 
b. Antigen presentation 
     Antigen presentation and T cell activation are the first steps in the generation of a specific 
adaptive immune response. In addition to their role in innate immune responses, HPMC are 
also involved in antigen presentation, and are recognised as non-professional antigen-
presenting cells (APC). Upon stimulation with IFNγ, HPMC secrete IL-15, a growth factor and 
activator of T cells, and express major histocompatibility complex class II molecules (i.e. HLA-
DR), which present foreign antigens to T-helper cells, leading to the release of potent immune 
mediators. CD154 (CD40L) expression on T cells and its cross-link with CD40 on APC is a 
central event in antigen presentation and regulation of cytokine secretion. Basal expression of 
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CD40 by HPMC was found increased following IFNγ and TNFα stimulation, and the CD40-
CD154 interaction was shown to trigger IL-15 and CCL5 secretion by HPMC. HPMC also 
express high levels of the adhesion molecule ICAM-1, a major accessory molecule for antigen 
presentation (Basok et al., 2001; Hausmann et al., 2000; Yao et al., 2003). Given their antigen 
presentation capacity and ability to respond to T cells by producing immune mediators, HPMC 
are involved in a positive feedback loop, further supporting the immune response during 
peritonitis. 
 
c. Expression of complement factors 
     The anaphylatoxins C3 to C9 of the complement pathway (detailed in section 1.5.2.6) have 
been detected in the supernatant of HPMC and in the peritoneal cavity of PD patients, 
suggesting an immunoregulatory role for the complement in the peritoneal cavity. CD59, which 
regulates the formation of the membrane attack complex, is also expressed on the HPMC 
membrane (Barbano et al., 1999; Tang et al., 2004). In addition, HPMC contain lamellar bodies 
that produce surfactant, which work synergistically with complement by promoting phagocytosis 
of bacteria, (Yao et al., 2003), thus contributing to mesothelial cell-mediated peritoneal defence. 
 
d. Role of HPMC-secreted glycosaminoglycans 
     Glycosaminoglycans on basement membranes have been shown to bind to chemokines and 
participate in their function by activating and stabilising them. They regulate cytokine activity 
and create a chemotactic gradient, and could potentially play a role in leukocyte recruitment in 
peritoneal inflammation. In addition HA, which HPMC secrete in large amounts, contribute to 
regulate inflammation by sequestering free radicals. Its synthesis is increased during 
inflammation, signalling to resident and infiltrating cells to initiate tissue survival and repair. HA 
is a macromolecule that participates in the resolution of inflammation. However, HA degradation 
products, resulting from HA turnover during tissue injury and present in the peritoneal cavity of 
PD patients, have pro-inflammatory activity, including induction of cytokine and chemokine 
secretion (CXCL8 and CCL2) by HPMC, and thus need to be removed in a timely fashion 
(Haslinger et al., 2001; Yung and Chan, 2009). 
 
e. Expression of cytokines and chemokines 
     It was demonstrated in the 1990’s that HPMC stimulated with inflammatory mediators such 
as IL-1β and TNFα, and also with whole bacteria including Staphylococcus epidermidis and 
Staphylococcus aureus, secrete several cytokines and chemokines including IL-1β, IL-6, 
CXCL8, CCL2 and CCL5. This demonstrated the potential role of HPMC in regulating 
inflammatory responses in the peritoneal cavity (Goodman et al., 1992; Li et al., 1998; Topley et 
al., 1993b; Visser et al., 1995b). Importantly, a polarised - predominantly apical - secretion of 
CXCL8 and other chemokines by HPMC was demonstrated (Li et al., 1998; Nasreen et al., 
2001). This emphasises the role played by HPMC in neutrophil (and other leukocytes) migration 
across the membrane during peritoneal inflammation.  
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HPMC showed the capacity to secrete CXCL1, a neutrophil chemoattractant, and also 
granulocyte colony-stimulating factor (G-CSF) in response to IL-17 - a cytokine mainly produced 
by T cells that induces neutrophil maturation and release from the bone marrow (Chien et al., 
2013). This capacity was synergistically increased in the presence of TNFα, secreted early in 
peritonitis, and likely contributes to neutrophil maturation and recruitment to the peritoneal cavity 
(Witowski et al., 2000; Witowski et al., 2007).  
As described below in section 1.4.3, HPMC secrete the mononuclear cell (MNC) 
chemoattractants CCL2 and CCL5, following stimulation with IL-6 in combination with soluble 
IL-6 receptor. In addition, HPMC express the CD40 receptor, a member of the TNF family of 
receptors whose ligand CD154 is found on activated MNC. It was demonstrated that, when 
stimulated with IFNγ, IL-1β or TNFα, CD40 expression on HPMC increases and that CD40-
CD154 ligation triggers CCL2 and CCL5 production (Man et al., 2003). This further 
demonstrates the important role played by HPMC in leukocyte recruitment in the peritoneal 
cavity during an inflammatory episode. 
 
f. Immunomodulatory role of HPMC 
     TGFβ is not only a potent pro-fibrotic agent, but also an anti-inflammatory cytokine capable 
of suppressing uncontrolled immune responses (Wynn and Ramalingam, 2012). In resting 
HPMC, the TGFβ signalling pathway has been demonstrated to be involved in suppressing 
cytokine production by γδ T cells - a small proportion of circulating T cells with an important role 
in the early phase of the immune response. HPMC-secreted TGFβ similarly inhibited CD4+ and 
CD8+ αβ T cells (Lin et al., 2013a). Furthermore, TGFβ-induced suppression of γδ T cell 
proliferation in the presence of the γδ T cell specific activator (E)-4-hydroxy-3-methyl-but-2-enyl 
pyrophosphate in PD effluent of non-infected patients, has also been demonstrated (Lin et al., 
2013a). 
 
g. Expression of adhesion molecules 
     ICAM-1 and VCAM-1 expression in HPMC has been demonstrated to be important in 
neutrophil and MNC adherence to HPMC, respectively. During peritonitis, ICAM-1 and VCAM-1 
expression increases in the microvilli, allowing binding and movement of leukocytes into the 
peritoneal cavity (Yao et al., 2003). Following the creation of a chemokine gradient across the 
mesothelium, up-regulation of ICAM-1 expression occurs on HPMC allowing migration of 
leukocytes (Li et al., 1998). 
 
HPMC are able to express and release a number of immune mediators, many of them are 
detailed above and are also listed in Table 1.2 (includes human and murine mesothelial cells).  
 
Notably, HPMC also interact with all other immunocompetent cells of the peritoneal cavity, 
being resident or infiltrating cells, which are described below. 
 
Table 1.2 Immune mediator production by Peritoneal Mesothelial Cells 
       Molecule                                            Stimulus  
Cytokines               
 IL-1    EGF, TNFα, 
 IL-6    TNFα, IL-1   
 IL-15    IFNγ  
 CSF (G, M, GM)   IL-1, TNFα, EGF, LPS 
  
Chemokines          
 CXCL8    IL-1, TNFα, LPS, macrophage CM, asbestos, talc 
 CCL2    IL-1, TNFα, IFNγ, LPS  
 CCL5    IL-1, TNFα, IFNγ   
 CXCL1    IL-1, TNFα, IFNγ   
 CXCL10   IL-1, TNFα, IFNγ  
 CCL11    IL-4, TNFα 
 Leukotriene B4   IL-1α, TNFα, IFNγ 
 
Growth factors          
 TGFβ    IL-1, hypoxia  
 PDGF, HGF    unknown 
 FGF    IL-1, TGFβ   
 HB-EGF   IL-1, TNFα   
 VEGF    IL-1, TNFα, TGFβ 
      
ECM-related molecules         
 Collagen I   IL-1, TNFα, EGF, PDGF   
 Collagen III   TGFβ, EGF, PDGF, hypoxia   
 Fibronectin   IL-1   
 Hyaluronan   IL-1, EGF, PDGF   
 Surfactant, Biglycan, Decorin unknown      
 MMP-2, 3, 9   TGFβ, PMA   
 TIMP-1-3   TGFβ, PMA   
 Integrins (α1–6, β1, β3, α4β3) EGF 
   
Coagulation cascade proteins       
 Tissue factor    unknown  
 tPA    TNFα   
 uPA    TGFβ   
 PAI    IL-1, TNFα, TGFβ, thrombin, LPS 
   
Adhesion molecules         
 ICAM    IL-1, TNFα, IFNγ   
 VCAM    IL-1, TNFα, IFNγ, LPS   
 E-Cadherin, N-Cadherin  unknown 
     
Other molecules        
 Cyclo-oxygenase/ prostaglandins IL-1, TNFα, thrombin, macrophage, CM 
 HSP    IL-1, TNFα   
 NO     Combinations of IL-1, TNFα, IFNγ, LPS   
       Reactive species scavengers        Asbestos 
Abbreviations: EGF, PDGF, FGF, HGF: epidermal, platelet-derived, fibroblast, hepatocyte growth factor, 
respectively; G-, M-, GM-CSF: granulocyte, macrophage and granulocyte-macrophage colony stimulating 
factor, respectively; LPS, lipopolysaccharide; CM, conditioned media; PMA, phorbol myristate acetate; HB-
EGF, VEGF, heparin-binding and vascular EGF, respectively; tPA, uPA: tissue and urokinase plasminogen 
activators, respectively; HSP, heat shock protein; NO, nitric oxide. (Adapted from Goodman et al. 1992; 
Mutsaers 2002)  
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1.4.1.2 Peritoneal macrophages 
The most abundant resident leukocyte population, the macrophages, are a heterogeneous and 
multipotential cell population. Tissue-resident macrophages are of prenatal origin or blood 
monocytes-derived (Davies et al., 2013). Macrophages are often functionally divided into the M1 
and M2 classes, where classically activated M1 present a pro-inflammatory profile - secreting 
IL-1β, TNFα and other pro-inflammatory cytokines and reactive oxygen species - that can be 
observed early in inflammation, whereas alternatively activated M2 display anti-inflammatory 
and tissue repair properties. However, the ‘M1-M2 paradigm’ is a simplified concept as 
macrophage differentiation and activation depends on regulatory signals from the local 
environment, and their functional phenotype can shift in response to changes in the milieu 
(Davies et al., 2013; Fieren, 2012). Macrophages are mostly free-floating cells, but tissue 
macrophages also reside in the peritoneal membrane close to the mesothelial basement 
membrane and in the perivascular regions (Nagy and Jackman, 1998). During peritonitis, their 
main functions are: 1) the production of pro-inflammatory cytokines, with IL-1β and TNFα 
playing a key role in the initiation of the inflammatory response; 2) phagocytosis of invading 
pathogens and 3) antigen presentation (Sammour et al., 2010; Topley et al., 1996b). With time 
on PD, macrophages progressively display a more immature phenotype, a decreased 
phagocytic activity and impaired cytokine production, changes that appear to be heightened 
with recurrent episodes of peritonitis (Broche and Tellado, 2001; Lin and Huang, 1990; 
McGregor et al., 1996). 
 
1.4.1.3 Peritoneal lymphocytes and dendritic cells 
The peritoneal lymphocyte population consists of 95-97% T cells and 3-5% B cells. The T cells 
display distinct properties compare to the intrathymically differentiated T cells, and express 
markers of activation such as CD69 and HLA-DR. A high proportion of T cells are CD45RO+, 
indicating a memory/effector phenotype (Broche and Tellado, 2001; Davies et al., 1989; 
Sammour et al., 2010). There is evidence of a key role of T cells in the peritoneal inflammatory 
response, suggested notably by the early detection of elevated levels of the T cell-derived IFNγ, 
and by knock-out (KO) mice studies demonstrating a critical role of IFNγ in leukocyte 
recruitment (McLoughlin et al., 2003).  
Two B cell subsets are found in the peritoneum: 1) B1a cells, which develop from progenitors in 
the omentum and 2) B2 cells, which migrate either directly from the circulation using α4β1 
integrins or through the milky spots and involving a different set of integrins (α4β7). They 
predominantly produce IgM, but CD8+ T cells also provide B cell helper function to synthesise 
IgG and IgA (Sammour et al., 2010).  
NK cells that can destroy virally infected cells and tumour cells are present in the resting 
peritoneum in small numbers and increase following cytokine stimulation. This tissue-specific 
subset of innate immune cells has a distinct phenotype and regulatory functions in the mouse 
(Gonzaga et al., 2011; Sammour et al., 2010). 
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DC represent up to 5-6% of the total peritoneal cell numbers, and are composed of several 
subsets. They have a higher capacity to activate T cell proliferation, and are better equipped as 
APC than macrophages. In PD patients, another subset of CD14+CD4+ cells representing 
approximately 2% of the peritoneal cells and with the characteristics of DC precursors has been 
described. Their number increases during peritonitis, and their recruitment occurs more rapidly 
with Gram-positive than with Gram-negative infections, suggesting a role in adaptive immune 
responses (Broche and Tellado, 2001; McCully and Madrenas, 2006). 
 
1.4.1.4 Other cells with immune activity in the peritoneal cavity 
Peritoneal mast cells, located in the proximity of blood capillaries, have been shown to be 
involved in neutrophil infiltration through their capacity to release leukotrienes. Degranulation of 
mast cells releases vasoactive substances, complement and opsonins, which coat bacteria and 
promote phagocytosis (Sammour et al., 2010). Mast cells also have a role in tissue repair 
following peritoneal membrane damage (Ramos et al., 1991; Zareie et al., 2006).  
Fibroblasts, a major resident cell type in the peritoneal membrane, have the capacity to release 
pro-inflammatory cytokines and chemokines (IL-6, CXCL1, CXCL8, G-CSF and CCL2) 
potentially contributing to the cytokine network and leukocyte recruitment of the inflammatory 
response (Witowski et al., 2009; Witowski et al., 2001). Through the secretion of 
macromolecules of the ECM and of various factors, fibroblasts also have a role in tissue repair 
and fibrosis (Nagy and Jackman, 1998). More recently, a potential inflammatory role of 
peritoneal adipocytes has been recognised, as they were found to secrete a variety of 
adipokines, including the cytokines TNFα and IL-6 and growth factors such as TGFβ, as well as 
expressing their receptors (Lai and Leung, 2010b). 
1.4.2 The role of IL-6 in inflammation and its mechanism of action  
IL-6 is a pleiotropic cytokine with a wide range of metabolic functions, including induction and 
differentiation of lymphocytes, cell proliferation and survival, involvement in haematopoiesis, 
bone metabolism and sexual reproduction. IL-6 has a crucial role in host defence due to its 
varied immune activities, including its ability to induce proteins of the acute phase response, C-
reactive protein (opsonin that binds to phosphocholine in bacterial surface molecules) and 
serum amyloid A (SAA, involved in leukocyte recruitment during infection). IL-6 has been 
implicated in various disease processes such as rheumatoid arthritis and other autoimmune 
conditions, Alzheimer’s disease, myocardial infarction, osteoporosis, various cancers and 
inflammation. IL-6 is secreted by a number of different cell types, and its blood and tissue levels 
are elevated in numerous infections, inflammatory and autoimmune diseases (Trikha et al., 
2003). IL-6 was demonstrated to be a good prognostic marker, with high plasma levels 
associated with poor outcomes in CAPD patients (Pecoits-Filho et al., 2002). High levels of IL-6 
are also found in PD effluent of patients, and are associated with up-regulation of intra-
peritoneal inflammatory and angiogenic mediators (Oh et al., 2010). Membrane function can be 
assessed by the peritoneal solute transport rate (PSTR). In CAPD patients, high PSTR appears 
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to be associated with worse survival, and increased levels of IL-6 are linked to increased PSTR 
but do not determine survival, indicating the importance of membrane function over the 
inflammation parameter (Lambie et al., 2013; Pecoits-Filho et al., 2006). These findings 
emphasise the potential detrimental role of IL-6, and thus the relevance of studying this cytokine 
in the context of PD. 
 
IL-6 belongs to a family of cytokines that promote cellular responses through a receptor 
complex consisting of at least one member of the ubiquitously expressed signal-transducing 
glycoprotein gp130. On target cells, IL-6 first binds to a specific membrane-bound IL-6 receptor 
(IL-6R), and the IL-6/IL-6R complex associates with gp130, inducing its dimerisation and 
subsequent intracellular signal transduction (Rose-John et al., 2006).  
Unlike gp130, IL-6R is mainly expressed by hepatocytes, neutrophils, monocytes/ macrophages 
and some lymphocytes (Scheller et al., 2013). A naturally occurring soluble form of the IL-6R 
(sIL-6R), found in various bodily fluids, is generated either by alternative RNA splicing (1-10%) 
or by shedding from the membrane IL-6R (90-99%). sIL-6R binds to IL-6 and then associate 
with gp130, activating target cells which do not express IL-6R and would otherwise not be 
responsive to IL-6. Of note, the IL-6/sIL-6R complex possesses agonistic properties, unlike 
other soluble receptors such as those for IL-1 or TNFα, which inhibit the cellular effects of their 
ligands. Activation of cells only expressing gp130 via the IL-6/sIL-6R complex is called trans-
signalling, whereas classic signalling defines the membrane-bound IL-6R activation (Fig 1.4) 
(Chalaris et al., 2011). Both sIL-6R isoforms elicit common cellular events via gp130 
(McLoughlin et al., 2004). Several cell types have been shown to respond to IL-6 exclusively via 
trans-signalling, among them embryonic stem cells, smooth muscle cells, many neural cells, 
endothelial cells and HPMC (Chalaris et al., 2011; McLoughlin et al., 2004).  
Binding of IL-6 to its receptor and to gp130 results in gp130 homodimerisation and activation of 
cytoplasmic, constitutively-associated, Janus kinases (JAKs), which phosphorylate tyrosine 
residues on gp130. This activates SH2-domain-containing tyrosine phosphatase (SHP) 2 and 
subsequently SHP2-mediated activation of mitogen activated protein kinase (MAPK) and 
phosphatidylinositol 3-kinase (PI3K) signalling pathways. Signal transducer and activator of 
transcription (STAT) 1 and STAT3 proteins are also activated. They directly bind to phospho-
tyrosine residues on gp130, resulting in their tyrosine phosphorylation, homo- and/or hetero-
dimerisation, nuclear translocation and transcriptional activation of target genes (Fig 1.4). By 
using different downstream signalling pathways linked to distinct intracellular regions of the 
gp130 receptor subunit, ligand- and tissue-specific activation of distinct set of target genes 
occurs, resulting in distinct physiological effects of IL-6 in vivo (Jenkins et al., 2007). This in turn 
is under the control of several negative-feedback mechanisms, notably the STAT-dependent 
transcriptional induction of the two suppressor of cytokine signalling, the (SOCS) 1 and 3 
proteins, which inhibit JAK phosphorylation of substrates (Fig 1.4). In addition, the 
transcriptional activity of STAT1 and STAT3 is repressed by their sequestration into complexes 
formed with STAT-specific members of the family of protein inhibitors of activated STAT (PIAS) 
Figure 1.4. Modes of IL-6 signalling and activation of the STAT or MAPK pathways through gp130-mediated 
pathways. 
IL-6 binds to its membrane-bound receptor (IL-6R, classical pathway) and to the soluble form of IL-6R (sIL-6R, 
trans-signalling pathway). Cytokine binding induces homodimerisation of the signal transducer unit, gp130, resulting 
in binding and activation of Janus kinases (JAKs). Activated JAKs phosphorylate tyrosine residues on the 
intracellular domain of gp130, creating docking sites for signal transducer and activator of transcription (STAT) 
proteins or SH2-domain-containing tyrosine phosphatase (SHP2). Following JAK phosphorylation of STAT 
monomers, homo- or hetero-dimerisation of STAT proteins occurs, leading to their translocation to the nucleus and 
transcription of their target genes. At the membrane level, receptor-bound SHP2 is phosphorylated by JAKs, leading 
to its association with one of two complexes, as indicated on the figure, and the activation of the MAPK or Akt 
cascades in a cell-type specific manner. IL-6 signalling is controlled by several negative-feedback mechanisms, 
which include the activity of the STAT-dependent transcriptional induction of suppressor of cytokine signalling 
(SOCS) 1 and 3 (inhibit JAK phosphorylation of substrates) and the repression of  STAT1 and STAT3 transcriptional 
activity by their sequestration into complexes formed with STAT-specific members of the family of protein inhibitors 
of activated STAT (PIAS). Abbreviations: PM, plasma membrane; Grb2, growth factor-receptor-bound protein; Sos, 
Son of Sevenless; Gab1, Grb2-associated-binder-1; PI3K, phosphatidylinositol 3-kinase; MAPK, mitogen-activated 
protein kinase. (Adapted from Heinrich 2003, Ernst 2004, Eulenfeld 2012) 
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(Ernst and Jenkins, 2004; Heinrich et al., 2003). A soluble form of gp130, notably found in high 
levels in blood (250-400 ng/ml), is a natural antagonist of IL-6 trans-signalling. Soluble gp130 
specifically binds to the IL-6/sIL-6R complex while leaving membrane-bound IL-6 classic 
signalling unaffected (Jostock et al., 2001; Scheller et al., 2013). Soluble gp130 has been used 
to determine the physiological involvement of IL-6 trans-signalling in vivo and represents a 
potential therapeutic agent in chronic inflammatory conditions such as Crohn’s disease and 
rheumatoid arthritis, where IL-6 trans-signalling is detrimental, and is now tested in clinical 
phase I studies  (Rose-John et al., 2006; Scheller et al., 2013). 
The activity of IL-6 is of particular interest in the context of the present study, as it plays pro- 
and anti-inflammatory roles. Indeed, it has been associated with infection, trauma and 
inflammatory events, but studies have also demonstrated a protective role in septic shock and 
its ability to promote resolution of inflammation, conferring both beneficial and detrimental 
properties to this cytokine (Diao and Kohanawa, 2005; Hurst et al., 2001; Jones et al., 2005). 
Identification of the diverse roles of IL-6 is partly due to a better understanding of sIL-6R 
properties and of the interplay between IL-6 and other inflammatory mediators (Jones, 2005). 
1.4.3 Leukocyte recruitment during peritoneal inflammation 
Patients’ data and animal models have shown that peritonitis is characterised by an initial influx 
of PMN into the peritoneal cavity, cleared in 4 to 6 days in humans and 48h in mice, replaced 
and followed by a more sustained population of mononuclear cells, namely monocytes and 
lymphocytes (Hurst et al., 2001). The transition from the PMN to the MNC population is the 
hallmark of a successful inflammation/infection resolution (Jones, 2005) (Fig 1.5). 
 
Resident cell populations orchestrate the peritoneal inflammatory response with a specific 
sequence of events occurring to allow movement of leukocytes across the capillary endothelium 
into the interstitial space, across the mesothelium into the peritoneal cavity and to the site of 
inflammation.  
Expression of specific pro- and anti-inflammatory cytokines and chemokines and their 
receptors, and specific adhesion molecules, guarantees the appropriate leukocyte infiltration 
pattern (McLoughlin, 2005). Cytokines and chemokines regulate leukocyte trafficking in and out 
of the peritoneal cavity, thus they are involved in a variety of physiological and pathological 
processes and control many immune functions.  
Belonging to the cytokine family, chemokines are a specific class of small, secreted molecules 
with chemotactic properties. Most chemokines have four conserved N-terminal cysteines and 
are divided into two major subgroups based on the arrangement of their two first cysteines: 
CXC, when the cysteines have an amino acid (X) between them or CC, when they are adjacent. 
A further subdivision has been made in the CXC group to differentiate the chemokines 
containing the ELR amino acid motif (ELR+) from the ELR- ones. Selective neutrophil 
recruitment is due to specific ELR+ CXC chemokines, whereas CC chemokines confer 
selectivity to monocytes/macrophages and T cells recruitment (Zlotnik and Yoshie, 2000). 
Figure 1.5. Typical kinetics pattern of leukocyte infiltration in the peritoneal 
cavity.  
Successful resolution of acute inflammation requires a transition from ELR+ CXC 
chemokine-driven neutrophil recruitment to CC chemokine-induced mononuclear 
cells infiltration . 
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Exposure to invading pathogens activates resident macrophages, triggering the release of pro-
inflammatory cytokines, and shortly following the onset of infection, IL-1β and TNFα cytokines 
are found in the peritoneal cavity. In addition to direct sensing of the infecting agents, this 
process drives HPMC to secrete CXCL8 and increase expression of ICAM-1 (Li et al., 1998). 
This results in neutrophil recruitment from the capillaries of the peritoneal membrane. Given the 
high numbers of HPMC, this process represents an amplification step, which is crucial for the 
resolution of inflammation (Topley and Williams, 1994). IFNγ, observed early in the infected 
peritoneal cavity, is also an important player. IFNγ controls the initial neutrophil recruitment by 
affecting IL-1β local activities and promoting IL-6 secretion (McLoughlin et al., 2003). 
In addition to macrophages, HPMC are the main producers of IL-6 within the peritoneal cavity. 
IL-6 signalling, via its sIL-6R, has been demonstrated to play a central role in peritoneal 
inflammation and in the typical transition from a neutrophil-rich population to mononuclear cell 
dominance (Hurst et al., 2001). Studies with IL-6 deficient mice (IL-6-KO mice) have shown that 
in the absence of IL-6 there is accumulation of neutrophils at sites of inflammation (McLoughlin 
et al., 2003; Xing et al., 1998). Furthermore, as stromal cells are mainly gp130+IL-6R-, the local 
concentration of sIL-6R is responsible for IL-6 signalling activity, with a correlation between 
infiltrating neutrophil accumulation in the peritoneal cavity and sIL-6R levels. These levels are 
increased by inflammatory chemokines and other chemotactic agents that activate neutrophils, 
promoting sIL-6R shedding (Marin et al., 2001; McLoughlin et al., 2004). IL-6 will subsequently 
combine with sIL-6R to stimulate HPMC secretion of CCL2 and CCL8, which drive mononuclear 
cells recruitment (Marin et al., 2001; Modur et al., 1997; Romano et al., 1997).  
1.4.4 Resolution of the early phase of peritoneal inflammation 
The transition from innate to adaptive immunity is the pivotal event towards the resolution of 
inflammation, with the removal of inflammatory leukocytes and replacement by a mononuclear 
cell population. This modifies the environment, with increasing concentration of anti-
inflammatory molecules and initiates tissue repair. In chronic inflammation, high levels of 
neutrophils and pro-inflammatory cytokines are still present in the peritoneal cavity for several 
weeks, even after clinical remission (Lai and Leung, 2010a). This prolongs the detrimental 
effects of the inflammatory status, as aberrant trafficking is characteristic of chronic 
inflammation, and retention of activated leukocytes at site of infection leads to tissue damage. 
IL-6 trans-signalling inhibits the IL-1β- and TNFα-induced production of CXCL1 and CXCL8, 
modulates the expression of ICAM-1 and VCAM-1 (Modur et al., 1997; Romano et al., 1997) 
and participates, with IFNγ acting upstream of IL-6, in neutrophil apoptosis through a caspase-3 
mechanism (McLoughlin et al., 2003). Furthermore, trans-signalling might be involved in 
bacterial clearance and in improved survival through an increased macrophage recruitment and 
phagocytosis activity of both neutrophils and macrophages (Onogawa, 2005; Onogawa et al., 
2013).  
 
 19 
Once this primary phase of the inflammatory process is ongoing, a secondary one takes place 
with the activity of infiltrating monocytes/macrophages and lymphocytes. IL-6 influences the 
inflammatory outcome by affecting both types of cells. Briefly, IL-6 is involved in skewing the 
differentiation of monocytes away from a dendritic lineage to a macrophage phenotype (Jones, 
2005). Furthermore, studies suggest that sIL-6R controls the homing capacity of T cells by 
affecting both T cell migration and adhesion (Chen et al., 2004; McLoughlin et al., 2005).  
Amongst other players, IL-6 is critical in orchestrating the transition from innate to acquired 
immunity. In chronic disorders, IL-6 role seems to be more detrimental and its interplay with 
other signalling pathways and pro-inflammatory mediators such as IFNγ and TGFβ might affect 
its activity (Jones, 2005). 
 
Figure 1.6 recapitulates the initial events of an inflammatory response taking place in the 
peritoneal cavity at the onset of infection. 
 
An overview of the role of the different players involved in innate immunity follows. 
 
1.5 The innate immune system and peritoneal immunity 
The inflammatory response is a coordinated sequence of events triggered by infection and 
tissue injury that aims to eradicate the insult and restore normal tissue function. At the centre of 
this response is the activity of the innate immune system. Many different types of inducers, 
exogenous and endogenous, can trigger the inflammatory response, but here the focus will be 
on microbial pathogens. 
1.5.1 Overview of the innate and adaptive immune responses 
In jawed vertebrates, the two arms of the immune system: the innate and adaptive immune 
systems, are characterised by the type of receptors utilised to recognise pathogens. The innate 
immune system uses pattern recognition receptors (PRRs), which are germline-encoded and 
recognise a broad array of conserved and invariant features of microorganisms. They will be 
described below, in section 1.6 and 1.7. The adaptive or acquired immune system utilises 
antigen receptors (Medzhitov, 2007), the T- and B-cell receptors, which are expressed on T- 
and B-lymphocytes, respectively. They are generated through gene recombination to provide an 
extensive variation of receptor specificity with unique antigen recognition capacity (Litman et al., 
2010). Adaptive immunity is characterised by antigen-specific responses with clonal expansion 
of lymphocytes following the recognition of, and activation by antigens, resulting in long-term 
memory. This provides a faster and stronger response in the event of encountering the same 
antigen again. This highly specific arm of the immune system is not immediately available, as 
several days are required to mount an adaptive response following first encounter with an 
antigen. Therefore, the two systems must cooperate, and the activity of the innate immune 
system, through the use of ready-made receptors, is critical to a prompt and efficient pro-
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Figure 1.6. IL-6 trans-signalling directs the temporal transition from neutrophils to mononuclear cells in the 
peritoneal cavity. 
(A) Upon bacterial insult, resident macrophages produce IL-1β and TNFα which stimulate HPMC to secrete CXC 
chemokines, notably CXCL8. A chemotactic gradient is created, attracting neutrophils from the blood stream into the 
peritoneal cavity. IFNγ, secreted early in inflammation, also stimulates HPMC to secrete IL-6. (B) In the peritoneal 
cavity, neutrophils shed sIL-6R - following migration and activation - which combines with IL-6 to form the IL-6/
sIL-6R complex. (C) This complex is responsible for the transition from the initial influx of neutrophils to the 
subsequent mononuclear cell recruitment by inhibiting CXCL8 secretion and stopping the neutrophil influx. (D) The 
IL-6/sIL-6R complex also induces CC chemokine secretion, therefore promoting mononuclear cell recruitment. In 
addition, the IL-6/sIL-6R complex is involved in neutrophil apoptosis,  a crucial event to avoid detrimental damage of 
the peritoneal membrane. 
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inflammatory response against a microbial challenge. This is a response to pathogens devoid of 
memory component (Medzhitov, 2008).  
 
Not only innate, but also adaptive immune responses play an important role in peritoneal 
immunity. The focus, however, of this thesis is on innate responses. Innate immunity is the most 
universal and most rapidly acting, with dynamic mechanisms that have been refined over 
hundreds of millions of years to achieve the three prime goals of recognising a vast array of 
pathogens, killing the pathogens once recognised and sparing the host tissues (Beutler, 2004). 
It was initially accepted that the innate immune response was an early event, whereas elements 
of the adaptive immune response took place later on. It is now clear that some cells 
participating in the later phase are also part of the innate immune system whereas some T cells 
(the hallmark “adaptive” cells) may play an important role in the early phase. In addition, 
traditional components of the innate immune system, such as NK cells, have been described to 
play a role in the adaptive arm, challenging the established dogma of two distinct systems 
(Biron, 2010).  
The inflammatory response initiates with the recognition of infection or tissue damage by either 
professional or non-professional immune cells. It is mostly mediated by tissue macrophages 
and mast cells, and triggers the activation and recruitment of other cells in conjunction with the 
secretion and release of a variety of pro-inflammatory mediators, including cytokines, 
chemokines, free radicals, hormones, vasoactive amines, eicosanoids and products of the 
proteolytic and complement cascades and other small molecules (Medzhitov, 2008). During an 
acute inflammatory response, controlled recruitment of leukocytes from the circulation to the site 
of infection is a critical step. Their subsequent timely removal is necessary to eliminate infection 
and achieve a successful resolution of inflammation while minimising the damage to host 
tissues. The different players of this early, innate, inflammatory phase will be described here. 
1.5.2 Components of the innate immune system  
Innate immunity is composed of an afferent and efferent arm, each of these arms further divided 
into cellular and humoral components. They form a complex network, and the precise distinction 
between sensors and effectors can be difficult to achieve, as some molecules such as cytokines 
have no direct effect on microbes but attract cells capable of killing them. Furthermore, a fine 
balance needs to be struck between harming the invading organism and preserving the normal 
function of the host.  
The cellular components of the innate immune system are composed of the mucosal epithelia, 
the first line of defence of the body and organs against invading pathogens, and the various 
leukocytes attracted to the site of infection following the action of cytokines and 
chemoattractants. Leukocytes subsequently signal, target and kill microorganisms, via the 
expression of a vast array of soluble molecules, direct destruction and phagocytosis. 
Hepatocytes and epithelial cells are also involved in the early phase of the immune response 
through the secretion of diverse antimicrobial molecules, cytokines and chemokines. 
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1.5.2.1 Mucosal epithelia 
The epithelium provides a tissue barrier against all external dangers. Epithelial cells of the 
airways, the intestinal tract and the skin represent the first line of defence, as they are the main 
interface between the host and the microbial world. They are polarised cells with apical and 
basolateral surfaces. The apical surface presents cilia and microvilli, involved in motility and 
transport of substances, respectively. The epithelium of the airways is covered by a surface fluid 
contributing to the mucociliary escalator, essential for the clearance of microbes and other 
particles. The basolateral surface is characterised by the expression of tight and adherens 
junctions, critical structures to maintain the structural integrity of the epithelium, and separate 
the lumen from the tissue compartment. Besides its mechanistic role, the epithelium can 
produce antimicrobial peptides to limit the growth of microorganisms, pathogens or commensals 
that colonise these sites. Through the secretion of a plethora of soluble mediators, epithelial 
cells also interact with cells in their environment and participate in defence mechanisms. The 
involvement of epithelial cells in the pathogenesis of inflammatory bowel disease, asthma, lung 
diseases and cancer, emphasises the central role of the epithelial barrier function (Shaykhiev 
and Bals, 2007; Tosi, 2005). 
 
1.5.2.2 Eosinophils, basophils and mast cells 
Eosinophils and basophils belong to the polymorphonuclear leukocyte group and are key 
players to contain infection, notably with an array of effector functions. Rare cells, eosinophils 
and basophils are recruited from the circulation and produce mediators thereby creating the 
inflammatory milieu. Their number can greatly increase, in particular with a parasitic infection or 
during an allergic response (Beutler, 2004).  
Mast cells, tissue-dwelling descendants of the myeloid lineage and important mediators of 
allergic responses, are distributed throughout tissues, notably near surfaces exposed to the 
environment, where they are sentinels likely to encounter pathogens and allergens. They are 
also strategically located near blood and lymphatic vessels. Mast cells, long-lived cells capable 
of surviving for months and years, greatly contribute to controlling a wide range of pathogenic 
infections, including those by parasites and bacteria. They are characterised by their ability to 
store and secrete different types of proteases and proteoglycans, and have the potential to 
respond to an invading pathogen within seconds to minutes, acting as first responders. Upon 
activation by various stimuli, mast cells can proliferate and secrete a wide range of biologically 
active products with pro- or anti-inflammatory activities. They express diverse types of 
receptors, which allow mast cells to recognise pathogens, and through chemokine secretion are 
involved in leukocyte recruitment, in particular eosinophils and NK cells (Abraham and St John, 
2010; Galli et al., 2011). 
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1.5.2.3 Phagocytes 
Neutrophils and macrophages are professional phagocytes with a common precursor; they are 
essential to eliminate pathogenic insults and to remove damaged tissue. The effectiveness of 
the phagocytes in regulating innate immunity depends on their mutual co-operation during the 
successive phases of the inflammatory response, from leukocyte recruitment to resolution. 
 
a.  Neutrophils 
     Neutrophils are short-lived cells (few hours, to potentially a few days, before undergoing 
apoptosis) and the most abundant circulating phagocytes. Unlike most other phagocytes and 
leukocytes, neutrophils are mature cells and do not proliferate (Galli et al., 2011). They engage 
in three major functions: migration to the site of infection, recognition and ingestion of 
microorganisms followed by the killing and the digestion of these organisms (Beutler, 2004; 
Tosi, 2005). Neutrophils are equipped with granules, which store reactive oxygen species and 
nitric oxide species, proteinase 3, cathepsin G and elastase as well as antimicrobial 
polypeptides. Other toxic molecules are generated by neutrophils to kill microorganisms by their 
rapid action on diverse molecular targets, which include lipids, proteins and nucleic acids 
(Beutler, 2004; Medzhitov, 2008; Soehnlein and Lindbom, 2010). This potent killing and non-
specific activity needs to be tightly regulated to avoid tissue damage and is partly 
counterbalanced and complemented by the activity of macrophages. 
 
b.  Macrophages  
     Morphologically and functionally diverse, macrophages are distributed throughout the body 
and likely to encounter invading organisms. One of their primary roles is to phagocytose and kill 
microbes, although they are less cytotoxic than neutrophils. But macrophages also have active 
roles in the induction of the innate immune response, by alerting and recruiting other cells to the 
site of infection, as well as in the resolution phase, via the generation of chemotactic cytokines, 
lipid mediators and the expression of a variety of molecules, including many types of receptors 
to sense infection (Beutler, 2004; Soehnlein and Lindbom, 2010). Macrophages participate – 
with the collaboration of other resident cells – in neutrophil trafficking to the site of infection and, 
following removal of foreign entities, to the inhibition of neutrophil recruitment and their 
elimination (Soehnlein and Lindbom, 2010). 
 
1.5.2.4 NK cells and DCs 
NK cells are specialised lymphocytes that do not express clonally distributed receptors, and 
play an important role in innate immunity. They contain viral infections before the development 
of adaptive immune responses and control malignant tumours. NK cells are found in the 
circulation, the spleen and bone marrow; they are recruited by diverse chemoattractants - 
CXCL8, CX3CL1, leukotrienes, chemerin and C5a (Gregoire et al., 2007; Parolini et al., 2007)- 
to sites of infection, where they induce apoptosis of target cells in two different ways: 1) granule 
exocytosis, which kills infected or malignant cells by releasing perforin or granzymes from 
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storage compartments, and 2) by death receptor engagement on target cells, leading to the 
activation of downstream intracellular pathways and apoptosis (Degli-Esposti and Smyth, 2005; 
Tosi, 2005). NK cells interact with other cells and express inhibitory receptors that bind MHC 
class I molecules present on the host cells but not on pathogens. NK cell inhibitory receptor 
binding to MHC class I molecules blocks their effector functions - cytotoxicity and cytokine 
production - providing protection for target cells expressing normal level of MHC class I 
molecules on their surface. Although MHC class I receptors play a key role in NK cell regulation, 
a low level of expression is not a prerequisite and in some circumstances, signals from 
activating receptors are sufficient to stimulate NK cells (Smyth et al., 2005). NK cells interact 
with DCs, which greatly influence their proliferation and activation. Following activation, NK cells 
secrete diverse cytokines and chemokines, notably IFNγ, affecting and defining the environment 
in which subsequent immune interactions occur. It has been demonstrated that IFNγ secretion 
by NK cells requires the formation of an immunological synapse and DC-derived cytokine 
production, emphasising the importance of the interaction between these two cell types (Borg et 
al., 2004; Degli-Esposti and Smyth, 2005).  
Of myeloid origin, DCs represent a minority population located in peripheral organs and 
mucosal surfaces, where they sample the environment for antigens. After antigen uptake, and 
following a maturation programme initiated by direct interaction with pathogens, DCs are highly 
efficient at antigens presentation to naïve T lymphocytes. Direct interaction with other immune 
cells also results in DC maturation. In this regard, NK cells affect DC functions and maturation. 
The complex bidirectional crosstalk between DCs and NK cells influences the nature of the 
response as well as its outcome. The initial stimulus received by DCs determines which 
cytokines they produce and, through differential receptor engagement, influences NK cells 
properties and effector functions - cytotoxicity, proliferation, survival and migration. In turn, 
soluble factors secreted by NK cells and cell-cell contact can induce maturation or kill immature 
DCs, potentially skewing the inflammatory response towards adaptive immunity (Degli-Esposti 
and Smyth, 2005; Wilson et al., 1999). 
The various cells participating in innate peritoneal immunity and their functions are summarised 
in Figure 1.7. 
 
1.5.2.5 Antimicrobial peptides, proteins and enzymes 
There are several major families of antimicrobial peptides, including α- and β-defensins, 
cathelicidins (expressed notably by leukocytes and epithelia), histatins in the saliva and 
dermcidin on the skin. They show broad-spectrum antimicrobial activities against a vast array of 
bacteria, fungi and viruses. They are small molecules, 20-50 amino acids long, mostly positively 
charged that act by creating membrane pores, through membrane disruption via electrostatic 
interaction with the membrane lipids, or by accumulating at the membrane surface resulting in 
membrane dissolution. They can also target intracellular cell components and act as metabolic 
inhibitors (Nguyen et al., 2011; Tavares et al., 2013). These peptides have also been shown to 
Figure 1.7. Schematic representation of the early events in peritoneal inflammation and the 
immunocompetent cells involved.  
Following pathogen invasion, resident macrophages, epithelial cells and mast cells sense PAMPs and secrete 
cytokines and chemokines to alert patrolling monocytes, neutrophils and other leukocytes present in the blood. This 
leads to neutrophil, inflammatory monocyte, NK cell, basophil and eosinophil recruitment to the infected tissue. This 
is facilitated by cytokine-induced increased vascular permeability and expression of adhesion molecules by 
epithellial cells. All cell types have the  capacity to express a variety of receptors and soluble mediators and interact 
with other cells. Basophils, eosinophils and NK cells contribute to create the inflammatory milieu. The NK cell-DC 
interaction is crucial for both cell activation and function. Following bacterial killing and phagocytosis, neutrophil 
clearance is primordial to avoid host tissue damage (See description of the specific role of each cell type in the text). 
(Adapted from Degli-Esposti 2005, Serhan 2008, Soehnlein 2010, Abraham 2010, Galli 2011) 
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play immunomodulatory roles, including chemotactic activity (Gallo and Hooper, 2012; Tosi, 
2005). 
Lysozyme, a glycosidase contained in the primary and secondary neutrophil granules and in 
epithelial cells, hydrolyses peptidoglycan (PGN) of bacteria cell walls. Lactoferrin, also present 
in neutrophil granules, alters the mobility of certain bacteria (e.g., Pseudomonas aeruginosa) 
and their ability to form biofilms, presumably also causing their destruction (Beutler, 2004; Gallo 
and Hooper, 2012). 
Other proteins present antimicrobial activities, such as cathepsin G and elastase in neutrophil 
granules. They play diverse roles in oxygen species formation, opsonisation, endotoxin 
neutralisation, iron sequestering and leukocyte activation (Nguyen et al., 2011). C-type lectins 
form another group of proteins with antimicrobial activities and will be discussed in section 
1.6.2.1. 
 
1.5.2.6 Complement 
The complement system plays a key role in innate immunity and in the development of an 
effective inflammatory response. It consists of 35 to 40 proteins and glycoproteins present in 
blood and on cell surfaces. The plasma proteins are mostly produced in the liver, and many are 
also secreted by a variety of cell types, notably monocytes and macrophages. Beside a role in 
homeostasis, the role of complement in immunity is to recognise and promote the elimination of 
microorganisms (bacteria, viruses and fungi) by generating active peptides including 
anaphylatoxins (complement components 3a (C3a), C4a and C5a). They have a wide range of 
pro-inflammatory and immunomodulatory properties including lysis and opsonisation of 
pathogens, induction of chemotaxis, anaphylatoxic effect, as well as generation of oxygen and 
nitrogen species by phagocytic cells and cytokine and chemokine production (Carroll and Sim, 
2011; Tang et al., 2004). Activation of the complement cascade leads to three main outcomes: 
1) opsonisation of microbes via the activation and binding of C3b; 2) recruitment of phagocytes 
through generation of the inflammatory and chemotactic molecules C4a and C5a; 3) direct 
killing of pathogens via the formation of the membrane-attack complex, leading to cell lysis and 
phagocytosis by macrophages (Carroll and Sim, 2011). Normally inactive, soluble complement 
proteins circulate in the blood where they encounter and recognise target molecules, leading to 
their activation and conformational change, which triggers a catalytic cascade resulting in the 
rapid generation of activated complement products. Activation occurs via any of three canonical 
pathways: classical, alternative and lectin. All three result in the activation of the most abundant 
component C3, leading to the activation of the terminal pathway. This pathway starts with the 
cleavage of C5 and the subsequent assembly of several complement proteins, namely C5b, C6, 
C7 and C8. The C5b678 complex, bound to plasma membranes, binds to 1-18 C9 molecules, 
forming a ring-shaped assembly of proteins subunits called the membrane-attack complex that 
can lyse bacteria and inactivate viruses through disruption of the proton gradient across the 
membrane (Beutler, 2004; Carroll and Sim, 2011; Podack, 1984; Podack and Tschopp, 1984). 
The existence of a fourth pathway has been suggested in phagocytic cells, where C3a and C5a 
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are generated independently of the canonical pathways, and directly activated by proteases of 
the coagulation cascade (Amara et al., 2008; Huber-Lang et al., 2006). Another important role 
of the complement is the activation of the adaptive immune system following ligation of 
complement receptors on B cells and DCs (Fearon, 1998). 
 
1.5.2.7 Additional components 
a.  Acute phase proteins 
     The acute phase response is an early event during the innate immune response to infection 
that involves the generation of proteins such as haptoglobin, fibrinogen, C-reactive protein and 
SAA as well as an array of secondary effects such as fever. Acute phase proteins are secreted 
by hepatocytes in response to the pro-inflammatory cytokines IL-1β and IL-6. They have 
defensive functions by binding to microbes and signal their presence, or isolating the infectious 
agent in the case of fibrinogen. Their concentration increases markedly following infection, and 
they act together with the complement system and soluble receptors (discussed in the next 
section) (Beutler, 2004; Medzhitov, 2007). 
 
b.  Lipid mediators 
     Lipid mediators such as eicosanoids, platelet-activating factors and prostaglandins, play an 
important role in initiating events of the inflammatory response, ranging from inducing fever, 
controlling the blood flow as wells as inducing vasodilatation needed for leukocytes recruitment. 
Some lipid mediators also have chemotactic activities, such as the leukotriene B4. Recently, a 
prominent role has been attributed to the anti-inflammatory lipoxins, resolvins and protectins in 
the switch from neutrophil to monocyte recruitment, phagocytosis and tissue repair (Medzhitov, 
2008; Serhan et al., 2008). 
 
c.  Inflammasomes 
     The inflammasome is a protein complex that activates inflammatory caspase-1 and triggers 
the processing of pro-IL-1β, pro-IL-18 and probably pro-IL-33, resulting in the secretion of their 
mature forms (Elinav et al., 2011; Martinon et al., 2002). Known inflammasomes are generally 
composed of at least one nucleotide-binding oligomerisation-domain protein (NOD)-like receptor 
protein (NLR, e.g. NALP-3, IPAF) or absent in melanoma-2 (AIM2) that function as sensors of 
endogenous or exogenous PAMPs or DAMPs, the apoptosis-associated speck-like protein 
containing a CARD (ASC) and pro-caspase-1 (Fig 1.8). Inflammasome components and the 
activation of downstream signalling pathways depend on the nature of the stimuli (Elinav et al., 
2011; Petrilli et al., 2007). Inflammasomes play a role in the very early stages of the 
inflammatory response, as IL-1β is one of the first cytokines to be produced and initiate host 
defence. Inflammasomes can be activated by various ligands from bacterial origin (PGN, 
flagellin), viral single stranded and double stranded RNA (ssRNA and dsRNA, respectively), 
fungi and parasites, crystalline or aggregated substances (including silica, uric acid, asbestos) 
or even by molecules produced as a result of the infection (potassium efflux and reactive 
Figure 1.8. Structural organisation of NALP3 and IPAF inflammasomes.  
The core structure of the NALP3 inflammasome is formed by NALP3, the adaptor ASC, and pro-caspase-1. PYD-
PYD and CARD-CARD homotypic interactions are crucial to the recruitment and activation of the  adaptor ASC and 
the inflammatory caspases, respectively (upper left panel). In the IPAF inflammasome, IPAF recruits pro-caspase-1 
directly via CARD-CARD interactions (upper right panel). The leucine-rich repeats of NALP3 and IPAF are proposed 
to sense the activating signals, leading to oligomerisation of the NACHT domain, and initiating the formation of the 
donut-shaped inflammasome. Based on the structure of the apoptosome, the caspases and IL-1β processing 
activity most likely face toward the inside of the donut (lower panel). Abbreviations: NALP, NACHT-LRR-PYD-
containing protein; ASC, apoptosis-associated speck-like protein containing a CARD; IPAF, ICE-protease-activating 
factor; LRR, leucine-rich repeats; PYD, pyrin domain; CARD, caspase recruitment domain; NAD, NACHT-
associated domain. (Adapted from Martinon 2009, Terlizzi 2014) 
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oxygen species production) (Elinav et al., 2011; Martinon et al., 2009). Even though some 
proteins of the NLR family (discussed in section 1.6.3.1) activate inflammasomes, not all of 
those proteins directly recognise activating ligands but rather utilise adaptor molecules. 
Activation usually requires two steps, the first being the transcription of the various elements of 
the inflammasome, and the second the interaction between the activators and the relevant 
sensor, leading to inflammasome assembly and cleavage of its substrate (Elinav et al., 2011).  
 
1.6 Receptors of the innate immune system 
The activity of the innate immunocompetent cells and the release of the innate immune 
mediators detailed above depend heavily on the capacity of an array of innate immune 
receptors (PRRs) to sense pathogens or danger signals.  
PRRs are involved in microbe internalisation by phagocytes (soluble PRRs and endocytic 
receptors) and/or cell activation (signalling PRRs). They can be either soluble or cell-
associated, expressed at the cell surface or intracellular. Pathogen detection by PRRs is 
achieved not only by immune cells but also by non-immune cells including epithelial cells, 
fibroblasts, and endothelial cells. This recognition leads to innate immune and inflammatory 
responses in the infected tissues. PRRs detect highly conserved motifs expressed by large 
families of microbes; they are called pathogen- or microbe-associated molecular patterns 
(PAMPs or MAMPs). In addition to recognising PAMPs/MAMPs, PRRs also sense danger 
signals by binding endogenous molecules whose presence in the extracellular milieu indicates 
host injury (danger-associated molecular patterns, DAMPs) as well as cell apoptosis or death. 
Based on their functions PRRs can be classified in three families: (i) Soluble PRRs, (ii) 
Endocytic receptors and (iii) Signalling receptors (Hoffmann and Akira, 2013; Jeannin et al., 
2008). The PRR families are represented in Figure 1.9. 
1.6.1 Soluble PRRs  
Direct contact between microbes and extracellular molecules of the host, which recognise 
specific residues on the surface of microorganisms, allows activation of downstream 
mechanisms (Beutler, 2004). Sometimes called soluble pattern recognition molecules, they are 
numerous, belong to different molecular families and represent the functional ancestors of 
antibodies (ante-antibodies). The three main families of soluble PRRs are the collectins, ficolins 
and pentraxins (Fig 1.9).  
Collectins and ficolins, produced in the liver, lung and by phagocytes, facilitate the recognition 
and elimination of their ligands by phagocytes through opsonisation of foreign particles via 
sugar recognition. Collectins include mannose-binding lectin and surfactant protein A and D; 
they share structural and functional homology with C1q, a member of the classical complement 
pathway (Jeannin et al., 2008).  
The pentraxin superfamily is composed of short pentraxins, serum amyloid P component and C-
reactive protein - produced in the liver - and long pentraxin 3, produced at sites of inflammation 
Figure 1.9. Schematic view of soluble and cell associated pattern recognition receptors. 
Soluble PRRs belong to different molecular families, including collectins, ficolins, C1q, and pentraxins. Cell-
associated PRRs are strategically located in different cellular compartments (plasma membrane, endosomes, 
cytoplasm) and belong to different molecular classes (e.g., TLRs, scavenger receptors, lectin receptors), some of 
which are shown here. The TLRs, the NOD- and RIG-like receptors are signalling receptors that induce activation of 
transcription factors, including NF-κB, IRFs, and MAPKs. The scavenger receptors, C-type lectins, integrins, and 
FcγR are capturing receptors. Peptidoglycan-derived fragments (e.g., MDP) are recognized by NODs (MDP, by 
NOD2) and by NALP3, a component of the inflammasome. NALP containing inflammosomes are activated by 
different danger signals, including lysosomal damage, whereas the AIM2 inflammosome and RIG-like receptors 
recognise viral DNA and dsRNA, respectively (see detailed description in the text). Abbreviations: CRP, C reactive 
protein; LPS, lipopolysaccharide; LRR, leucine-rich repeat; MAPK, mitogen-activated protein kinase; MBL, mannan-
binding lectin; MDA5, melanoma-differentiation-associated gene 5; MDP, muramyl dipeptide; NALPs, NACHT-LRR-
PYD-containing proteins; NF-κB, nuclear factor-κB; NOD, nucleotide-binding oligomerization domain; OmpA, Outer 
membrane protein A; PGN, peptidoglycan; PTX3, pentraxin 3; RIG-I, retinoic acid–inducible gene I; SAP, serum 
amyloid P component; SP-A/-D, surfactant protein A/D; SR, scavenger receptor; TIR, Toll/interleukin-1 receptor 
domain; TLR, Toll-like receptor; TRIF, Toll-IL-1 receptor domain-containing adaptor-inducing interferon-β; IRFs, IFN-
regulatory factors. (Adapted from Bottazzi 2010) 
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by many different cell types. They are proteins of the acute phase response, with plasma C-
reactive protein concentration increasing greatly following the onset of inflammation in response 
to pro-inflammatory mediators, mainly IL-6 (Manfredi et al., 2008). Soluble PRRs have also 
been called opsonins, due to their capacity to facilitate target recognition and effector function of 
phagocytes. Collectins and ficolins are involved in the activation of the lectin pathway of the 
complement system, while pentraxins activate the classical pathway. Some members of 
different families of soluble PRRs interact with each other to form heterocomplexes, such as L- 
and M-ficolins, which are ligands for the short pentraxins. This cooperation is likely to increase 
their repertoire of recognition and actions. Soluble PRRs also play an important role in the 
elimination of apoptotic cells by recognising damaged cells and their constituents. C-reactive 
protein binds to membranes of damaged and apoptotic cells during late phase of apoptosis via 
various phospholipids, and also binds to chromatin/nucleolar components that redistribute to the 
plasma membrane. Several other members of the pentraxin family, collectins and ficolins bind 
apoptotic cells. This leads to phagocytosis and clearance of apoptotic cells (Bottazzi et al., 
2010; Jeannin et al., 2008). 
 
Many other molecules can serve as soluble PRRs, such as SAA, induced by pro-inflammatory 
cytokines (IL-1β, TNFα and IL-6) and mainly synthesised by the hepatocytes on the onset of an 
inflammatory response. SAA recognises a variety of pathogens (bacteria and virus) and 
opsonise them to facilitate the response of phagocytic cells with cytokines and reactive oxygen 
production. SAA also has cytokine-like properties, induces the production of chemokines, 
MMPs, nitric oxide and oxygen species and can interact with TLR2 to trigger nuclear factor-κB 
(NF-κB) activation (Bottazzi et al., 2010; He et al., 2009; O'Reilly et al., 2014). 
 
The description and modulatory activity of soluble PRRs of the Toll-like receptor family will be 
discussed in section 1.7.6.1. 
1.6.2 Endocytic receptors  
Endocytic receptors, expressed at the cell surface, mediate the internalisation and recognition 
of microbes or microbial components. The recognition can be direct or mediated via 
heteromultimeric complexes. There are two main types of endocytic receptors: C-type lectin and 
scavenger receptors (Fig 1.9). 
 
1.6.2.1 C-type lectin receptors (CLRs) 
CLRs constitute a superfamily that recognises a variety of ligands, including sugar moieties of 
bacteria and fungi (mannose, mannose- and fucose-glycans, galactose or αmannans, among 
others) and oxidised lipids or self-ligands from damaged or dead cells. They are expressed 
mainly on myeloid cells (Sancho and Reis e Sousa, 2012). Dectin-1, one of the prototypes of 
the C-type lectin family is a transmembrane receptor that binds β-glucan, and is expressed on 
DCs and macrophages. Dectin-1 has an important role in antifungal defence, being involved in 
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phagocytosis of fungal pathogens and the production of antimicrobial molecules (Medzhitov, 
2007). Another typical CLR, the mannose receptor, mediates recognition and phagocytosis of a 
range of viral, bacterial, fungal and protozoan pathogens by binding to mannose residues 
[Sancho and Reis e Sousa 2012]. In general, CLR activation promotes microbicidal activity, 
engages the phagocytic machinery to engulf microbes or viruses, and triggers pro- or anti-
inflammatory processes. CLRs also interact with other PRR families to modulate and adapt the 
response to infection (Sancho and Reis e Sousa, 2012). 
 
1.6.2.2 Scavenger receptors 
Scavenger receptors (SR) are multidomain proteins, which were first described to bind oxidised 
low-density lipoproteins (LDL), but not native ones (Brown and Goldstein, 1979). It has since 
been shown that SR mediate the uptake of a diverse range of ligands including modified LDL, 
various polyanionic ligands, microorganisms, apoptotic and necrotic cells, and self-components 
such as ECM molecules. SR such as SR-A, CD36, LOX-1 and macrophage receptor with a 
collagenous structure (MARCO), form a heterogenous group with a common function. SRs are 
divided into 8 classes (SR-A to -H, including class C, which is only present in Drosophila 
melanogaster) on the basis of the structure of their extracellular domains (Canton et al., 2013). 
They are mainly expressed at the cell surface of macrophages, DCs and specific endothelial 
cells. Recognition of SR ligands is followed by their rapid internalisation, resulting either in 
accumulation (generation of foam cells after oxidised-lipoprotein internalisation) and/or 
destruction (endosome–lysosome fusion after microorganism internalisation) (Jeannin et al., 
2008). SR have a broad range of other functions as they are thought to be involved in 
phagocytosis and antigen presentation, among others, but their exact mechanism of action 
remains unclear as they do not have a signalling domain (Canton et al., 2013). 
1.6.3 Signalling receptors  
Signalling receptors trigger cell activation in response to recognition of diverse microbial 
components, such as proteins, glycans, lipoproteins, and nucleic acids. They are expressed at 
the surface of the cells or intracellularly (Fig 1.9). 
 
1.6.3.1 Nucleotide-binding oligomerisation-domain protein (NOD)-like receptors (NLRs) 
NLRs are one class of intracellular and cytoplasmic proteins that sense bacterial components 
present in the cytoplasm. The NLR family consists of more than 20 members, including NOD1 
and 2, the NACHT-LRR-PYD-containing protein (NALP or NLRP) family - the largest subfamily 
of NLRs - NAIP, IPAF (NLRC4) and CIITA, which respond to various PAMPs, including bacterial 
motifs and flagellin (NAIP5 and IPAF). NLRs also trigger pro-inflammatory responses following 
recognition of non-PAMP particles and cellular stress (Kawai and Akira, 2011). Notably, several 
NLR members (NALP1, NALP3 and IPAF) form the caspase-1 activating complexes called 
inflammasomes (discussed in section 1.5.2.7c) (Akira et al., 2006; Elinav et al., 2011).  
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NOD1 and NOD2, the namesake of the NLRs, are crucial for innate immune responses to 
specific bacterial infections. NOD1 is expressed in diverse cell types, whereas NOD2 
expression is restricted to myeloid and lymphoid cells of the haematopoietic compartment. 
However, its expression in intestinal epithelial cells and Paneth cells of the intestinal crypts has 
been reported. NOD2 is being extensively studied, as it is one of the genetic risk factors for the 
development of Crohn’s disease (Hugot et al., 2001; Philpott et al., 2014). NOD1 and NOD2 
lack transmembrane domains, but are recruited to the plasma membrane and detect bacteria at 
the entry point. Both NOD1 and NOD2 recognise and directly bind intracellular fragments of 
bacterial PGN. NOD1 detects D-glutamyl-meso-diaminopimelic acid (iE-DAP), a dipeptide 
present in a PGN mainly found in Gram-negative bacteria and certain categories of Gram-
positive bacteria, including Listeria spp. and Bacillus spp. NOD2 senses muramyl dipeptide 
(MDP), ubiquitously found in bacterial PGN. Their activation triggers their auto-oligomerisation, 
forming the NOD signalosome, which activates receptor-interacting protein-2. This is followed 
by NF-κB and MAPK activation and downstream signalling, leading to the production of pro-
inflammatory mediators (TNF, IL-6, CXCL8, CCL2) and antimicrobial factors, such as defensins 
(Martinon et al., 2009; Philpott et al., 2014). 
 
1.6.3.2 Retinoic-acid-inducible protein I (RIG-I)-like receptors (RLRs)  
Also located in the cytoplasm, RLRs are important in antiviral defence, as they can sense RNA 
species generated during viral replication. RLRs, which include RIG-I, MDA5 and LGP2, are 
RNA helicases with an ATP-binding motif. RIG-I recognises ssRNA and short dsRNA, whereas 
MDA5 detects long dsRNA, structural features absent from cellular RNA, thus allowing 
discrimination between viral from self-RNA. LGP2 has been suggested to regulate RIG-I/MDA5, 
but whether in a negative or positive manner it is still a matter of debate (Kawai and Akira, 
2009). Cardif (also known as IPS1/MAVS/VISA), another member of the NLR family, is a crucial 
adaptor of RIG-I and MDA5-mediated downstream signalling, with a C-terminal end that is 
required for mitochondrial targeting, suggesting a role of the mitocondria in innate immunity and 
IFN responses (Meylan et al., 2005; Seth et al., 2005). Activation of these proteins results in the 
production of type I IFNs (IFNα and IFNβ) and IFN-inducible genes, thereby inducing a broad 
range of antiviral activities (Medzhitov, 2007). Several NLRs also activate NF-κB and MAPK, 
leading to the expression of an array of immune and inflammatory genes (Kawai and Akira, 
2009; Meylan et al., 2005; Seth et al., 2005).  
 
HPMC have been shown to express RIG-1 and MDA5, whose stimulation triggers the up-
regulation of pro-inflammatory cytokines and chemokines and type I IFNs, thus indicating a role 
of these cells in immunity against viral infection (Wornle et al., 2009). 
 
1.6.3.3 Additional receptors 
Other cytosolic proteins, not belonging to the NLR or RLR families, such as DAI, IFI16, DDX41 
and AIM2, have been reported to be involved in the recognition of cytosolic DNA or retrovirus 
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infection, inducing the production of type I IFN and IL-1β secretion (Kawai and Akira, 2011). 
Many of these DNA binding proteins are ubiquitous and have the potential to engage 
endogenous DNA. It is therefore crucial that the DNA recognition process is tightly regulated. 
When mitochondrial DNA is released from a damaged mitochondria, caspase-1 activation is not 
dependent on AIM2, which is part of the AIM2 inflammasome, but instead it depends on the 
NALP3 inflammasome, potentially leading to a different response (Holm et al., 2013). 
 
Another important family of signalling PRRs, the toll-like receptors (TLRs), is of particular 
relevance to this thesis and will be described in more detail in the following section. 
 
1.7 The Toll-like receptor family 
TLRs were the first PRRs to be discovered, and represented the missing link between innate 
and adaptive immunity. TLRs mediate a phylogenetically primitive, non-clonal mechanism of 
pathogen recognition based on binding to structurally conserved PAMPs.  
It all started in the late 1980’s, with the identification of the IL-1R type 1 (Sims et al., 1988). IL-1 
is a pleiotropic pro-inflammatory cytokine involved in the initiation of the acute phase response, 
pyrogenicity, promotion of cartilage breakdown and T cell activation (Dinarello, 1991). The IL-1R 
type 1 signalling mechanism was not known, as there was no recognisable signalling motif in its 
cytoplasmic domain. In 1991, it was reported that the IL-1R cytoplasmic domain shared some 
homology with the cytoplasmic domain of a Drosophila melanogaster protein called Toll (Gay 
and Keith, 1991). Toll was initially known to promote dorsoventral polarity during fly 
development, involving a protein, Dorsal, which contains a REL domain with homology with 
members of the NF-κB family of transcription factors (Anderson et al., 1985; Steward, 1987). 
NF-κB was emerging as an important player in gene transcription, as many genes with a role in 
inflammation and infection were reported to be regulated by NF-κB. Notably, lipopolysaccharide 
(LPS) – a main component of the Gram-negative bacterial cell wall – was demonstrated to 
activate NF-κB, as did IL-1 (Baeuerle and Henkel, 1994; Sen and Baltimore, 1986). This 
suggested a common signalling mechanism between Drosophila melanogaster development 
and pro-inflammatory signalling in mammals. In 1994, a plant protein providing resistance to 
tobacco mosaic virus - the N protein - was characterised. The N protein presented some 
homology with the cytoplasmic domains of Toll and IL-1R type 1, indicating that a conserved 
region within the cytoplasmic domain had a role in host defence in the plant and animal 
kingdoms, emphasising its importance. It was therefore initially called the Toll-IL-1-resistence 
(TIR) domain and later renamed Toll/IL-1 receptor domain (Whitham et al., 1994). Parallel work 
unravelled mechanism of action of NF-κB, demonstrating that its activation triggered the 
production of antimicrobial peptides (Ip et al., 1993). This led to Jules Hoffmann’s laboratory to 
investigate a potential role of Toll in immune gene expression. Hoffmann and colleagues 
demonstrated that following fungal infection, the antimicrobial peptide Drosomycin was 
expressed through activation of the Toll pathway (Lemaitre et al., 1996). The first human 
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homologue of Toll, called hToll was cloned in 1997 and showed to activate NF-κB and NF-κB-
dependent genes (Medzhitov et al., 1997). Importantly, hToll triggered the expression of CD80, 
a protein involved in co-stimulation of T cells, providing one of the first links between innate and 
adaptive immunity. More Toll homologues were then cloned and named Toll-like receptors, and 
hToll was renamed TLR4 (Chiang and Beachy, 1994; Rock et al., 1998). 
The discovery of the TLR family is paralleled and linked to the search for the LPS receptor, as 
LPS (the main component of bacterial endotoxin) was being extensively studied due to its role 
as the causative agent of Gram-negative bacteria-induced sepsis. A spontaneous mutation in 
the C3H/HeJ mouse strain rendered these mice resistant to LPS. This mutation was shown to 
be due to a single autosomal gene named Lpsd, which Bruce Beutler’s group positionally cloned 
in 1998 and identified as being Tlr4. Notably, Beutler and his colleagues demonstrated that a 
single point mutation in the cytoplasmic domain of Tlr4 (P 712 H) was responsible for the LPS 
resistance in the C3H/HeJ mice, thus defining TLR4 as the signalling receptor of LPS (Poltorak 
et al., 1998). In the following two years, Lpsd was also reported to be Tlr4 by another group 
using a similar approach (Qureshi et al., 1999), and a TLR4 KO mouse strain was shown to fail 
to respond to LPS, confirming that TLR4 was indeed the LPS signalling receptor (Hoshino et al., 
1999). The subsequent identification of co-receptors and understanding of the molecular 
mechanism of LPS recognition established TLR4 as a PRR. Ten TLR genes have now been 
identified in humans and twelve in mice (O'Neill et al., 2013). 
1.7.1 Tissue distribution of TLRs  
When the first human TLRs were cloned (TLR1-5), they were shown to be expressed 
differentially in a variety of organs and tissues, with TLR1 expressed ubiquitously, TLR2 mainly 
expressed in the heart, brain, lung and muscle, like TLR3, which was also found in the pancreas 
and placenta. TLR4 was only found in placenta, and TLR5 in ovaries and peripheral blood 
monocytes (Rock et al., 1998). Most tissue tested since then have shown to express at least 
one TLR, if not all (Sandor and Buc, 2005). An extensive study observed that the most diverse 
repertoire of TLRs was present in tissues involved in immune functions (spleen and peripheral 
blood leukocytes) and in organs most likely to encounter microbes (lung, small intestine, colon). 
The pancreas, placenta and ovary also displayed some variety (Zarember and Godowski, 
2002). Notably, leukocytes were found to express the greatest variety of TLRs (Table 1.3).  
 
TLRs are also expressed on non-haematopoietic cells. Notably, they are widely present on 
epithelial cells of the skin, lungs and intestines, tissues in direct contact with microorganisms, as 
mentioned above. Keratinocytes express TLR1, TLR2, TLR3, TLR5 but not TLR7, TLR8, TLR9, 
whereas data on TLR4, TLR6 and TLR10 are conflicting (Kollisch et al., 2005; Sandor and Buc, 
2005). TLR2 and TLR4 are expressed throughout the epithelium of the airways, with some cell 
type specificity. Intestinal epithelial cells also express TLR2, TLR4 and TLR5. Despite constant 
exposure to the commensal flora in the gut, homeostasis is maintained, and TLR ligands do not 
necessarily trigger pathologic inflammation. This is achieved in part by their localisation (e.g. 
  
 
 
 
 
 
 
 
 
 
 
Table 1.3 Expression of TLRs on leukocytes 
TLR  
Cell type 
TLR1 TLR2 TLR3 TLR4 TLR5 TLR6 TLR7 TLR8 TLR9 TLR10 
Neutrophils + + - + + + + + + + 
Monocytes + +++ - ++ + + + + + + 
Macrophages + + - + + + + + + + 
Eosinophils + + - + - + + - - + 
Basophils ND +/- ND +/- ND ND ND ND ND ND 
Mast cells + + + + + + + ND + ND 
NK cells + + + + + + + + + - 
pDC + +/- - +/- - + ++ - ++ +/- 
iDC + + - ++ + - - + + + 
mDC + + + + + + +/- + - +/- 
*CD4 T cells ND + + + + ND + + + ND 
*CD8 T cells ND + + + + ND + + + ND 
*T reg ND + +/- + + ND + + + ND 
*γδ T cell + + ++ +/- + + + + + ND 
*B1 cells + +/- - +/- - + +/- - + + 
*Marginal 
zone B cells + +/- - +/- - + +/- - + + 
*Of note, TLR expression on B and T cells is highly variable depending on their subset and level of differentiation and 
activation. Abbreviations: pDC, iDc, mDC, plasmacitoid, immature and myeloid DC, respectively; ND, not determined. 
(Adapted from Muzio, Bosisio et al. 2000; Jarrossay, Napolitani et al. 2001; Hornung, Rothenfusser et al. 2002; Sabroe, 
Jones et al. 2002; Chalifour, Jeannin et al. 2004; Kokkinopoulos, Jordan et al. 2005; Sandor and Buc 2005; Kabelitz 
2007; Cole, Georgiou et al. 2010; Kulkarni, Behboudi et al. 2011; Rawlings, Schwartz et al. 2012) 
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TLR5: basolateral expression, not apical), low or potential expression (mRNA, but not protein) 
or by triggering signalling pathways by commensal bacteria different from those induced by 
pathogens (Melmed et al., 2003; Sandor and Buc, 2005). TLRs expression on HPMC has also 
been investigated, mainly at the mRNA expression level, showing a potential expression of 
most TLRs. However, only the HPMC expression of TLR3 and its responses to TLR3-specific 
agonists was clearly demonstrated (Wornle et al., 2009). TLRs expression in vessels depends 
on the location. Smooth muscle cells constitutively express TLR1, TLR3 TLR4 and TLR6, while 
TLR2 can be induced by Chlamydia pneumoniae (Cole et al., 2010). Normal vessels only 
express low levels of TLRs, but TLR1, TLR2 and TLR4 protein expression is increased in 
atherosclerotic vessels, while TLR2 is detected in endothelial cells in atheroprone regions, with 
a detrimental role in the initiation and development of atherosclerotic lesions such as leukocyte 
recruitment and foam cell formation (Cole et al., 2010). TLR expression depends on various 
factors, including the presence of pathogens, cytokines and environmental stress signals. 
1.7.2 Cellular localisation of TLRs 
TLRs can be divided into two groups according to their cellular localisation. TLR1, TLR2, TLR4, 
TLR5 and TLR6 are mainly expressed at the cell surface, while TLR3, TLR7, TLR8 and TLR9 
are intracellular receptors, expressed on vesicles such as the endosome, lysosome, 
endolysosome and endoplasmic reticulum (Beutler, 2009; Kawai and Akira, 2009; Miggin and 
O'Neill, 2006). This suggests that the TLR system is not used to detect pathogens that are in 
the cytosol, these pathogens are detected by cytoplasmic PRRs (described in section 1.6.3). 
The intracellular localisation of some TLRs enables them to recognise nucleic acids delivered to 
the intracellular compartments after the uptake of viral particles or after viral or bacterial 
infections. By contrast, host nucleic acids are normally confined to the nucleus or cytoplasm and 
are not present in endosomes, thus avoiding TLR recognition. Thus, compartmentalisation 
permits avoiding unwanted TLR activation (Barton and Kagan, 2009; Kawai and Akira, 2011; 
Takeuchi and Akira, 2010).  
1.7.3 TLR ligands, co-receptors and accessory molecules 
Based on their primary sequence, TLRs can be further divided into subfamilies, which recognise 
related ligands: TLR1, TLR2 and TLR6 recognise mainly lipids whereas the highly related TLR7, 
TLR8 and TLR9 recognise nucleic acids. TLRs however are able to recognise a wide variety of 
structurally unrelated ligands. Cell-surface TLRs - TLR1, TLR2, TLR4, TLR5, TLR6, TLR10 - 
recognise mainly microbial membrane components, including lipoproteins, glycolipids and 
proteins, whereas intracellular TLRs - TLR3, TL7, TLR8, TLR9 - sense different types of nucleic 
acids. Therefore, many microbes such as bacteria, fungi or viruses are sensed by several TLRs, 
recognising the various PAMPs of a given pathogen (Akira et al., 2006). TLRs and their ligands 
are summarised in Table 1.4. 
 
  
Table 1.4 TLRs agonists and co-receptors 
TLR Ligand Origin of ligand Accessory molecule 
and co-receptor 
TLR1-TLR2 
Triacyl lipopeptides 
Soluble factors 
Pam3Cys 
Bacteria and mycobacteria 
Neisseria meningitides 
Synthetic compounds 
CD14, CD36, 
Dectin1 
TLR2 
Lipoprotein/lipopeptides 
Peptidoglycan 
Lipoteichoic acid 
Lipoarabinomannan  
Phospholipomannan 
Phenol-soluble modulin 
Glycoinositolphospholipids 
Glycolipids 
Porins  
Atypical lipopolysaccharide 
Atypical lipopolysaccharide 
Zymosan  
t-GPI-mucins 
Haemagglutinin protein 
Heat-shock protein 60 
Heat-shock protein 70 
HMGB1 
Various pathogens 
Gram-positive bacteria 
Gram-positive bacteria 
Mycobacteria 
Candida albicans 
Staphylococcus epidermidis 
Trypanosoma cruzi Treponema 
maltophilum 
Neisseria 
Leptospira interrogans 
Porphyromonas gingivalis 
Fungi 
Trypanosoma 
Measles virus 
Host 
Host 
Host 
 
TLR2-TLR6 
Diacyl lipopeptides 
Lipoteichoic acid 
Zymosan 
Pam2Cys 
Mycoplasma  
Gram-positive bacteria  
Fungi 
Synthetic compounds 
CD14, CD36, 
Dectin1 
TLR3 Double-stranded RNA 
Poly (I:C) 
Viruses 
Synthetic compounds 
CD14, TRIL, HMGB 
TLR4 
Lipopolysaccharide  
Fusion protein  
Envelope protein  
Mannan 
Heat-shock protein 60 
Heat-shock protein 70  
Type III repeat extra domain 
A of fibronectin 
Oligosaccharides of HA 
Polysaccharide fragments of 
heparan sulphate  
Fibrinogen 
-Defensin 
HMGB1 
Gram-negative bacteria 
Respiratory syncytial virus 
Mouse mammary-tumour virus 
Candida albicans 
Host 
Host 
 
Host 
Host 
 
Host 
Host 
Host 
Host 
CD14, MD2, CD36, 
TRIL 
TLR4-TLR6 Oxydised LDL 
Amyloid-β fibrils 
Host 
Host 
 
TLR5 Flagellin Bacteria  
TLR7 
Single-stranded RNA 
Imidazoquinoline  
Loxoribine 
Bropirimine  
Viruses  
Synthetic compounds 
Synthetic compounds  
Synthetic compounds   
CD14, LL37, 
HMGB1, HMGB3 
TLR8 
Single-stranded RNA 
Imidazoquinoline  
Resiquimod 
Viruses  
Synthetic compounds 
Synthetic compounds 
CD14, LL37 
TLR9 
CpG-containing DNA 
Haemozoin 
CpG-A, CpG-B, CpG-C 
Bacteria and viruses 
Plasmodium falciparum 
Synthetic compounds 
CD14, progranulin, 
HMGB1, LL37 
TLR10 Peptidoglycan ND 
Might heterodimerise 
with TLR2 
Abbreviations: ND, not determined; Pam3Cys, Pam3-Cys-Ser-(Lys)4; t-GPI-mucins, glycosylphosphatidylinositol-mucin; 
HMGB, High-mobility group box; Pam2Cys, Pam2-Cys-Ser-(Lys)4; poly I:C, polyinosine-deoxycytidylic acid; HA, 
hyaluronan; MD2, myeloid differentiation protein 2; TRIL, TLR4 interactor with leucine-rich repeats; LDL, low-density 
lipoproteins. (Adapted from Akira and Takeda 2004; Akira, Uematsu et al. 2006; Guan, Ranoa et al. 2010; Lee, Avalos 
et al. 2012; Mulla, Myrtolli et al. 2013) 
 
 
 
 
 
 33 
1.7.3.1 TLR1, TLR2 and TLR6 
TLR2 recognises a wide range of components derived from bacteria, mycoplasma, fungi, 
parasites and viruses. Bacteria can be classified into Gram-positive and Gram-negative bacteria 
depending on the characteristics of their cell walls, and some of their unique components 
constitute PAMPs that are recognised by specific TLRs. Lipoteichoic acid (LTA, of Gram-
positive bacteria), lipoproteins and PGN (both present in Gram-positive and Gram-negative 
bacteria) and mycobacteria, are potent immunostimulants (Fig 1.10). TLR2 plays a major role in 
detecting Gram-positive bacteria, including Staphylococcus aureus (S. aureus), S. epidermidis 
and Streptococcus pneumoniae (Echchannaoui et al., 2002; Takeuchi et al., 2000), and is 
involved in the recognition of LTA, lipoproteins and PGN. To achieve the recognition of various 
ligands, TLR2 is able to heterodimerise with TLR1 or TLR6, allowing discrimination between 
subtle changes in the lipid portion of lipoproteins (Alexopoulou et al., 2002; Ozinsky et al., 2000; 
Takeuchi et al., 2001; Takeuchi et al., 2002). The resulting TLR1/TLR2 heterodimer recognises 
triacyl lipopeptides from bacteria and mycobacteria - including Mycobacterium leprae and its 
triacylated 19 kDa and 33 kDa lipoproteins (Krutzik et al., 2003) - as well as synthetic 
lipopeptides such as Pam3-Cys-Ser-(Lys)4 (Pam3Cys) (Nakata et al., 2006). By contrast, 
TLR6/TLR2 recognises diacyl lipoproteins from bacteria, or its synthetic counterpart Pam2Cys 
as well as zymosan from fungi, LTA and macrophage-activating lipopeptide 2 (MALP2) from 
Mycoplasma fermentans. Additional cell wall components from diverse organisms detected by 
TLR2 include lipoarabinomannan from mycobacteria such as Mycobacterium smegmatis 
(Gilleron et al., 2003) and β-glucan from fungi, including Candida albicans and Aspergillus 
fumigatus (Netea et al., 2004). TLR2 is also involved in parasite recognition, such as 
Trypanosoma-derived glycosylphosphatidylinositol-mucin (Gazzinelli et al., 2004), and is able to 
sense viral components including measles virus hemaglutinin protein, human cytomegalovirus 
and herpex simplex virus 1 (Akira et al., 2006; Lee et al., 2012).  
 
Several molecules act as co-receptors/cofactors for TLR2, allowing discrimination between, and 
facilitating recognition of, diverse agonists. TLR2 has been shown to use CD36 - a scavenger 
receptor found in lipid rafts - to discriminate between ligands. CD36 uniquely enhances immune 
responses to TLR2/TLR6 ligands, namely LTA and MALP2, and its deficiency results in 
increased susceptibility to S. aureus (Hoebe et al., 2005; Stuart et al., 2005). CD14, another 
TLR co-receptor, is a glycoprotein present in soluble form in plasma and other biological fluids 
as well as a glycosylphosphatidylinositol-anchored membrane protein on myeloid cells (Durieux 
et al., 1994; Haziot et al., 1988). It interacts with TLR ligands and enhances their ability to 
activate TLRs. CD14 is an important co-receptor for several TLRs, mediating pro-inflammatory 
cytokine production induced by TLR2/TLR6 ligands such as Pam2Cys, zymosan, LTA and 
MALP2. LPS-binding protein (described below), a TLR cofactor, can bind to LTA, PGN and 
lipopeptides and transfer them to CD14, indicating an assisting role in TLR1, TLR2 and TLR6 
activation (Lee et al., 2012). In addition, Dectin-1, a C-type lectin receptor (described in section 
Figure 1.10. Schematic representation of bacterial cell walls. 
Gram-positive bacteria have a thick porous layer of peptidoglycan (PGN). Lipoteichoic acids and lipoproteins are 
embedded in this cell wall. Gram-negative bacteria is characterized by the presence of LPS in the outer layer 
covering a thinner PGN layer. Mycobacteria produce a thick hydrophobic layer containing mycolyl arabinogalactan 
and dimycolate, in addition to a lipid bilayer and a PGN layer. Lipoarabinomannan (LAM) is a major cell-wall-
associated glycolipid. Lipoproteins are common structures for various types of bacteria. Abbreviations: OM, outer 
membrane; IM, inner membrane; PS, periplasmic space. (Adapted from Akira 2006) 
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1.6.2.1), can collaborate with TLR2 to elicit a strong inflammatory response to yeast β-glucan 
and zymosan (Gantner et al., 2003). 
Based on sequence similarity, TLR10 is related to TLR1 and TLR6 and one report showed that 
it could form a complex with TLR2 (Guan et al., 2010). TLR10 could be involved in PGN sensing 
(Mulla et al., 2013) but no definite ligand has been identified so far. 
 
1.7.3.2 TLR4 
TLR4 recognises, among other PAMPs, the main constituent of the outer membrane of Gram-
negative bacteria, LPS (Fig 1.10) (Poltorak et al., 1998), and in particular its lipid portion called 
lipid A, which is responsible for most of the pathogenic effects associated with LPS and Gram-
negative bacterial infection. LPS forms micelles poorly recognised by TLR4. Therefore it 
requires co-receptors and accessory molecules to detect it as well as to bind and activate signal 
transduction. LPS first associates with high affinity with LPS-binding protein, an acute phase 
protein present in the bloodstream. This interaction facilitates the disaggregation of LPS and its 
transfer to CD14 (Hailman et al., 1994). CD14 then chaperones LPS from LPS-binding protein 
to myeloid differentiation protein 2 (MD2) (Shimazu et al., 1999), a secreted protein that is 
bound to the extracellular domain of TLR4 and is part of the TLR4 receptor complex. LPS 
binding to MD2 leads to TLR4 oligodimerisation and downstream signalling (Akira et al., 2006; 
Lee et al., 2012). CD14 is also involved in LPS-induced endocytosis of TLR4, which is required 
for TRIF-mediated signalling (described in section 1.7.5.2) (Zanoni et al., 2011).  
TLR4 participate in antifungal immunity - as initially suggested by its homology with Drosophila 
melanogaster Toll - by detecting fungal PAMPs in the cell wall or on the cell surface of Candida 
albicans and Aspergillus fumigatus (Netea et al., 2004). In addition, TLR4 is involved in the 
detection of respiratory syncytial virus fusion protein, the envelope protein of mouse mammary 
tumor virus, Streptococcus pneumoniae pneumolysin, some lipomannan from mycobacterial cell 
wall and parasite Trypanosoma-derived glycoinositolphospholipids (Akira et al., 2006). 
Additional co-receptors have been described for TLR4, including: 1) CD36, which mediates 
responses to oxidised LDL and amyloid-β fibrils through the assembly of a TLR4-TLR6 
heterodimer (Stewart et al., 2010) and 2) TLR4 interactor with leucine-rich repeats, a 
transmembrane protein highly expressed in the brain, which can be induced by LPS and 
mediates TLR4 signalling and has been suggested to be involved in ligand delivery (Carpenter 
et al., 2009). 
 
1.7.3.3 TLR5 
TLR5 detects flagellin, the main protein constituent of bacterial flagella, the motility apparatus 
used by many microbial pathogens, and a potent activator of innate immune responses. TLR5 
specifically recognises a relatively conserved domain of flagellin, the constant domain D1 in 
Salmonella, amongst other flagellated bacteria (Andersen-Nissen et al., 2007; Hayashi et al., 
2001). Helicobacter pylori and Campylobacter jejuni are able to produce different types of 
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flagellins, enabling them to evade the flagellin-specific host immune responses (Andersen-
Nissen et al., 2005). 
 
1.7.3.4 TLR3 
TLR3 recognises dsRNA, a major component of many viruses that mediates the activation of 
NF-κB and type I IFN signalling pathways. dsRNA can be generated during viral infection as a 
replication intermediate for ssRNA viruses, such as respiratory syncytial virus, 
encephalomyocarditis virus and West Nile virus, or as a by-product of symmetrical transcription 
of DNA viruses (Akira et al., 2006). TLR3 senses the genomic RNA of reoviruses and can also 
recognise a synthetic analogue of dsRNA, polyinosine-deoxycytidylic acid (poly I:C) 
(Alexopoulou et al., 2001). TLR3 has been shown to associate with CD14, which mediates 
ligand trafficking and enhances immune responses to TLR3 ligands (Lee et al., 2006). TLR4 
interactor with leucine-rich repeats also appears to be able to mediate TLR3 signalling 
(Carpenter et al., 2011). High-mobility group box (HMGB) proteins form a family of nuclear 
proteins associated with chromatin and involved in transcription regulation by facilitating DNA 
access. HMGB proteins bind to RNA and are required for signalling downstream of TLR3 by 
mediating RNA delivery to the receptor, although their mechanism of action has not been 
elucidated (Yanai et al., 2009). 
 
1.7.3.5 TLR7 and TLR8  
TLR7 and TLR8 are highly homologue and detect ssRNA from RNA viruses – vesicular 
stomatitis virus, influenza A virus and human immunodeficiency virus - as well as purine 
analogue compounds with antiviral activity (imidazoquinolins). TLR8 also recognises uridin-rich 
or uridin/guanosin-rich ssRNA of both viral and host origin (Diebold et al., 2004; Hemmi et al., 
2002). Many enveloped viruses traffic into the cytosol through the endosomal compartment, but 
in the phagolysosome (an acidic compartment containing degradation enzymes), viral particles 
can be damaged and ssRNA released, enabling its recognition by TLR7 and TLR8 and the 
subsequent production of potent anti-viral type I IFNs. TLR7 can also detect RNA species from 
bacteria such as group B Streptococcus (Kawai and Akira, 2010). Co-receptors and accessory 
molecules act also in concert with TLR7 and 8. CD14 acts as a co-receptor for TLR7 and TLR8, 
and probably promotes the general internalisation of nucleic acids (Baumann et al., 2010). LL37 
- an amphipathic peptide activated through the cleavage of cathelicidin antimicrobial peptide - 
has been shown to form complexes with self RNA and to mediate its delivery to endosomal 
TLRs. LL37-self RNA complexes initiate TLR7- and TLR8-dependent signal transduction (Lee et 
al., 2012). HMGB1 and HMGB3 also facilitate ligand delivery to TLR7 and are required for type I 
IFN and pro-inflammatory cytokine production in response to RNA (Yanai et al., 2009). 
 
1.7.3.6 TLR9 
TLR9 senses unmethylated 2’-deoxyribo (cytidine-phosphate-guanosine) (CpG) DNA motifs that 
are frequent in bacteria and viruses but rare in mammalian cells. These motifs are found in 
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genomic DNA from bacteria, mycobacteria and parasites, as well as viral DNA from DNA 
viruses such as murine cytomegalovirus and herpex simplex virus 1 (Gazzinelli et al., 2004; 
Hemmi et al., 2000; Hochrein et al., 2004; Krieg, 2002; Tabeta et al., 2004). Synthetic 
oligonucleotides containing the CpG motif mimic bacterial DNA, thus activating TLR9 (Akira et 
al., 2006). TLR9 was also reported to recognise hemozoin, a crystalline metabolite of 
haemoglobin produced by the malaria parasite Plasmodium falciparum (Coban et al., 2005). 
However, it was later demonstrated that TLR9 senses not hemozoin, but the parasite DNA 
(highly pro-inflammatory) present in purified hemozoin; this haemoglobin metabolite appears to 
target the parasite DNA to endosomes (Parroche et al., 2007). Similar to other TLRs, TLR9 
activation benefits from the collaboration of co-receptors and accessory molecules. Indeed, 
CD14 associates with TLR9 and mediates ligand trafficking (Baumann et al., 2010), while LL37 
has been reported as a TLR9 accessory molecule. LL37 is implicated in the delivery of self-DNA 
to TLR9, via the formation of LL37-DNA complexes, which are internalised and localise to early 
endosomes to mediate TLR9-dependent signalling (Lande et al., 2007). HMGB1 is a pro-
inflammatory molecule, as it is a TLR2 and TLR4 ligand (Andersson and Tracey, 2011), and has 
also been described as a TLR9 cofactor based on its ability to bind CpG DNA, interact with 
TLR9 and enhance TLR9 delivery to endosomes in response to its ligand (Tian et al., 2007). 
HMGB proteins may be universal mediators of innate immunity, as they are required for normal 
inflammatory responses to nucleic acids. The multifunctional protein granulin is present at high 
levels in serum as progranulin. Granulin processing is required for subsequent contribution to 
TLR9 signalling, as granulin fragments help deliver CpG DNA to the appropriate compartment 
to promote TLR9 responses (Park et al., 2011). 
 
The use of diverse co-receptors and accessory molecules (summarised in Table 1.4), although 
sometimes common to different TLRs, but used in various combinations, increases the 
complexity of the mechanisms of ligand recognition and TLR signalling and allows ligand 
discrimination by different TLRs. 
 
As described above, TLRs can also recognise endogenous ligands - generated by tissue injury, 
damaged or dying cells as well as tumour cells - that trigger inflammatory responses (Table 
1.4). Endogenous ligands include degradation products of the ECM such has hyaluronan 
fragments, heat shock proteins, HMGB1 and self nucleic acids (Kawai and Akira, 2010). SAA, 
an acute phase protein whose concentration can increase up to 1,000-fold early upon onset of 
inflammation, has been reported to be a TLR2 ligand, leading to NF-κB activation (Cheng et al., 
2008) and IL-6 secretion (O'Reilly et al., 2014). MicroRNAs (described in section 1.7.6.2) have 
also been reported to be intracellular TLR ligands (Fabbri et al., 2012).  
1.7.4 Structure and activation 
All TLRs share a conserved modular structure. They are type I transmembrane proteins - N-
terminal is outside the membrane - composed of three major domains: 1) the ectodomain, 
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mostly composed of blocks of leucine-rich repeats that mediate ligand recognition; 2) a single 
transmembrane α-helix domain and 3) an intracellular domain, containing the TIR domain 
required to trigger downstream signal transduction following receptor engagement. About 80% 
of the polypeptide chain is above the plasma membrane (for TLRs 1, 2, 4, 5 and 6) or into the 
endosomal vesicle (for TLRs 3, 7, 8 and 9). The leucine-rich repeat units adopt a curved, 
solenoid shape, with conserved residues forming the hydrophobic core of each leucine-rich 
repeat. The inner surface of the solenoid, where specific molecular recognition takes place, 
presents side chains of variable residues, generating a wide range of binding specificities for 
diverse biological molecules (Beutler, 2009; Gay et al., 2006).  
Ligand recognition and binding is a crucial step to initiate the homo- or heterodimerisation of the 
receptor, which induces a series of conformational changes in the receptor. The first 
conformational change following receptor crosslinking takes place in the C-terminal region of 
the ectodomain, allowing stable receptor-receptor interactions. This in turn promotes the 
rearrangement of the transmembrane helices, and allows signal transduction to occur. The 
intracellular TIR domain is required for coupling extracellular dimerisation to downstream 
signalling adaptor molecules (Gay et al., 2006).  
 
A number of proteins play important roles in TLR expression and activation. Glucose-regulated 
protein of 94 kDa (GRP94) - found in the endoplasmic reticulum - mediates protein folding, and 
is necessary for the function of TLR1, TLR2, TLR4, TLR5, TLR7 and TLR9. GRP94 is required 
for the surface expression of TLR1, TLR2 and TLR4, and for the maturation and cleavage of 
TLR9. By mediating the folding and maturation of TLRs, GRP94 allows them to exit the 
endoplasmic reticulum. Protein associated with TLR4 A is also important for the maturation of 
multiple TLRs and may act as a co-chaperone for GRP94, because these two proteins interact 
to ensure that the unique requirements of TLR folding are fulfilled (Lee et al., 2012). 
TLR3, TLR7, TLR8 and TLR9 are sequestered in the endoplasmic reticulum and are delivered 
to the endosomes via the Golgi apparatus. In the endosomes, they are processed by lysosomal 
proteases including cathepsins and asparagine endopeptidase, and become functional 
receptors that encounter and respond to their specific ligands (Blasius and Beutler, 2010; Kawai 
and Akira, 2011). Uncoordinated 93 homolog B1 is an endoplasmic reticulum-resident 
membrane glycoprotein required for endosomal TLR responses that associates with nucleic 
acid-sensing TLRs via their transmembrane domains and mediates their delivery to 
endolysosomes. Another protein involved in TLR trafficking is adaptor protein 3, member of a 
family of tetrameric complexes that mediate the sorting of membrane proteins in the secretory 
and endocytic pathways (Nakatsu and Ohno, 2003). Adaptor protein 3 recruits cargo proteins 
into endosomes for delivery to lysosomes and lysosome-related organelles. A mutation in a 
subunit of adaptor protein 3 reduced IFN expression in response to CpG, suggesting a role for 
adaptor protein 3 in recruiting TLR9 to lysosomes (Sasai et al., 2010). Whether other 
endosomal TLRs also require adaptor protein 3 for trafficking is not yet known (Lee et al., 2012).  
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1.7.5 TLR signalling pathways 
TIR-containing receptors do not have enzymatic activity and rely on the adaptor proteins to 
trigger the inflammatory response. Once TLRs are activated, they recruit a specific set of 
adaptor proteins that form distinct complexes, tailoring a specific response to a particular ligand. 
Adaptors also contain TIR domains, which are rearranged following receptor dimerisation, 
providing the binding specificity required to recruit the appropriate adaptors (Gay et al., 2006). 
The TIR-domain-containing adaptor proteins involved in TLR signalling pathways are: 1) 
myeloid differentiation gene product 88 (MyD88), 2) MyD88 adaptor-like protein (MAL or TIR 
domain-containing adaptor protein (TIRAP)), 3) TIR domain-containing inducing IFNβ (TRIF or 
TIR-containing adaptor molecule 1 (TICAM1)) and 4) TRIF-related adaptor molecule (TRAM or 
TICAM2) (O'Neill and Bowie, 2007). 
 
1.7.5.1 The MyD88-dependent pathway 
MyD88 is a TIR-containing adaptor protein used by all TLRs except TLR3 (Kawai and Akira, 
2011). MyD88 recruitment to TLR2 and TLR4 requires another TIR domain-containing adaptor 
called MAL, which is a bridging adaptor that links MyD88 to the TLR (Fitzgerald et al., 2001; 
Horng et al., 2001). MyD88 also possesses a death domain, involved in its interaction with IL-
1R-associated kinase 4 (IRAK4) death domain (Flannery and Bowie, 2010). The conformational 
changes induced by receptor crosslinking leads to the sequential recruitment of several layers 
of MyD88, IRAK4 and IRAK2 monomers, forming the Myddosome signalling complex (Gay et 
al., 2011; Lin et al., 2010). IRAK1 is next recruited and activated, leading to its dissociation from 
the Myddosome and association with TNFα receptor-associated factor 6 (TRAF6). Further 
downstream signalling proteins associate with TRAF6, ultimately leading to NF-κB activation as 
well as MAPK and downstream transcription factors activation (Fig 1.11) (Kawai and Akira, 
2010; O'Neill et al., 2013). The TIR domain plays a crucial role in the activation of TLR-induced 
signalling. This is emphasised by the fact that some pathogens have developed innate immune-
evasion strategies by producing molecules containing homologues of the TIR domain that 
interfere with TLR2-MyD88-MAL signalling pathway (Askarian et al., 2014). 
TLR7/8 and TLR9 also signal through the MyD88-dependent pathway and this can either lead 
to NF-κB activation or alternatively - and exclusively in plasmacytoid DCs TLR7 and TLR9 
(Gilliet et al., 2008) - to the induction of type I IFN via binding of IFN-regulatory factor 7 (IRF7) to 
MyD88 (Kawai and Akira, 2010; O'Neill et al., 2013) (Fig 1.11). 
Typically, TLR2 stimulation induces the production of pro-inflammatory cytokines via NF-κB 
activation. However, it has been reported that a MyD88-, IRF3- and IRF7-dependent type I IFN 
production - requiring TLR2 internalisation - is triggered by viral infection exclusively in 
inflammatory monocytes, suggesting a cell-type and ligand-specific response (Barbalat et al., 
2009). 
 
Figure 1.11. TLR signalling pathways in humans and mice.  
TLR5, TLR11, TLR4, and the heterodimers of TLR2-TLR1 or TLR2-TLR6 – and potentially TLR2-TLR10 - bind to 
their respective ligands at the cell surface, whereas TLR3, TLR7–TLR8, TLR9 and TLR13 localise to the 
endosomes, where they sense microbial and host-derived nucleic acids. TLR4 is found expressed in both the 
plasma membrane and the endosomes. TLR signalling is initiated by ligand-induced dimerisation of the receptor. 
Subsequently, the Toll–IL-1-receptor (TIR) domains of TLRs engage TIR domain-containing adaptor proteins (either 
myeloid differentiation primary-response protein 88 (MyD88) and MyD88-adaptor-like protein (MAL), or TIR domain-
containing adaptor protein inducing IFNβ (TRIF) and TRIF-related adaptor molecule (TRAM)). TLR4 moves from the 
plasma membrane to the endosomes in order to switch signalling from MyD88 to TRIF. Engagement of the 
signalling adaptor molecules stimulates downstream signalling pathways that involve interactions between IL-1R-
associated kinases (IRAKs) and the adaptor molecules TNF receptor-associated factors (TRAFs), leading to the 
activation of the mitogen-activated protein kinases (MAPKs), JUN N-terminal kinase (JNK) and p38, and 
transcription factors. Two important families of transcription factors that are activated downstream of TLR signalling 
are nuclear factor-κB (NF-κB) and the interferon-regulatory factors  (IRFs), but other transcription factors, such as 
cyclic AMP-responsive element-binding protein (CREB) and activator protein 1 (AP1), are also important. A major 
consequence of TLR signalling is the induction of pro-inflammatory cytokines, and in the case of the endosomal 
TLRs, the induction of type I interferons (IFNs). Additional abbreviations: dsRNA, double-stranded RNA; IKK, 
inhibitor of NF-κB kinase; LPS, lipopolysaccharide; MKK, MAP kinase kinase; RIP1, receptor-interacting protein 1; 
rRNA, ribosomal RNA; ssRNA, single-stranded RNA; TAB, TAK1-binding protein; TAK, TGFβ-activated kinase; 
TBK1, TANK-binding kinase 1; TLR, Toll-like receptor. (Adapted from O’Neil 2013) 
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Studies using MyD88 KO mice showed that type I IFN induction via the transcription factor IRF3 
and the delayed NF-κB activation that are downstream of TLR4 were MyD88-independent 
(Yamamoto et al., 2002), suggesting the existence of an alternative signalling pathway.  
  
1.7.5.2 The TRIF-dependent pathway 
In contrast to the MyD88-dependent pathway, TLR3 and TLR4 activate a distinct signalling 
pathway, where TRIF is recruited to the receptor instead of MyD88 (Hoebe et al., 2003; Oshiumi 
et al., 2003a; Yamamoto et al., 2003a; Yamamoto et al., 2002). TRIF recruits either TRAF6, 
which activates the NF-κB and MAPK pathways, or TRAF3, activating IRF3 and the induction of 
type I IFN genes (Fig 1.11).  
In the case of TLR4, an additional TIR domain-containing molecule, TRAM, is used as the 
bridging molecule, which helps recruit TRIF to the TLR4 TIR domain (Fitzgerald et al., 2003; 
Oshiumi et al., 2003b; Yamamoto et al., 2003b). TLR4 is the only TLR activating both the 
MyD88- and TRIF-dependent pathways. TLR4 activates sequentially the MAL-MyD88 pathway 
to trigger NF-κB and MAPK activation and the TRAM-TRIF pathway to induce IRF3 as well as 
the late-phase activation of NF-κB and MAPK. The TRIF-dependent pathway relies on 
endocytosis of TLR4 and its trafficking to the endosome, where it forms a signalling complex 
with TRAM and TRIF, rather than MAL and MyD88 (Barton and Kagan, 2009). As a 
consequence, TLR4 activates the MyD88-dependent pathway earlier than the TRIF-dependent 
pathway. This emphasises the importance of subcellular localisation for differential signalling by 
TLRs (Kawai and Akira, 2010; O'Neill et al., 2013).  
TLR10 recruits MyD88, but its signalling pathway has not been elucidated yet, and one report 
failed to show the activation of NF-κB- or IFNβ-driven reporters, suggesting that TLR10 could 
trigger activation of alternative signalling pathways (Guan et al., 2010). 
The TLR signalling pathways are summarised in Figure 1.11. 
1.7.6 Regulation of TLR signalling 
TLR activation is essential to initiate innate immune responses and modulate the quality and 
extent of the adaptive immunity. However, overactivation or dysregulation of TLRs and 
molecules involved in their signalling pathway may lead to severe acute and chronic 
inflammatory conditions and autoimmunity. A negative regulation of TLR-induced responses is 
therefore necessary to reduce inflammation and avoid its deleterious effects. Many negative 
regulators have been identified and can be soluble, membrane bound or intracellular (Kawai 
and Akira, 2010; Liew et al., 2005b). They are summarised in Table 1.5. 
 
1.7.6.1 Soluble TLRs 
The first reported, and best-described, naturally-occurring soluble form of a TLR is sTLR2, 
which was found to modulate TLR2-mediated responses. It corresponds to the extracellular 
domain of membrane-bound TLR2. sTLR2 was first found in human plasma and breast milk as 
Table 1.5 Negative regulators of TLRs in humans 
Regulator Expression and induction Targeted TLR Suggested mechanism 
sTLR2 
Constitutively expressed in breast 
milk, plasma, saliva and amniotic 
fluid 
TLR2 Blocks interaction of TLR2 with its ligands (decoy receptor) and co-receptor CD14  
sTLR4 Constitutively expressed in saliva TLR4 Blocks interaction of TLR4 and MD2 
sTLR9 ND TLR9 Blocks interaction of TLR9 with its ligands (decoy receptor) 
RP105 LPS-induced in several cell types TLR4 Inhibits LPS binding to TLR4-MD2 
ST2 LPS-induced expression in macrophages TLR2,4,9 Sequesters MyD88 and MAL 
SIGIRR 
Mainly expressed by epithelial cells 
and immature DCs, but 
downregulated by activation 
TLR4,9 Interacts with TRAF6 and IRAK 
TRAILR Constitutively expressed in most cells TLR2,3,4 Stabilises Iκ-Bα 
MyD88s  LPS-induced expression, mainly in spleen TLR4 Inhibits phosphorylation of IRAK1 
IRAKM LPS-induced expression by monocytes TLR4,9 Inhibits phosphorylation of IRAK1 
IRAK1c ND ND Interferes with TLR signalling 
IRAK2c/d ND ND Prevent recruitment of MyD88 
SARM LPS-induced TLR3,4 Inhibits TRIF-dependant signalling 
TAG LPS-induced TLR4 Disrupts TRIF-TRAM complex and promotes TLR4 degradation 
SOCS1 LPS- and CpG-induced expression in macrophages TLR4,9 Mediates MAL degradation 
TRIAD3A Constitutively expressed in most cells and tissues TLR4,9 Ubiquitylates TLRs 
β-arrestin LPS-induced TLR4 Prevents TRAF6 oligomerisation 
PI3K Constitutively expressed by most cells TLR2,3,4,5,9 Inhibits p38, JNK and NF-κB function 
TOLLIP Constitutively expressed in most tissues TLR2,4 Autophosphorylates IRAK1 
TRAF1 ND TLR3 Inhibits TRIF-dependant signalling 
TRAF4 ND TLR2,3,4,9 Inhibits TRIF- and TRAF6-dependent signalling 
A20 LPS-induced expression in macrophages TLR2,3,4,5,9 
De-ubiquitylates TRAF6, Suppresses 
TRAF6 and RIP1 
TANK Ligand-induced in macrophages, B cells, cDCs and glomeruli TLR2,4,5,6,7,9 Inhibits TRAF6 ubiquitination 
SHP-1 AMPK-induced expression in macrophages and splenocytes TLR1,2,3,4,5,6 
Suppresses IRAK1 and IRAK2- Inhibits 
TRAF6 ubiquitination and suppresses p65 
WWP1 ND TLR4 Ubiquitylates and mediates TRAF6 degradation 
BCAP Agonist-induced in B cells and DCs TLR2,4,9 Binds PI3K and inhibits TLR responses 
CYLD Inducible in T and B cells ND Inhibits TRAF 2 (and to a lesser extent TRAF6) ubiquitination 
TRIM30α Agonists-induced TLR4 Targets TAB2 and TAB3 for degradation 
Atg16L1 Inducible in Paneth cells TLR3,4 Suppresses inflammasome activation 
Zc3h12a Inducible in macrophages and cDCs Several TLRs Affects IL-6 and IL-12p40 mRNA stability 
Tristeraprolin Inducible in macrophages and cDCs Several TLRs Affects TNF mRNA stability 
ATF3 Inducible in macrophages and cDCs TLR4 
Affects mRNA stability and prevents IL-6 
and IL-12p40 transcription 
Pin1 Agonist-induced in macrophages TLR3 Degrades IRF3  
DUBA  Agonist-induced TLR3,4,9 Suppresses IRF3 and IRF7 
miR-105 Many cell types TLR2 Decreases receptor mRNA levels 
miR-223 Many cell types TLR3,4 Decreases receptor mRNA levels 
let7i, let7e Many cell types TLR4 Decreases receptor expression 
Abbreviations: ND, not determined; RP105, radioprotective 105; ST2, Suppressor of tumorigenicity 2; SIGIRR, single 
immunoglobulin IL-1R-related molecule; TRAF6, TNF receptor-associated factor 6; TRAILR, TNF-related apoptosis-
inducing ligand; IRAK1, interleukin receptor-associated kinase1; SARM, sterile alpha and HEAT-Armadillo motifs; TAG, 
TRAM adaptor with GOLD domain; SOCS1, suppressor of cytokine signaling 1; TRIAD3A, Triad-domain containing protein 
3A; PI3K, phosphoinostol-3-kinase; JNK, c-jun N-terminal Kinase; p38, p38 mitogen activated protein kinase; TOLLIP, Toll-
interacting protein; TANK, TRAF family member-associated NF-κB activator; SHP-1, Src homology-2 containing tyrosine 
phosphatase-1; AMPK, AMP-activated protein kinase; WWP1, WW domain containing E3 ubiquitin protein ligase 1; BCAP, 
B-cell adapter for PI3K; CYLD, tumor suppressor cylindromatosis; TRIM30α, tripartite-motif 30α. ATF3, activating 
transcription factor; peptidyl-prolyl isomerase Pin1; DUBA, Deubiquitylating enzyme A. (Adapted from Trompouki, 
Hatzivassiliou et al. 2003; Liew, Liu et al. 2005; Liew, Xu et al. 2005; Saitoh, Tun-Kyi et al. 2006; Hazeki, Nigorikawa et al. 
2007; Kawai and Akira 2007; Kayagaki, Phung et al. 2007; Brikos and O'Neill 2008; Kenny and O'Neill 2008; Shi, Deng et 
al. 2008; Sun 2008; Kawagoe, Takeuchi et al. 2009; Zunt, Burton et al. 2009; Kawai and Akira 2010; McGettrick and 
O'Neill 2010; Chockalingam, Cameron et al. 2011; Yuk, Shin et al. 2011; Ni, MacFarlane et al. 2012; Troutman, Hu et al. 
2012; Virtue, Wang et al. 2012; Lin, Xu et al. 2013).  
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well as in pig and mouse plasma (LeBouder et al., 2003), and later reported present in amniotic 
fluid and saliva (Dulay et al., 2009; Kuroishi et al., 2007). sTLR2 is secreted by monocytes upon 
stimulation of TLR2 or other TLRs, or by non-TLR mediated cell activation, and data suggested 
that it originates from proteolytic cleavage of membrane-bound TLR2 (LeBouder et al., 2003). 
sTLR2 was demonstrated to exert an anti-inflammatory effect in vitro and in vivo by inhibiting 
TLR2-mediated CXCL8, CCL2, CXCL1/KC (murine counterpart of human CXCL3), TNFα 
secretion as well as NF-kB activation. It exerts its modulatory effect by sequestering the ligand 
(decoy receptor) and by disrupting the interaction between TLR2 and its co-receptor CD14, as 
sTLR2 was found to associates with CD14 (Kuroishi et al., 2007; LeBouder et al., 2003; Raby et 
al., 2009). Iwami et al. reported the existence of an alternatively spliced variant of mouse TLR4 
mRNA that, when transiently transfected in CHO cells, expressed a partially secreted soluble 
form of TLR4 (Iwami et al., 2000). The existence of four human TLR4 splice variants was later 
described (Jaresova et al., 2007), and a functional sTLR4 was found in saliva with a modulatory 
effect on TNFα secretion (Zunt et al., 2009). Two other negative modulators, a naturally-
occurring sTLR9 (Chockalingam et al., 2011) and sTLR3 generated by cloning of the 
extracellular domain of TLR3 (Sun et al., 2006) have been described. By contrast, a naturally 
occurring sTLR5, only found in fish, has shown some synergistic activity with the membrane-
bound TLR5 (Tsoi et al., 2006; Tsujita et al., 2006).  
 
1.7.6.2 Transmembrane and intracellular modulators 
TLR signalling pathways are modulated at multiple levels and by molecules assuming various 
functions, including splice variants for adaptors or related proteins, ubiquitin ligases, 
deubiquitinases, transcriptional regulators and microRNAs. Regulators include PI3K, TOLLIP, 
SOCS1, A20, SIGRR, TRIAD3A, TANK and TRAILR, and the ligand-induced MyD88s, IRAKM 
and ST2L. They are constitutively expressed in diverse cells and tissues. Negative regulators 
act by a variety of ways, for example, by direct suppression of a TLR signalling pathway protein 
activity (ST2L), by inhibiting signal intermediate ubiquitination (TANK), by inhibiting transcription 
factor activity (SOCS1) or by affecting messenger RNA stability such as the zinc-finger RNAse 
Zc3h12a (Kawai and Akira, 2010; Liew et al., 2005b). 
MicroRNAs are small (21-24 nucleotides) RNA molecules and are important regulators of gene 
expression. MicroRNAs decrease target mRNA levels - through either mRNA decay or 
translational inhibition - and control the protein content of a cell. Their expression is highly 
regulated, and they function as immunomodulators. Indeed, microRNAs can control TLR 
expression and target many TLR signalling proteins, transcription factors, cytokines and 
chemokines. In turn, targets can reciprocally control the expression and function of microRNAs. 
While some microRNAs are ubiquitous, such as miR-155, miR-146 and miR-21, TLR activation 
seems to result in the sequential induction of important microRNAs that can control the strength 
and longevity of an inflammatory response (Huntzinger and Izaurralde, 2011; O'Neill et al., 
2011). TLR negative regulators are summarised in Table 1.5. 
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Cooperation and synergy between various TLRs has been demonstrated (Trinchieri and Sher, 
2007). TLR signal transduction can also be affected, in a negative or positive way, by the 
activity, interaction and crosstalk with other signalling pathways. 
1.7.7 TLR interaction with other signalling pathways 
In addition to their first-responder roles in inducing an inflammatory response to invading 
pathogens, TLRs can network with other components of the innate or adaptive immune system. 
Many reports studying the involvement of TLRs, NLRs, CLRs and other PRRs in the recognition 
of various pathogens, including mycobacteria, viruses and fungi - notably using KO mice - have 
demonstrated that none of them is responsible for the full innate immune response but rather 
act in synergy to mount an appropriate response and circumvent pathogen evasion 
mechanisms (Kawai and Akira, 2011; O'Neill, 2008). Notably, dectin-1 collaborates with TLR2 or 
TLR4 to trigger cytokine production upon recognition of C. albicans and zymosan (Goodridge 
and Underhill, 2008). Synergy has also been shown between TLRs and the complement system 
to produce pro-inflammatory molecules. In particular, TLRs showed a positive modulatory effect 
on C5a-induced responses by targeting a negative modulator of C5a receptor (Raby et al., 
2011). Similarly, signal transduction crosstalks exist between TLRs and other signalling 
pathways. Notably in macrophages, IFNγ - and its downstream JAK/STAT signalling pathway - 
has been reported to enhance TLR responses by increasing TLR expression or blocking TLR-
induced feedback-inhibition loops, such as the suppression of TLR-mediated IL-10 expression 
and downstream STAT3 activation (Hu et al., 2006; Schroder et al., 2006; Spiller et al., 2008).  
TLR and IL-6 signalling pathways are also inter-connected. While IL-6 is an obvious 
downstream transducer of TLR-driven pro-inflammatory responses, several endogenous TLR 
agonists, such as SAA and HMGB1, are regulated by STAT3, downstream of IL-6 (Tye and 
Jenkins, 2013). IL-6 trans-signalling via STAT3 has been shown to play an important role in 
modulating TLR4-driven pro-inflammatory responses (Greenhill et al., 2011). TLR and IL-6 have 
been the particular focus of interest in cancer - notably in cancers of the liver, colon, lung and 
pancreas - where there is a recurrent dysregulated co-activation of STAT3 and NF-κB, the 
archetypal downstream transcription factors of the IL-6 and TLR families. These transcription 
factors are of particular interest due to their ability to propagate inflammation, which plays a 
crucial role in the promotion of carcinogenesis (Mansell and Jenkins, 2013). In gastric cancer, 
IL-6 signalling has been shown to modulate TLR responses by a STAT3-driven upregulation of 
TLR2, promoting tumorigenesis independently of tumour inflammation (Tye et al., 2012).  
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1.8 Hypotheses, aims and objectives of the project 
The work conducted to date in humans and mice, and discussed in previous sections, 
demonstrated the pivotal role that peritoneal mesothelial cells play in the initiation, progression 
and resolution of inflammatory responses in the peritoneal cavity. Their activity is critical to 
maintaining the integrity of the peritoneal membrane, which is required for an efficient PD 
therapy. The critical role that the TLR family of innate immune receptors and the IL-6 cytokine 
and its receptors play in the inflammatory response has been well documented, and discussed 
previously. However, the expression of TLRs in HPMC and their role in HPMC-mediated pro-
inflammatory responses to infection have not been investigated. Similarly, the capacity of IL-6 
and its receptors to modulate microbial-induced peritoneal inflammation and TLR-mediated 
peritoneal responses remained to be fully evaluated.  
Given the pivotal role that HPMC play in peritoneal inflammation, it was hypothesised in the 
present study that HPMC express TLRs, and that these receptors are critical to HPMC-
mediated pro-inflammatory responses to most common pathogens affecting PD. Furthermore, it 
was hypothesised that IL-6 and its receptors may modulate the putative expression and activity 
of TLRs in HPMC. The putative activity of TLRs and IL-6 and its receptors in HPMC-mediated 
responses may contribute to guaranteeing a prompt, strong and efficient response to the 
microbial challenge and a rapid clearance of infection, and thus may impact on PD outcomes. 
The aim of the project was therefore to evaluate the role that TLRs and IL-6/ IL-6 receptors play 
in peritoneal inflammatory responses to infection, with particular emphasis on the responses of 
HPMC in vitro and in vivo. 
 
Objectives 
This study sought to: 
1. Characterise the expression of TLRs in HPMC. 
2. Evaluate the capacity of HPMC in vitro to mount pro-inflammatory responses to microbial 
components through TLRs and its main co-receptor, CD14. 
3. Study the modulation of the putative expression of TLRs in HPMC.  
4. Evaluate the capacity of well-documented modulators of pro-inflammatory responses, soluble 
TLR2 (sTLR2) and the IL6/sIL6R, to modulate TLR-mediated HPMC responses in vitro. 
5. Evaluate further the effect of sTLR2 on peritoneal inflammation by using mouse models of 
peritoneal inflammation and infection. 
6. Study in more detail how the IL-6/sIL-6R trans-signalling complex contributes to peritoneal 
responses in vivo. 
7. Develop a suitable in vivo model of bacterial peritonitis to address some of the questions 
detailed above. 
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RESULTS 
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2.1 Expression and activity of TLRs in human peritoneal mesothelial 
cells 
 
The ability of HPMC to directly respond to a bacterial challenge has been suggested, but the 
responses have not been fully characterised (Kato et al., 2004; Visser et al., 1995b). As 
discussed previously (Introduction, section 1.7.1), only HPMC expression of TLR3 and 
responses to TLR3-specific agonists were clearly demonstrated (Wornle et al., 2009). 
Therefore, a full characterisation of the expression of TLR family members by primary HPMC 
remained to be conducted, and the capacity of HPMC to mediate inflammatory responses via 
TLRs following stimulation with Gram-positive and Gram-negative bacteria remained to be 
evaluated.  
 
Therefore, the first part of this study aimed to evaluate the potential involvement of TLRs in 
HPMC-mediated microbial recognition and responses during a peritonitis episode. To this end, 
the expression of different TLR family members in HPMC as well as the ability of TLR-specific 
ligands to induce chemokine expression by HPMC was investigated. Furthermore, the effect of 
a clinically relevant bacterial-derived preparation on HPMC’s pro-inflammatory responses and 
its dependence on TLR activity was examined, as well as the effect of inflammatory cytokines 
and TLR ligands on TLR expression in HPMC. 
2.1.1 TLR expression in HPMC  
In order to fully characterise TLR family expression (TLR1-TLR10) in HPMC, real-time PCR 
(qRT-PCR) analysis of both growth arrested un-stimulated mesothelial cells and cells growing in 
medium containing 0.1% (v:v) or 10% (v:v) FCS was performed. This analysis showed a range 
of relative Tlr mRNA expression, from the most highly expressed members (Tlrs 1-3), those 
which were expressed at low to moderate levels (Tlrs 4-6) to barely detectable or undetectable 
levels (Tlrs 7-10) (Fig 2.1.1). A comparison with Tlr mRNA expression in peripheral blood 
mononuclear cells (PBMC) revealed lower levels of all Tlrs in HPMC, except for Tlr3 (Table 
2.1.1). 
 
In order to evaluate the capacity of HPMC to respond to Gram-positive bacteria through TLR2 
and Gram-negative bacteria through TLR4, confirmation of the qRT-PCR results for TLR2 and 
TLR4 expression by RT-PCR and flow cytometry was sought first (Fig 2.1.2A and 2.1.2B, 
respectively). TLR1 and TLR6 expression was also tested, as both receptors are capable of 
forming heterodimers with TLR2 thereby allowing the recognition of triacyl (TLR2/TLR1) and 
diacyl lipopeptides (TLR2/TLR6) (Kawai and Akira, 2010). Clear bands corresponding to Tlr2 
(632 pb) and Tlr6 (500 bp) were obtained by RT-PCR, but no band was observed for Tlr4 (781 
bp) (Fig 2.1.2A). The presence of TLR1 and TLR2 on the cell surface of HPMC was confirmed 
by flow cytometric analysis (Fig 2.1.2B); no cell-surface expression of TLR6 was detectable, in 
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Figure 2.1.1. TLR expression in primary HPMC. 
Analysis of Tlr1-Tlr10 mRNA expression in HPMC was performed by qRT-PCR. Specific primers were used to 
amplify human Tlr1-Tlr10 cDNAs prepared from total RNA extracted from non-stimulated HPMC. Expression of each 
mRNA was determined by calculating the 2-ΔCt, as described under Materials and Methods, and was expressed 
relative to the expression of the housekeeping gene GAPDH. Results (±SD) presented are representative of five 
experiments performed using primary cells from different donors. 
qRT-PCR evaluation of Tlr1 to Tlr10 mRNA expression in HPMC (as 
shown in Figure 2.1.1) and PBMC. Results are expressed as the ratio of 
the Tlr gene (2-ΔCt) to the housekeeping gene GAPDH (2-ΔCt) for each cell 
type as described under Materials and Methods, and as the relative 
expression of each Tlr in HPMC to that in PBMC (HPMC/PBMC). Results 
shown are of one experiment representative of four experiments 
performed using HPMC and PBMC from different donors.  
Table 2.1.1. Relative TLR expression in HPMC 
D
TLR2 Ab IgG control
A
E
Figure 2.1.2. Analysis of TLR1, TLR2, TLR4 and TLR6 expression in primary HPMC. 
(A) TLR2, TLR4, TLR6 and β-actin mRNA expression in non-stimulated HPMC was assessed by RT-PCR followed 
by agarose gel electrophoresis using specific primer pairs, as described under Materials and Methods. (B) Cell-
surface expression of TLR2, TLR4, TLR1 and TLR6 was assessed by flow cytometry in growth-arrested HPMC 
using specific antibodies (open plots). Control fluorescent histogram profiles corresponding to the immunostaining 
with isotype-matched control antibodies are also shown (shaded plots). Results are representative of seven different 
cell lines from individual donors. In each experiment, human PBMC were used as a positive control for TLR4 and 
TLR6 expression. (C) In addition to (B), the cell-surface expression of TLR4 in HPMC was assessed by flow 
cytometry following cell stimulation with IL-1β (100 pg/ml) and Pam3Cys (2 µg/ml). Data presented are 
representative of five experiments performed with HPMC derived from five different donors. (D) Non-stimulated 
HPMC were tested for TLR2 expression by immunocytochemistry using the TLR2-specific mAb TLR2.5. An isotype-
matched antibody was used as a staining control. Results are representative of immunostaining of two different 
primary cells. (E) Primary HPMC originating from four different donors were tested for TLR2 expression by flow 
cytometry using the TLR2-specific mAb TLR2.1. The negative control staining with the isotype control antibody 
(shaded plot) was identical for all donors. 
Figure 2.1.3. Analysis of TLR2 and TLR4 expression in freshly-isolated primary HPMC. 
Mesothelial cells were tested for TLR2 and TLR4 cell-surface expression immediately after tryptic digestion of 
omental tissue. Cells were stained for TLR2, TLR4 and the HPMC-specific marker CA125, and analysed by flow 
cytometry. Results shown are representative of four experiments performed using primary cells from different 
donors. 
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spite of the positive detection of Tlr6 mRNA. Similarly, no TLR4 protein expression could be 
detected on the mesothelial HPMC surface, either on growth-arrested cells (Fig 2.1.2B) or 
following stimulation with various stimuli such as the pro-inflammatory cytokine IL-1β and the 
specific TLR2 and TLR4 ligands Pam3-Cys-Ser-(Lys)4 (Pam3Cys) and LPS, respectively (Fig 
2.1.2C and data not shown). By contrast, TLR6 and TLR4 cell-surface expression was readily 
detectable by flow cytometry in resting PBMC used as controls (Fig 2.1.2B). TLR2 expression 
was also consistently detected in HPMC by immunocytochemistry (Fig 2.1.2D), although 
expression levels showed a substantial inter-subject variation, as indicated by the flow 
cytometric analysis of individual HPMC isolates obtained from different donors (Fig 2.1.2E). 
 
The phenomenon of ‘LPS tolerance’ is associated with loss of LPS responsiveness, partly as a 
consequence of TLR4 down-modulation following persistent exposure to endotoxin challenge 
(Nomura et al., 2000). Thus, to test the possibility that LPS tolerance might have been 
responsible for the lack of detection of TLR4 in cultured HPMC, cells were tested by flow 
cytometry for TLR4 expression immediately following their isolation by tryptic digestion of 
normal omental tissue, instead of after 1-2 weeks in cell culture. HPMC displayed high cell 
surface expression of the HPMC-specific marker CA125 (Visser et al., 1995a) as expected. 
TLR2 expression was also detectable, as observed previously, but TLR4 was not detectable on 
the cell surface of HPMC primary isolates (Fig 2.1.3).  
2.1.2 HPMC responses to TLR2, TLR4 and TLR5 ligands 
To characterise HPMC responses to Gram-positive and Gram–negative bacteria, HPMC were 
treated with known ligands of TLR2/1 (Pam3Cys, PGN) and TLR4 (LPS) and a well-
characterised cell-free supernatant derived from a clinical isolate of Staphylococcus epidermidis 
termed SES, which has been previously used to investigate the regulation of Staphylococcal 
spp.-induced inflammation in vivo (Hurst et al., 2001; McLoughlin et al., 2003). The production 
of the CXCL8 and CCL2 chemokines and inflammatory cytokines TNFα and IL-6 was assessed. 
SES and the synthetic TLR2 ligand Pam3Cys induced a dose-dependent increase in CXCL8, IL-
6, CCL2 and TNFα levels (Fig 2.1.4). HPMC were also found to respond to PGN (Fig 2.1.4). 
The TLR4 ligand LPS had no effect on CXCL8, IL-6, CCL2 or TNFα secretion by HPMC (Fig 
2.1.4), even in the presence of LPS concentrations as high as 5 µg/ml (Fig 2.1.5A). As 
mentioned previously, cells may lose responsiveness to LPS, but certain genes have been 
reported to be resistant to LPS tolerance (Foster et al., 2007). The chemokine CCL5 belongs to 
this class of ‘non-toleriseable’ gene products, but its levels were not up-regulated following 
stimulation of HPMC by LPS at any dose tested (Fig 2.1.5B). 
 
Stimulation with the diacyl lipopeptide Pam2Cys (MALP-2 analogue, a TRL2/TLR6 ligand), also 
triggered a dose-dependent increase in CXCL8 secretion (Fig 2.1.6A), despite the undetectable 
cell-surface expression of TLR6 on HPMC. Zymosan is another TLR2/6 ligand, however HPMC 
did not respond to zymosan stimulation (Fig 2.1.6B). This result might be explained by a lack of 
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Dectin-1 expression in HPMC, the co-receptor required for zymosan-mediated responses in 
concert with TLR2/6 (Ikeda et al., 2008), and/or the extremely low levels of TLR6 expression in 
these cells, but this would require further investigation. 
 
The data previously presented demonstrated that although HPMC responded to Gram-positive 
bacterial ligands through TLR2, they were unable to respond to the TLR4 agonist and main 
component of the Gram-negative cell wall, LPS (Fig 2.1.4 and 2.1.5), as they lack TLR4 
expression (mRNA and protein). qRT-PCR data suggested low expression levels of TLR5 (Fig 
2.1.1), which is capable of recognising flagellin, a protein component of bacterial flagellum, 
commonly found in many Gram-negative bacteria (Hayashi et al., 2001). Therefore, the capacity 
of HPMC to respond to flagellin was tested. Flagellin induced a dose-dependent increase in 
CXCL8 secretion (Fig 2.1.6C), indicating that HPMC can mediate a selective response to Gram-
negative bacteria through TLR5 recognition of flagellin, but not through recognition of LPS. The 
ability of mesothelial cells to recognise Gram-negative bacteria was later confirmed when 
HPMC were stimulated with heat-killed E. coli bacteria and showed a dose-dependent 
(moderate) release of CXCL8 (Fig 2.1.6D). 
 
NF-κB activation downstream of TLR signalling was measured by electrophoretic mobility shift 
assay (EMSA) in nuclear extracts prepared from HPMC that had been treated with LPS, 
Pam3Cys, SES or Pam2Cys for different time intervals. The results of NF-κB activation 
experiments were consistent with the selective response of HPMC to TLR ligands described 
previously. NF-κB activation was sustained over a 3-4h period following stimulation with 
Pam3Cys, SES or Pam2Cys (Fig 2.1.7A). LPS stimulation however did not up-regulate NF-κB 
DNA-binding signal above that observed for the control growth-arrested non-stimulated cells 
(Fig 2.1.7A, top panel). To examine the NF-κB subunits activated by TLR2 signalling in HPMC, 
a ‘supershift’ EMSA analysis was performed using antibodies directed against specific NF-κB 
family members. This analysis identified NF-κB DNA-binding complexes consisting of the p50 
and p65 subunits for Pam3Cys, SES and Pam2Cys stimulations (Fig 2.1.7B). 
2.1.3 HPMC responses to TLR3 and TLR7/8 ligands 
To examine HPMC responses to viruses, HPMC were treated with known ligands for TLR3 
(Poly I:C, synthetic mimetic of dsRNA) and TLR7/8 (Imiquimod, synthetic mimetic of ssRNA), 
and the production of the chemokine CXCL8 was assessed. Poly I:C induced a response as 
strong as that to IL-1β, used as a positive control (Fig 2.1.8A). By contrast, imiquimod failed to 
induce CXCL8 release (Fig 2.1.8B), consistent with the lack of TLR7/8 mRNA expression in 
HPMC observed by using qRT-PCR (Fig 2.1.1). 
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Figure 2.1.7. Activation of NF-κB in HPMC by TLR ligands. 
(A) HPMC were stimulated for up to 4h with LPS (500 ng/ml), Pam3Cys (2 µg/ml), SES (neat), Pam2Cys (1 µg/ml) or 
left untreated (NS). At the indicated time points, nuclear extracts were prepared and NF-κB activation was analysed 
by EMSA, as described under Materials and Methods. Data presented is a representative result of three 
experiments performed using primary cells from different donors. (B) The composition of the NF-κB DNA binding 
complexes in HPMC stimulated with Pam3Cys, SES or Pam2Cys was determined by supershift EMSA analysis of 
nuclear extracts by using specific antibodies for the p65, p50, Rel-B, p52 and c-Rel subunits of NF-κB. Control 
samples without the addition of antibody are shown, and ‘supershifted’ complexes are indicated. Data presented is a 
representative result of three experiments performed using primary cells from different donors. 
Figure 2.1.8. Response of HPMC to viral TLR agonists. 
(A and B) HPMC were cultured for 24h in the presence of the indicated concentrations of poly I:C (TLR3 agonist) or 
Imiquimod (TLR7/8 agonist). Following incubation, CXCL8 levels in the cell-free culture supernatants were 
quantified by ELISA. Data presented are results (±SD) representative of two independent experiments performed 
using primary cells from different donors ( *, p < 0.05; **, p < 0.01 non-stimulated vs. stimulated cells). 
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2.1.4 Further evaluation of HPMC responses to SES 
Given the clinical relevance of the SES preparation in the context of Staphylococcal spp.-
induced peritoneal inflammation in PD patients, the mechanism used by SES to stimulate 
mesothelial cells was investigated further. HEK293 cells stably transfected with either TLR2 
(HEK-TLR2) or mock-transfected with a plasmid control (HEK-pDR2) were used. No TLR2 was 
detectable in the mock-transfected cells (Fig 2.1.9A, left panel), consistent with the well-
documented lack of constitutive expression of TLR2 (and TLR4) in these cells (Erridge et al., 
2007). By contrast, TLR2 was found highly expressed in HEK-TLR2 cell transfectants (Fig 
2.1.9A, right panel and 2.1.9B). The mock-transfected cells did not respond to SES stimulation 
at any dose tested (Fig 2.1.9C). The presence of serum, added as a source of sCD14 (HEK293 
cells do not express this TLR co-receptor), had no effect on the response of the mock-
transfected cells (Fig 2.1.9C). 
 
The TLR2-transfected cells responded to SES stimulation in a dose-dependent manner (Fig 
2.1.9C), which suggested that SES stimulation of HPMC is mediated at least in part by TLR2. 
The response of the TLR2-transfected cell line was increased in the presence of serum, 
suggesting that one or several serum components are involved in SES-induced TLR2 signalling 
(Fig 2.1.9C). An NF-κB reporter assay was used to further confirm the involvement of TLR2 in 
SES signalling. Whereas HEK-TLR2 cells did not show any NF-κB reporter activity in the 
absence of SES, regardless of the presence of serum, all SES concentrations tested triggered a 
7-fold increase in NF-κB activation (Fig 2.1.10A). In contrast, HEK cells transfected with TLR4 
and its cofactor MD2 (HEK-TLR4/MD2), and expressing high levels of TLR4 (Fig 2.1.10A, 
inset), showed no increase in NF-κB reporter activity in the absence or presence of SES and 
serum (Fig 2.1.10A), indicating a lack of involvement of TLR4 in governing responsiveness to 
SES. The HEK-TLR4 cell transfectants showed however a dose-dependent response to LPS 
(Fig 2.1.10B).  
 
SES may activate other pattern recognition pathways, in particular the NLRs NOD1 and NOD2. 
NOD1 and NOD2 recognise dipeptides derived from bacterial peptidoglycan (NOD1, Gram-
negative and several Gram-positive bacteria; NOD2, all Gram-negative and Gram-positive 
bacteria) (Inohara et al., 2001; Kawai and Akira, 2009). An analysis of HPMC responses to 
NOD1 and NOD2 specific agonists (D-glutamyl-meso-diaminopimelic acid/iE-DAP and muramyl 
dipeptide/MDP, respectively) revealed a modest induction of CXCL8 in response to iE-DAP and 
no induction or a slight inhibition in response to MDP (Fig 2.1.11A and B). These results are 
similar to the findings of Park et al. in murine mesothelial cells, which identified responses to 
NOD1, but not to NOD2 (Park et al., 2007).   
2.1.5 Examination of the involvement of CD14 in HPMC responses to SES  
In order to test whether CD14 was required for TLR2-mediated responses to SES in HPMC, 
first, the cell-surface expression of CD14 was analysed by flow cytometry. No cell-surface 
Figure 2.1.9. TLR2 and TLR4 expression by HEK cell transfectants. 
(A) TLR2 expression detected by immunocytochemistry using the TLR2.5 mAb in HEK293 cells stably transfected 
with a TLR2 expression vector (HEK-TLR2). HEK293 cells transfected with the empty plasmid vector (HEK-pDR2) 
were used to confirm the specificity of the staining. (B) Fluorescence profile of TLR2 expression in the HEK-TLR2 
cell transfectants obtained by staining with the PE-conjugated anti-TLR2 mAb TLR2.1, or its isotype-matched control 
IgG (shaded histogram), and analysis by flow cytometry. (C) HEK-pDR2 and HEK-TLR2 cell transfectants were 
stimulated for 15h with the indicated serial dilutions of SES in the presence or absence of 1% FCS. CXCL8 levels in 
the cell-free culture supernatants were quantified by ELISA. Data presented is a representative result of three 
experiments (±SD) performed in triplicate (*, p < 0.05; **, p < 0.01; ***, p < 0.001 HEK-pDR2 no serum vs. HEK-
TLR2 no serum, and HEK-TLR2 no serum vs HEK-TLR2 1% FCS).  
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Figure 2.1.10. NF-κB acivationin HEK-TLR2 and HEK-TLR4/MD2 cell transfectants. 
(A and B) HEK-TLR2 and HEK-TLR4/MD2 stable cell transfectants were transiently transfected with an NF-κB 
luciferase Firefly reporter and constitutive Renilla luciferase vectors and after 48h in culture they were stimulated 
(16h) with the indicated serial dilutions of SES (A) and concentrations of LPS in the presence of sCD14 and LBP 
(0.5 µg/ml and 0.1 µg/ml respectively) (B). NS, non-stimulated cells. Dual luciferase activity was subsequently 
assayed and the Firefly reporter results normalised against the Renilla signal obtained as the fold-change above the 
control. (A inset) Fluorescence profile of TLR4 expression in the HEK-TLR4 cell transfectants obtained by staining 
with the non-conjugated anti-TLR4 mAb HTA125, or its isotype-matched control IgG (shaded histogram), followed 
by incubation with a secondary PE-conjugated anti-mouse Ab and analysis by flow cytometry. Result are 
representative of three experiments. 
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Figure 2.1.12. Evaluation of the role of serum and CD14 in HPMC and leukocyte stimulation.  
(A) Flow cytometric analysis of HPMC immunostained with a PE-conjugated CD14 mAb in the presence or absence 
of 10% fœtal calf serum (FCS). Human PBMC were used as a positive control of CD14 expression; isotype-
matched control antibody staining is shown as shaded histograms. Data presented are results representative of six 
experiments performed with primary cells derived from separate donors. (B and C) HPMC were stimulated for 24h 
with Pam3Cys (2 µg/ml, B) or SES (neat, C) in the presence or absence of 0.1% FCS. NS, non-stimulated cells. 
Following incubation, CXCL8 levels in the cell-free culture supernatants were quantified by ELISA. NS, non-
stimulated cells. Data presented are representative of three experiments performed in triplicate (±SD) with primary 
cells derived from three different donors (*, p < 0.05; no serum vs. 0.1% serum).  
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Figure 2.1.11. Response of HPMC to NOD agonists. 
(A and B) HPMC were cultured for 24h in the presence of the indicated concentrations of D-glutamyl-meso-
diaminopimelic acid (iE-DAP, Nod1 ligand) or muramyl dipeptide (MDP, Nod2 ligand). Following incubation, CXCL8 
levels in the cell-free culture supernatants were quantified by ELISA. NS, non-stimulated cells. Data presented are 
results (±SD) representative of two independent experiments (*, p < 0.05; **, p < 0.01; ***, p < 0.001 non-stimulated 
vs. stimulated cells).  
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expression of CD14 was detected in HPMC regardless of serum, unlike PBMC, which 
expressed high levels of cell-surface CD14 (Fig 2.1.12A). This finding implied that if TLR2 
requires CD14 for efficient signalling in HPMC, the soluble form of the TLR co-receptor (sCD14) 
may be involved. CXCL8 production was therefore measured in HPMC treated with Pam3Cys 
and SES with or without serum, as a source of sCD14. Pam3Cys and SES triggered a 
significantly higher response in the presence of serum (Fig 2.1.12B and C). To investigate 
whether serum sCD14 was involved in enhancing the TLR2-mediated responses, stimulation 
experiments in the presence of serum using an anti-CD14 blocking antibody were performed. 
The anti-CD14 blocking antibody had no effect on SES-induced CXCL8 in HPMC (Fig 2.1.13A), 
while it significantly reduced CXCL8 production induced by both SES and LPS in PBMC (Fig 
2.1.13B). To directly investigate the role of sCD14 in the HPMC responses to SES, the cells 
were stimulated in the presence or absence of purified human natural sCD14. As shown in Fig 
2.1.13C, SES-induced CXCL8 secretion was not altered by the addition of sCD14. Therefore, 
these results indicated that CD14 is required for fully efficient SES-induced responses of PBMC, 
but not for those of HPMC. These observations however do not exclude the possibility that 
serum component(s) other than sCD14 may play a role in enhancing SES-induced signalling in 
HPMC.  
2.1.6 Evaluation of the effect of inflammatory cytokines and TLR ligands on 
HPMC TLR2 expression 
In view of the involvement of TLR2 in HPMC responses to Gram-positive bacteria-derived 
components demonstrated previously, and the capacity of this TLR to recognise a wide range of 
PAMPS and DAMPs, the modulation of TLR2 expression in HPMC was studied next. TLR2 
expression can be modulated in a diversity of cell types following activation with various stimuli, 
in particular cytokines and microbial ligands (Faure et al., 2001; Homma et al., 2004). Here, 
HPMC TLR2 cell-surface expression was examined by flow cytometry following treatment with 
different cytokines and the TLR2 ligand Pam3Cys. An up-modulation of TLR2 expression was 
detected following treatment for 1h or 30 min with IL-1β or IFNγ, respectively (Fig 2.1.14A and 
B), but not with Pam3Cys or TNFα at any time point tested (Fig 2.1.14C and D). To further 
characterise TLR2 modulation, experiments were subsequently carried out in which Tlr2 mRNA 
expression in HPMC was analysed by qRT-PCR. Tlr2 mRNA expression was significantly up-
regulated upon stimulation (3h) with the pro-inflammatory cytokine IL-1β and the TLR2 ligand 
Pam3Cys (Fig 2.1.15A), as previously described for epithelial cells (Sakai et al., 2004) and 
mouse pleural mesothelial cells (Hussain et al., 2008). The up-regulation of TLR2 protein upon 
stimulation with Pam3Cys was confirmed by immunocytochemistry (Fig 2.1.15B). By contrast, 
the pro-inflammatory cytokine TNFα and the TLR4 ligand LPS did not show any significant 
effect on TLR2 expression (Fig 2.1.15A). A similar examination of Tlr1 and Tlr6 mRNA 
expression following stimulation with a number of cytokines and TLR ligands failed to show any 
significant major changes compared to the level of expression of non-stimulated cells (Fig 
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Figure 2.1.13. Evaluation of the role of CD14 as a TLR co-receptor in HPMC stimulation. 
(A) HPMC were stimulated for 24h in medium containing 0.1% FCS and SES (1/10 dilution) in the presence or 
absence of an anti-CD14 blocking mAb (10 µg/ml). CXCL8 levels were quantified in the cell-free culture 
supernatants by ELISA. NS, non-stimulated cells. Shown are results (±SD) representative of three experiments 
performed with HPMC derived from different donors (*, p < 0.05 non-stimulated vs. stimulated cells). (B) PBMC 
were cultured overnight in medium containing 0.5% human AB serum, LPS (50ng/ml) or SES (1/80 dilution) in the 
presence or absence of an anti-CD14 blocking mAb (10 µg/ml). CXCL8 levels were quantified in the cell-free culture 
supernatants by ELISA. NS, non-stimulated cells. Data presented are representative of three experiments (±SD) 
performed with PBMC derived from three different donors (*, p < 0.05; ***, p < 0.001; stimulated cells in the absence 
vs. presence of anti-CD14 blocking mAb). (C) HPMC were stimulated for 24h with the indicated dilutions of SES in 
medium without serum, supplemented or not with purified human natural sCD14 (500 ng/ml). CXCL8 levels were 
quantified in the cell-free culture supernatants by ELISA. Data presented are representative of three experiments 
performed in triplicate (±SD) with HPMC derived from three different donors (*, p < 0.05 non-stimulated vs. 
stimulated cells). 
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Figure 2.1.14. Modulation of TLR2 cell-surface expression on HPMC by pro-inflammatory stimuli. 
The cell-surface expression of TLR2 in HPMC was assessed by flow cytometry following cell stimulation with 
Pam3Cys (2 µg/ml), IL-1β (100 pg/ml), IFNγ (10 ng/ml) or TNFα (100 pg/ml) for the indicated times. Control profiles, 
which correspond to immunostaining with the isotype-matched control antibody are also shown (shaded plots). Data 
presented are representative of five experiments performed with HPMC derived from five different donors. 
Pam3Cys
IL-1β
IFNγ
TNFα
B
A
C
D
BTLR2 Ab IgG control
NS Pam3Cys
TLR2 Ab
A
Tl
r2
 m
RN
A 
fo
ld 
ind
uc
tio
n
**
*
3h
24h
0
1
2
3
4
5
6
7
NS Pam3 LPS IL-1β TNFα
Figure 2.1.15. Analysis of the TLR2 modulation in HPMC by pro-inflammatory stimuli.  
(A) Tlr2 mRNA expression assessed by qRT-PCR following stimulation of HPMC for 3h or 24h with Pam3Cys (2 µg/
ml), LPS (250 ng/ml), IL-1β (100 pg/ml) or TNFα (100 pg/ml); NS, non-stimulated cells. Fold inductions were 
determined as described under Materials and Methods. Data presented are representative of three experiments 
performed in triplicate (±SD) with primary cells derived from three different donors (*, p < 0.05; **, p < 0.01; 
stimulated vs. non-stimulated). (B) TLR2 expression in HPMC detected by immunocytochemistry using the TLR2.5 
mAb following cell stimulation (2h) with Pam3Cys (5 µg/ml). NS, non-stimulated cells. Control staining was carried 
out using an isotype-matched control antibody. Shown are HPMC staining results representative of two donors.  
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2.1.16A and B). Similarly, TLR4 mRNA expression did not show any significant change upon 
HPMC stimulation, and its basal level was very low (Fig 2.1.16C). 
 
The IFNγ and TLR signalling pathways are known to interact to regulate macrophage function 
(Hu et al., 2006), and IFNγ has been demonstrated to up-regulate several TLR family’s mRNAs, 
including Tlr2 (Faure et al., 2001; Homma et al., 2004). Given the crucial role played by IFNγ in 
regulating the immune response in the peritoneal cavity (McLoughlin et al., 2003; Robson et al., 
2001), and its positive effect on HPMC TLR2 surface expression described previously (Fig 
2.1.14C), its effect on HPMC Tlr2 expression was analysed in more detail by qRT-PCR. 
Additionally, the effect of SES on TLR2 mRNA was tested in parallel. HPMC stimulation with 
IFNγ over a 24h period showed a 7-fold increase in Tlr2 mRNA at the 6h time point, followed by 
a return to baseline levels by 12h (Fig 2.1.17A). A similar pattern, but with an earlier kinetics, 
was observed following stimulation with SES, with a peak (8-fold Tlr2 mRNA increase) at 3h 
followed by a drop by 6h and subsequent return to basal level of expression by 12h (Fig 
2.1.17A). The effect of SES was studied further in a peritoneal model of inflammation that 
closely resembles the clinical situation (Hurst et al., 2001; McLoughlin et al., 2003) and 
complemented the in vitro observations. Biopsies of the parietal peritoneal membrane were 
taken at various time points following injection of SES into the peritoneal cavity of mice. qRT-
PCR analysis of RNA extracted from the peritoneal membrane of one mouse showed a rapid 
and transient increase of Tlr2 mRNA expression (Fig 2.1.17B). A 3-fold increase in Tlr2 
expression above the baseline level at 1h was observed, and followed by a down-regulation 
below the baseline level from 3h up to 12h.  
2.1.7 Discussion 
Repeated peritonitis, a feature of PD treatment, is predominantly caused by Gram-positive 
bacteria, especially Staphylococcus species (Szeto et al., 2005). However, Gram-negative 
bacterial infections also represent a significant problem and, overall, have a worse prognosis in 
terms of patient outcomes (Szeto and Chow, 2007). It is believed that host defences are 
compromised in PD patients as a result of exposure to dialysis solution, dilution of humoral 
factors, and alteration in the function of resident and recruited leukocytes (Devuyst et al., 2010; 
Topley and Williams, 1994). The initial peritoneal immune response, however, involves 
contributions not only from resident peritoneal leukocytes (Cailhier et al., 2005; Roberts et al., 
2009), but also from the peritoneal mesothelial cells, lining the parietal and visceral peritoneum 
(Yung and Chan, 2009). Therefore, the expression of TLRs, critical mediators of initial immune 
responses, was examined in HPMC and the responses of these cells to bacterial products 
characterised.  
 
The analysis of TLR expression by HPMC identified expression of a restricted subset of TLR 
family members (TLR1-6), which was in agreement with findings in mouse peritoneal 
mesothelial cells (Kato et al., 2004; Park et al., 2007). However, experiments examining the 
Figure 2.1.16. Modulation of HPMC TLR1/4/6 mRNA expression by pro-inflammatory cytokines and TLR 
ligands.  
Tlr1 (A), Tlr6 (B) and Tlr4 (C) mRNA expression was assessed by qRT-PCR following stimulation of HPMC for 3h or 
24h with Pam3Cys (2 µg/ml), SES (neat), LPS (250 ng/ml), IL-1β (100 pg/ml), IFNγ (10 ng/ml) or TNFα (100 pg/ml). 
NS, non-stimulated cells. Fold inductions were determined as described under Materials and Methods. Data 
presented are representative of four or five experiments (±SD) performed with primary cells derived from different 
donors.  
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Figure 2.1.17. Kinetics of TLR2 mRNA expression in vitro and in vivo.  
(A) Tlr2 mRNA expression in HPMC was assessed by qRT-PCR following cell culture for 24h in the presence or 
absence (Control) of SES (neat) or IFNγ (10 ng/ml). Data presented is a representative result of three experiments 
performed using primary cells derived from different donors. (B) The mouse was i.p. injected with neat SES, and at 
the indicated time points, Tlr2 mRNA expression levels were quantified by qRT-PCR following total RNA extraction 
from samples of parietal peritoneal membrane. Fold inductions were determined as described under Materials and 
Methods.  The data represents the results of one experiment.  
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responsiveness of HPMC to bacterial TLR agonists revealed important differences between 
human and mice. Although HPMC, like mouse cells, responded to TLR2/1, TLR2/6 and TLR5 
ligands, the human cells did not respond to the TLR4 agonist LPS, unlike mouse cells (Kato et 
al., 2004; Park et al., 2007). In the present study great care was taken (using differential sub-
cultures) to ensure that HPMC cultures were not contaminated with peritoneal fibroblasts or 
residual resident macrophages that might contribute to apparent TLR4 expression (Lang and 
Topley, 1998; Topley et al., 1993a; Topley et al., 1993b; Topley et al., 1994).  
 
Lack of TLR4 responsiveness may also be due to TLR4 down-regulation at the cell surface, 
which is known to contribute to ‘LPS tolerance’ (Nomura et al., 2000). Analysis of the response 
of freshly-isolated mesothelial cells and the absence of the tolerisation-resistant chemokine 
CCL5 (Foster et al., 2007), in the supernatants of LPS-treated HPMC appears to exclude 
tolerance as a reason for the TLR4 unresponsiveness of these cells. Poor responses to TLR4 
ligands in airway smooth muscle cells were overcome by co-culture with PBMC in an IL-1β-
dependent manner (Morris et al., 2005). Therefore, peritoneal macrophages may act as 
important sensors of Gram-negative bacterial infections, indirectly activating mesothelial cells 
(Devuyst et al., 2010; Topley et al., 1996a; Topley and Williams, 1994). The lack of mesothelial 
cell responsiveness to LPS may be beneficial to avoiding excessive inflammation. In this 
respect, intestinal epithelial cells lose their ability to respond to LPS after birth, a phenomenon 
interpreted as one way to avoid excessive inflammatory responses to the microbial flora (Lotz et 
al., 2006). Overall, the data suggest that HPMC respond to bacterial infections mainly through 
TLR2 (Gram-positive bacteria) and TLR5 (flagellated bacteria, predominantly Gram-negative) 
and possibly through NOD1 (PGN components), and to viral pathogens via TLR3 recognition of 
double-stranded RNA (Wornle et al., 2009). These data do not exclude the possibility that other 
pattern recognition receptor families may play a role in pathogen recognition by HPMC (Kawai 
and Akira, 2009). 
 
TLR5 mediates recognition of flagellin, a flagellum component, present on many motile bacteria 
(Hayashi et al., 2001). Interestingly, TLR5 expression in the intestinal epithelium is limited to the 
basolateral surface, and is activated upon bacterial invasion of the gut wall (Gewirtz et al., 
2001a; Gewirtz et al., 2001b). TLR5-deficient mice develop a TLR4-dependent spontaneous 
colitis, suggesting a critical role for TLR5 in maintaining the host-microflora balance within the 
gastro-intestinal tract (Vijay-Kumar et al., 2007). TLR5 expression on mesothelial cells may 
therefore be critical in sensing invasion of flagellated bacteria into the peritoneal cavity. 
Translocation of intestinal bacteria is a potential cause of infection in PD patients, along with 
access through the intra-peritoneal catheter (Szeto and Chow, 2007). Most flagellated bacteria 
found in PD-associated peritonitis patients are Gram-negative species, which are associated 
with poor outcomes (Szeto et al., 2005), hence the need for efficient, but not excessive, sensing 
of these pathogens. 
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TLR2, but not TLR4, expression was critical for the recognition of a Staphylococcus epidermidis 
(S. epi.)-derived cell-free supernatant (SES), which has been extensively utilised to model acute 
peritoneal inflammation (Hurst et al., 2001; McLoughlin et al., 2003). Similarly, Strunk et al. 
recently demonstrated that TLR2 is required for cellular responses to and clearance of S. epi. 
(Strunk et al., 2010). TLR2 is known to recognise microbial components by forming 
heterodimers with TLR1 and TLR6, depending on the ligand. The expression in HPMC of these 
two TLR2 partners for bacterial recognition and signalling was also investigated in this study. Of 
note, the response of HPMC to the TLR2/TLR6 ligand Pam2Cys suggested that, although 
undetectable by flow cytometry, TLR6 is expressed and functional in HPMC, as suggested by 
the results of qRT-PCR and RT-PCR studies. TLR2 may also act in concert with co-receptors 
e.g. Dectin-1, CD36 or CD14, the latter a co-receptor for both TLR2 and TLR4 (Kawai and 
Akira, 2010; Yoshimura et al., 1999). CD14 blockade significantly reduced SES-induced 
responses in PBMC indicating that, in leukocytes, TLR-mediated responses are highly CD14-
dependent. Notably, HPMC lacked cell surface expression of CD14, and although serum, a 
source of soluble CD14, had a significantly positive effect on SES-mediated responses of 
HPMC, purified sCD14 did not. These results indicate that (i) the requirement for CD14 in TLR2 
activation is cell-specific and (ii) there may be other soluble cofactors in serum that co-operate 
with TLR2 signalling.  
 
The modulation of TLR2 expression in HPMC in response to both TLR2-specific agonists and 
pro-inflammatory cytokines as well as in response to in vitro and in vivo SES stimulation was 
also studied. It is well documented through work with other cell types that both TLR and 
cytokine signalling may influence TLR expression and responsiveness (Faure et al., 2001; 
Homma et al., 2004; Hussain et al., 2008; Sakai et al., 2004; van Aubel et al., 2007). This is 
supported by the findings of the present study showing up-modulation of TLR2 expression by 
using a number of cytokines, TLR ligands and also the SES preparation. In particular, van Aubel 
et al. described a differential cross-talk between TLRs 2, 4 and 5 (van Aubel et al., 2007), and 
TLR4-induced IFNγ production leading to a sensitisation of TLR2-dependent activation in a 
model of Gram-negative sepsis (Spiller et al., 2008). Interestingly, the induction of TLR2 
expression in vivo coincides with the peak of neutrophil-attracting chemokine expression 
(Fielding et al., 2008; Hurst et al., 2001; McLoughlin et al., 2003), suggesting the involvement of 
TLR2 in these critical early immune activation events. 
 
Mesothelial cells are a major resident cell type within the peritoneal cavity, and are therefore 
likely to encounter infecting bacteria, triggering local inflammation and host defence (Topley et 
al., 1996a). Therefore, understanding how TLRs mediate HPMC responses during peritonitis 
will help to improve compromised host defense of PD patients, reducing infection and improving 
clinical outcome. To this end, in the next phase of this study the modulatory mechanisms 
controlling TR2-mediated HPMC responses were examined. 
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2.2 Modulation of TLR2-mediated human peritoneal mesothelial cell 
responses: effect of soluble TLR2 and IL-6 receptor activation 
 
The study of the mechanisms controlling TLR2-mediated HPMC responses focused on two 
potential modulatory pathways: 1) the activity of soluble TLR2, and 2) the activation of the IL-6-
IL-6 receptor pathway. The TLR2-mediated responses of HPMC may be controlled by 
modulating cell membrane receptor expression, as described in the previous section. However, 
the presence of a naturally-occurring soluble form of human TLR2 (sTLR2) in biological fluids 
such as human plasma, breast milk and saliva and its activity as a decoy microbial receptor and 
modulator of membrane-bound TLR2-mediated responses of human monocytes (Kuroishi et al., 
2007; LeBouder et al., 2003; Raby et al., 2009), prompted the examination of its role as a 
modulator of HPMC-mediated responses. Furthermore, a critical checkpoint in the resolution of 
inflammation is the transition from innate to adaptive immunity (Hoebe et al., 2004). 
Inflammatory cytokines regulate this immunological switch by controlling the recruitment, 
activation and apoptotic regulation of leukocytes (Hoebe et al., 2004; Jones, 2005); one such 
cytokine is IL-6. The contribution of IL-6 signalling in peritoneal inflammation has been reported, 
in particular the critical role of IL-6 trans-signalling in the initiation of the resolution phase by 
regulating the transition from a neutrophil-rich population to a mononuclear cell dominance 
(Hurst et al., 2001). This therefore led to investigate the potential effect of IL-6 signalling on 
TLR2-mediated responses in HPMC. 
2.2.1 Production of sTLR2 by HPMC and its detection in PD fluid 
In order to assess the relevance of sTLR2 as a modulator of HPMC responses to infection, first, 
its production by HPMC and presence in PD fluid was investigated. The presence of sTLR2 in 
the serum-free culture supernatants of HPMC that had been stimulated with Pam3Cys, SES or 
left untreated was tested by Western blot. sTLR2 polypeptides were not detected in the culture 
supernatants of non-stimulated or stimulated HPMC (Fig 2.2.1A, left panel). PD effluent of 
patients in stable condition and during a peritonitis episode was also tested for sTLR2. Unlike 
the culture supernatants of HPMC, the typical 66-kDa sTLR2 polypeptide previously identified in 
human plasma (LeBouder et al., 2003), was readily detectable in both the PD effluent of stable 
and peritonitis patients (Fig 2.2.1A, right panel). 
2.2.2 Effect of sTLR2 on cytokine release and NF-κB activation in mesothelial 
cells 
Although sTLR2 was not detected in HPMC culture supernatants, its presence in the PD 
effluent suggested that peritoneal sTLR2 (most likely myeloid derived) may modulate HPMC 
pro-inflammatory responses to pathogens. To test this possibility, HPMC were stimulated with 
Pam3Cys or SES in the absence or presence of human recombinant sTLR2, and CXCL8 levels 
Figure 2.2.1. Detection of sTLR2 and its effect on cytokine release and NF-κB activation in HPMC.  
(A) PD effluents (PDE) from stable and infected patients, the cell-free culture supernatants of non-stimulated, 
Pam3Cys (10 µg/ml)- and SES (neat)-stimulated HPMC were tested for sTLR2 by Western blot, as described under 
Materials and Methods. (B) HPMC were stimulated (24h) with the indicated concentrations of Pam3Cys or dilutions 
of SES in the absence or presence of recombinant human soluble TLR2 (sTLR2, 5 µg/ml), and CXCL8 levels in the 
cell-free culture supernatants were quantified by ELISA. Results shown (±SD) are of one experiment representative 
of three independent experiments (***, p < 0.001; sTLR2-treated vs non-treated cells). (C) HPMC were treated with 
medium alone, Pam3Cys (3 µg/ml) or SES (1/10 dilution) in the absence or presence of sTLR2 (5 µg/ml) for the 
indicated times, nuclear extracts were then prepared and NF-κB activation monitored by EMSA, as described under 
Materials and Methods. The fold induction relative to non-stimulated cells (control) was calculated following 
densitometry scanning analysis of the EMSA gels. Data presented is representative of three different donors. Inset 
in C shows NF-κB activation kinetics in HPMC stimulated with Pam3Cys (3 µg/ml) or SES (1/10 dilution) for up to 5h. 
At the indicated time points, nuclear extracts were prepared, NF-κB activation evaluated by EMSA and NF-κB 
relative ODs (to control) estimated as described in (C). Values are expressed as the mean (± SEM) of three 
independent experiments.  
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in the cell culture supernatants were quantified by ELISA. The TLR2-mediated release of 
CXCL8 by HPMC was found reduced in the presence of sTLR2 (Fig 2.2.1B).  
TLR2 triggering in HPMC leads to NF-κB activation, as shown in Figure 2.1.7, which in turn 
induces the transcription of a wide range of pro-inflammatory and immunomodulatory cytokines, 
including CXCL8 (Doyle and O'Neill, 2006). To test the magnitude of the inhibitory effect of 
sTLR2 on mesothelial cells, NF-κB activation was measured by EMSA in nuclear extracts of 
HPMC that had been stimulated with Pam3Cys or SES in the presence or absence of sTLR2. In 
order to maximise the sensitivity of the experiments, the effect of sTLR2 was tested at time 
points when the levels of NF-κB activation were sub-optimal, as indicated by preliminary studies 
on the kinetics of Pam3Cys- and SES-induced NF-κB activation (Fig 2.2.1C, inset). Notably, 
HPMC stimulation with Pam3Cys (Fig 2.2.1C, left panel) or SES (Fig 2.2.1C, right panel) in 
combination with sTLR2 substantially reduced the extent of NF-κB activation, when compared 
with that induced by Pam3Cys or SES alone.  
2.2.3 Effect of IL-6 trans-signalling on TLR2-mediated HPMC responses 
Next, the potential effect of IL-6 signalling on TLR2-mediated responses in HPMC was 
investigated. HPMC do not express the membrane-bound IL-6R (McLoughlin et al., 2004), 
therefore require the sIL-6R to respond to IL-6 by IL-6 trans-signalling. The inability of HPMC to 
produce sIL-6R, which is generated mainly (90-99%) by proteolytic cleavage of membrane IL-
6R (Scheller et al., 2013), indicates that they depend on the sIL-6R released by other cells from 
their environment. Infiltrating neutrophils are the main source of sIL-6R in the peritoneal cavity 
and resident leukocytes may constitute an additional source of sIL-6R. To test whether sIL-6R 
was present in the mesothelial cells environment, PD effluent of patients in stable condition was 
tested for sIL-6R by ELISA. Significant levels of sIL-6R was detected in the PD effluent, 
confirming previous findings (Oh et al., 2010; Pecoits-Filho et al., 2006), whereas sIL-6R was 
undetectable in the supernatant of resting or activated HPMC (Fig 2.2.2A). In addition to sIL-6R, 
IL-6 trans-signalling requires the expression and activity of the signal transducer gp130, thus, its 
expression on HPMC was also tested. Immunostaining and flow cytometry analysis of primary 
cultures of HPMC revealed a strong expression of the IL-6 signal transducer (Fig 2.2.2B), 
confirming previous findings (McLoughlin et al., 2004). 
 
To test whether TLR2-mediated responses were affected by IL-6 trans-signalling pathway 
activation, HPMC were simultaneously stimulated with the TLR2 ligands Pam3Cys or SES in 
combination with increasing concentrations of IL-6, sIL-6R or IL-6/sIL-6R, and CXCL8 
expression levels were determined in the cell culture supernatants by ELISA (Fig 2.2.3A and B). 
The IL-6/sIL-6R complex caused a significant dose-dependent inhibition of basal, Pam3Cys- 
and SES-induced CXCL8 production (Fig 2.2.3A and B). The inhibitory activity of 100 ng/ml IL-
6/sIL-6R on basal CXCL8 secretion was 56 ± 44% (range of 12-88%; n=5); on Pam3Cys-
induced CXCL8, 78 ± 8% (range of 61-88%; n=4) and on the SES response, 54 ± 59% (range 
of 45-57%; n=3) (Fig 2.2.3A and B). Notably, the inhibitory activity of the IL-6/sIL-6R complex on 
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Figure 2.2.3. Effect of IL-6 trans-signalling on TLR2-induced CXCL8 release by HPMC. 
HPMC were stimulated for 24h with Pam3Cys (0.5 µg/ml) (A), SES (1/5 dilution) (B) or left untreated (-). The culture 
were supplemented with the indicated concentrations of IL-6, sIL-6R or IL-6 + sIL-6R and CXCL8 levels in the cell-
free culture supernatants were quantified by ELISA. Results are means (±SEM) of three (Pam3Cys) and five (SES) 
independent experiments (*, p < 0.05; **, p < 0.01; ***. p < 0.001; non-stimulated vs. stimulated cells or Pam3Cys- or 
SES-treated vs. indicated conditions; 	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Figure 2.2.2. Production of sIL-6R and expression of gp130 by HPMC. 
(A) HPMC were stimulated (24h) with Pam3Cys (10 µg/ml) or SES (neat), and sIL-6R levels in the cell-free culture 
supernatants were quantified by ELISA. sIL-6R in PD effluent from a stable patient was used as a positive control. 
Results shown are of one experiment (±SD) representative of two. (B, left panel) Non-stimulated HPMC were tested 
for gp130 expression by immunocytochemistry. An isotype-matched antibody was used as a staining control. 
Results are representative of immunostaining of two different primary cells. (B, right panel) Cell-surface expression 
of gp130 was assessed by flow cytometry in freshly-isolated HPMC using a gp130 specific antibody (open plot). 
Control fluorescence histogram profile corresponding to the immunostaining with isotype-matched control antibody 
is shown (shaded plot). The result is representative of seven different cell lines from individual donors.  
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SES-induced CXCL8 production was significant only at the 100 ng/ml dose (Fig 2.2.3 B). 
Although addition of IL-6 alone had no effect on Pam3Cys- and SES-induced CXCL8 secretion, 
sIL-6R alone significantly inhibited Pam3Cys-induced CXCL8 production (Fig 2.2.3A), 
suggesting that the documented basal release of IL-6 by HPMC (Witowski et al., 1996) was 
sufficient to facilitate the formation of an active IL-6/sIL-6R complex and IL-6 trans-signalling. 
This finding also indicates that IL-6 signalling in HPMC can be triggered mainly when both IL-6 
and sIL-6R are present.  
 
Pam3Cys and SES stimulation of HPMC also results in a dose-dependent increase in CCL2 
production, as previously shown in Fig 2.1.4. This finding, together with the documented 
capacity of IL-6/sIL-6R signalling to induce secretion of CCL2 in many cell types (Jones and 
Rose-John, 2002), and the modulatory effect of IL-6 trans-signalling on Pam3Cys- and SES-
induced CXCL8 described previously, posed the question of whether IL-6/sIL-6R signalling 
modulates Pam3Cys- and/or SES-induced CCL2 secretion in HPMC. To address this question, 
HPMC were stimulated with Pam3Cys or SES in the absence or presence of IL-6, sIL-6R or IL-
6/sIL-6R, and the levels of CCL2 in the cell culture supernatants were determined by ELISA. 
Unlike the inhibitory effect on Pam3Cys- and SES-induced CXCL8 described previously, IL-
6/sIL-6R exerted a significant positive modulatory effect on CCL2 production by HPMC, when 
they were stimulated with a combination of Pam3Cys or SES and 50 or 100 ng/ml of IL-6/sIL-6R 
(Fig 2.2.4A and B). These findings were consistent with previously reported work showing 
release of CCL2 by activation of both IL-6- and TLR2 signalling pathways, and when HPMC 
were stimulated with IL-6/sIL-6R in combination with IL-1β (Hurst et al., 2001). 
 
Effect of IL-6 signalling on TLR2-mediated NF-κB activation  
To establish whether the modulatory effect of IL-6 trans-signalling on TLR2-driven CXCL8 
production occurs at the level of the signal transduction pathway, NF-κB activation was 
examined by EMSA. Addition of IL-6, sIL-6R or IL-6/sIL-6R did not significantly increase NF-κB 
basal activation, when considering the sensitivity of the technique (Fig 2.2.5A). The Pam3Cys-
triggered NF-κB activation previously shown in Figure 2.1.7 was not modified by addition of IL-6 
or sIL-6R alone (Fig 2.2.5A). By contrast, Pam3Cys-mediated NF-κB activation was attenuated 
by the addition of IL-6/sIL-6R, which correlated with the CXCL8 inhibition previously observed 
(Fig 2.2.2). Conversely, SES-induced NF-κB activation showed a slight attenuation with the 
addition of IL-6 or sIL-6R, but no change with the addition of IL-6/sIL-6R (Fig 2.2.5A). To 
examine the NF-κB subunits activated by TLR2 signalling in combination with IL-6 trans-
signalling in HPMC, a ‘supershift’ EMSA study was performed using antibodies directed against 
specific NF-κB family members. This analysis identified the involvement of NF-κB DNA-binding 
complexes consisting of the p50 and p65 NF-κB subunits for Pam3Cys and SES in combination 
with IL-6/sIL-6R (Fig 2.2.5B and C), as previously described for Pam3Cys and SES alone (Fig 
2.1.7B and Fig 2.2.5B and C). 
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Figure 2.2.4. Effect of IL-6 trans-signalling on TLR2-induced CCL2 release by HPMC. 
HPMC were stimulated for 24h with Pam3Cys (0.5 µg/ml) (A), SES (1/5 dilution) (B) or left untreated (-). The culture 
were supplemented with the indicated concentrations of IL-6, sIL-6R or IL-6 + sIL-6R and CCL2 levels in the cell-
free culture supernatants were quantified by ELISA. Values are expressed as the mean (±SEM) of three 
independent experiments (***, p < 0.001 non-stimulated vs stimulated cells; *, p < 0.05; **, p < 0.01; Pam3Cys- or 
SES-treated vs indicated conditions).  
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Figure 2.2.5. Effect of IL-6 signalling on TLR2-mediated NF-κB activation in HPMC.  
(A) HPMC were stimulated (4h) with medium (Control), Pam3Cys (0.5 µg/ml) or SES (1/5 dilution) alone or in 
combination with 50 ng/ml of IL-6, sIL6-R or IL-6 + sIL-6R. Nuclear extracts were prepared and NF-κB activation 
was analysed by EMSA. NF-κB fold induction relative to non stimulated cells was calculated from densitometry 
analysis of EMSA gels. Data presented is a representative result of four experiments performed using primary cells 
from different donors. (B and C) The composition of the NF-κB DNA binding complexes was studied by supershift 
EMSA analysis of nuclear extracts prepared from HPMC stimulated with Pam3Cys alone or in combination with 
IL-6+sIL-6R (B), or with SES alone or in combination with IL-6+sIL-6R (C). Control samples without the addition of 
antibody, and samples analysed with specific antibodies for the p50, p65, and p52 subunits of NF-κB are shown. 
NF-κB binding and ‘supershifted’ complexes are indicated. Data shown are results of one experiment. 
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Effect of TLR2 signalling on IL-6-mediated STAT activation 
The modulatory effect of IL-6/sIL-6R on TLR2-mediated HPMC responses described in the 
previous section suggested the possibility of cross-talk between the IL-6 and TLR2 signalling 
pathways. To examine this possibility, STAT activation downstream of IL-6 signalling was 
evaluated by EMSA following HPMC activation with Pam3Cys or SES alone or in combination 
with IL-6, sIL-6R or IL-6/sIL-6R. Using a consensus oligonucleotide (SIE m67) containing a DNA 
binding motif for STAT1 and STAT3, a low level of STAT1/3 activation was observed for the 
non-stimulated, IL-6 and sIL-6R stimulated cells, when considering the sensitivity of the 
technique. The IL-6/sIL-6R complex triggered STAT1/3 activation, as previously reported 
(McLoughlin et al., 2004). Pam3Cys did not trigger an increase of STAT1/3 activation over the 
basal level. Similarly, SES alone did not seem to activate STAT1/3 (Fig 2.2.6A). These results 
were consistent across five different experiments. STAT1/3 activation observed following cell 
activation with Pam3Cys + sIL-6R was similar to Pam3Cys alone, whereas a more pronounced 
increase was observed in cells stimulated with SES + sIL-6R (Fig 2.2.6A). These findings may 
be explained by the HPMC’s basal secretion of IL-6 as well as by the SES-driven IL-6 secretion, 
which can combine with sIL-6R and trigger trans-signalling. Addition of the IL-6/sIL-6R complex 
to Pam3Cys or SES triggered a similar response to that of IL-6/sIL-6R complex alone (Fig 
2.2.6A).  
‘Supershift’ EMSA experiments were then performed using STAT-specific antibodies to identify 
the STAT family member(s) involved in HPMC activation. This analysis identified the 
involvement of STAT3 in cell activation by Pam3Cys and SES in combination with IL-6/sIL-6R 
(Fig 2.2.6B and C, right panels), as previously reported for the IL-6/sIL-6R complex (McLoughlin 
et al., 2004). Interestingly, STAT3 activation, albeit low, was also observed when HPMC were 
stimulated with Pam3Cys or SES alone (Fig 2.2.6B and C, left panels).  
2.2.4 Effect of sTLR2 on STAT activation 
STAT activation was further examined over time in nuclear extracts from cells non-stimulated or 
stimulated with Pam3Cys or SES. A low level of basal activation was observed, increasing 
slightly at later time points, but neither Pam3Cys nor SES stimulation did up-regulate STAT1/3 
DNA-binding signal above that observed for the control growth-arrested non-stimulated cells 
(Fig 2.2.7A). To investigate whether sTLR2, in addition to its modulatory role on NF-κB 
activation, could affect the status of STAT1/3 activation, HPMC were stimulated with Pam3Cys 
and SES in the presence or absence of human recombinant sTLR2. A range of time points were 
tested but no signal was detected in the absence or presence of TLR2 ligands, and no change 
was observed following the addition of sTLR2 (Fig 2.2.7B). 
2.2.5 Discussion 
Collectively, the data described in this section demonstrated a negative modulatory role of 
sTLR2 in TLR2-driven HPMC responses and a potential role of IL-6 signalling in modulating the 
TLR2-mediated responses of these cells.  
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Figure 2.2.6. Effect of TLR2 signalling on IL-6-mediated STAT activation in HPMC.  
(A) HPMC were stimulated (4h) with medium (Control), Pam3Cys (0.5 µg/ml) or SES (1/5 dilution) alone or in 
combination with 50 ng/ml of IL-6, sIL6-R or IL-6 + sIL-6R, or with Oncostatin M (OSM) (15 min; 30 ng/ml) used as a 
positive control. Nuclear extracts were prepared and total STAT activation was analysed by EMSA. STAT fold 
induction relative to non stimulated cells was calculated from densitometry analysis of EMSA gels. Data shown are 
representative results of five experiments performed using primary cells from different donors. (B and C) The 
composition of the STAT DNA binding complexes was analysed by supershift EMSA experiments in nuclear extracts 
prepared from HPMC stimulated with Pam3Cys (B) or with SES (C), alone or in combination with IL-6+sIL-6R. 
Control samples without the addition of antibody and samples analysed with specific antibodies for STAT 1, 3 and 5 
are shown. STAT binding and ‘supershifted’ complexes are indicated. Data shown are results of one experiment. 
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Figure 2.2.7. Examination of STAT activation in HPMC following TLR2 activation. 
(A and B) HPMC were stimulated for the indicated time periods with Pam3Cys (A, 2 µg/ml; B, 3 µg/ml) or SES (A, 
neat; B, 1/10 dilution) alone or in the presence of soluble TLR2 (sTLR2, 5 µg/ml), or with Oncostatin M (OSM) (15 
min; 30 ng/ml) used as a positive control. At the indicated time points nuclear extracts were prepared and total STAT 
activation was analysed by EMSA. Data presented are representative results of three experiments performed using 
primary cells from different donors.  
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sTLR2 showed a substantial negative modulatory effect not only on the TLR2-mediated release 
of CXCL8, but also on the activation of the transcription factor NF-κB. The inhibitory effect on 
NF-κB activation indicated that sTLR2 has a wide spectrum of effects on HPMC responses, 
which may not be limited to CXCL8 production and may extend to a number of 
immunomediators. Notably, although HPMC showed cell-surface expression of TLR2, they do 
not seem to release sTLR2, as it was not detected in the culture supernatants of non-
stimulated, Pam3Cys- or SES-stimulated cells. Thus, HPMC, unlike other cell types, may lack 
the machinery required to shed sTLR2 from the membrane. Alternatively, HPMC might only 
release sTLR2 in specific conditions determined by their environment. Nevertheless, sTLR2 
was readily detectable in PDE from stable and infected patients; its presence in the peritoneal 
cavity, presumably released by resident macrophages as well as by recruited neutrophils and 
monocytes during infection, may contribute to an efficient control of the local inflammatory 
response.  
 
The simultaneous activation of IL-6 trans-signalling - via STAT3 - and TLR2 pathways in HPMC 
had a dampening effect on pro-inflammatory NF-κB activation and subsequent CXCL8 
expression levels, compared with the TLR2-mediated responses to Pam3Cys alone. This shows 
the potential of IL-6 trans-signalling to control the TLR2-mediated release of CXCL8 - a potent 
neutrophil chemoattractant - by HPMC. By contrast, IL-6 trans-signalling and Pam3Cys-induced 
TLR2 activation showed a positive effect on CCL2 release. This data confirmed previous results 
(Hurst et al., 2001), and considering the main cell targets of these chemokines - namely 
neutrophils for CXCL8 and mononuclear cells for CCL2 - indicates the potential of IL-6 trans-
signalling to inhibit neutrophil recruitment while increasing mononuclear cell influx. This 
combination of effect on various chemokine secretion could contribute to limit the detrimental 
effect of a prolonged presence of neutrophils in the peritoneal cavity, while promoting the 
initiation of the resolution phase. 
 
IL-6 trans-signalling also showed the capacity to modulate SES-mediated responses of HPMC. 
Notably here, the positive effect on CCL2 release was similar to that observed on Pam3Cys-
stimulated HPMC, the negative effect on CXCL8 release was modest, only observed at the 
highest IL-6/sIL-6R concentration tested, and no effect on NF-κB was observed. These findings 
may be partly due to the complex nature of SES, comprising a variety of molecules released by 
Staphylococcus epidermidis (S. epi.). Various strains of S. epi. secrete virulence factors called 
phenol soluble modulins, which may signal via TLR2 (Hajjar et al., 2001; Otto, 2009). While 
some of the TLR2-triggering modulins are most likely present in SES, other factors might also 
be present and presumably activate an array of signaling pathways - challenging to identify - 
leading to the resulting effects observed here.  
The regulatory effects of IL-6 trans-signalling on pro-inflammatory signals described here 
extended previous in vitro observations made in HPMC, where IL-1β- and TNFα-mediated pro-
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inflammatory cytokine release was attenuated by IL-6 trans-signalling activation (Hurst et al., 
2001). In addition, in vivo results with IL-6KO mice i.p. challenged with SES showed that 
deficiency of IL-6 heightened the level and prolonged the presence of pro-inflammatory 
cytokines and neutrophils in the peritoneal cavity (Hurst et al., 2001; Robson et al., 2001), 
suggesting an inhibitory effect of IL-6 signalling on pro-inflammatory responses while promoting 
the transition between innate and acquired immunity.  
The negative modulatory effect of IL-6 signalling pathway activation via STAT3 on TLR2-
mediated CXCL8 release in HPMC was also consistent with the results of a study using knockin 
mice genetically modified in the gp130 signalling pathway, with one strain presenting 
hyperactivation of STAT1/3 and a second strain with an abolished STAT1/3 signalling. Using 
the SES in vivo model of peritoneal inflammation, the study demonstrated a modulating role of 
IL-6 via STAT3 activation in neutrophil trafficking in the peritoneal membrane, by negatively 
regulating the production of the neutrophil chemoattractant CXCL1 (a mouse functional 
counterpart of CXCL8), leading to neutrophil clearance (Fielding et al., 2008). Lining the 
peritoneal membrane, mesothelial cells are the main cells in contact with the environment and 
leukocytes present in the cavity and could be responsible for these modulating activities 
(Hoentjen et al., 2005; Nishinakamura et al., 2007; Tilg et al., 1994; Xing et al., 1998; Yu et al., 
2002).  
 
In order to obtain a better understanding of the modulatory capacity of sTLR2 and IL-6 
signalling, in the next phase of the project, the modulatory role of sTLR2 and IL-6 signalling in 
inflammation and infection was evaluated in vivo.  
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2.3 Role of TLR2, soluble TLR2 and IL-6 signalling in peritoneal 
inflammation and infection in vivo 
 
In order to better evaluate the involvement of TLR2 and the modulatory capacity of sTLR2 in 
Gram-positive induced peritoneal inflammation and infection, their activity was investigated in 
two mouse models of acute peritoneal inflammation based on the injection of SES or live S. epi. 
(the development of the S. epi. model was part of this thesis and is described below in section 
2.4). Furthermore, the live in vivo model was also used to better evaluate the impact of IL-6 
signalling on S. epi.-induced peritoneal responses. 
2.3.1 Effect of sTLR2 on SES-induced leukocyte recruitment and cytokine 
production 
The role of sTLR2 was first evaluated in mice inoculated intraperitoneally (i.p.) with SES in the 
presence or absence of sTLR2. SES-induced peritoneal inflammation was monitored over time 
and the neutrophil, macrophage and lymphocyte numbers in the peritoneal lavages were 
determined by differential cell counting using cytospin. As observed in episodes of human 
peritonitis (Hurst et al., 2001), i.p. injection of SES resulted in an initial rapid and transient 
neutrophil influx, peaking at 2-3h (depending on the experiment) (Fig 2.3.1A), while 
mononuclear cell numbers were decreasing (Fig 2.3.1B and C), followed by a more sustained 
mononuclear leukocyte infiltration in the peritoneal cavity at later time points (Fig 2.3.1B and C). 
Neutrophils were maintained in the peritoneal cavity up to 12h following SES administration, 
decreasing thereafter, and were eliminated by 48h (Fig 2.3.1A, right panel). By contrast, 
mononuclear cells were maintained (lymphocytes) or even gradually increased (macrophages) 
by 48h (Fig 2.3.1B and C, right panels). The simultaneous administration of SES and sTLR2 
significantly impaired the extent of neutrophil recruitment observed with SES alone at the 2h 
peak time, with a reduction also observed at 3h and 6h (Fig 2.3.1A, left panel), whereas later 
time points showed similar neutrophil numbers (Fig 2.3.1A, right panel). Unlike neutrophils, 
monocyte/macrophage and lymphocyte populations were not affected by the presence of 
sTLR2 over the entire time course (Fig 2.3.1B and C). Quantification of the neutrophil 
chemoattractant CXCL1/KC expression profile in the peritoneal lavages by ELISA showed a 
transient secretion, peaking at 1h after SES injection. Addition of sTLR2 significantly reduced 
the levels of CXCL1, which was consistent with the inhibitory effect of sTLR2 on neutrophils 
recruitment (Fig 2.3.2A). Biopsies of parietal peritoneal membrane were taken at the peak time 
of neutrophil recruitment following injection of SES, in order to look at the response of non-
hematopoietic stromal cells (mainly mesothelial cells and fibroblasts). qRT-PCR analysis of 
RNA extracted from the peritoneal membrane of one mouse showed that the reduction in the 
levels of CXCL1 protein in the presence of sTLR2 correlated with a decrease in Cxcl1 mRNA 
(Fig 2.3.2A, inset). Interestingly, at the peak of neutrophil infiltration in the peritoneal cavity, the 
simultaneous injection of sTLR2 and SES also resulted in a reduction in Tlr2 mRNA levels in the 
Fig 2.3.1. Effect of sTLR2  on leukocyte recruitment in the SES-induced inflammation model. 
In two different experiments (1h-6h left panels and 6h-48h right panels), mice were i.p. inoculated with SES, SES + 
100 ng sTLR2 or PBS (controls). At the indicated time points mice were sacrificed, the peritoneal cavity was lavaged 
and neutrophil (A), macrophage (B) and lymphocyte (C) numbers were determined by differential cell counting using 
cytospin. Values are expressed as the mean ± SEM (n=3 or 4/condition; *, p < 0.05; SES vs. SES + sTLR2). 
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Fig 2.3.2. Effect of sTLR2 on cytokine production and Tlr2 expression in the SES-induced inflammation 
model. 
(A-C) Mice were i.p. inoculated with SES, SES + 100 ng sTLR2 or PBS (controls). At the indicated time points in (A), 
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mouse peritoneal membrane (Fig 2.3.2B), as compared with the levels in the mice injected with 
SES alone, which had shown a transient increase, as previously discussed in section 2.1 
(Figure 2.1.17B). 
The effect of sTLR2 on IL-6 and sIL-6R levels in the peritoneal lavages was also quantified. At 
the peak time of neutrophil recruitment, inoculation of sTLR2 in combination with SES showed a 
reduction (although not statistically significant) in the amount of IL-6 secreted in the peritoneal 
cavity, and a slight decrease in sIL-6R levels (Fig 2.3.2C). 
2.3.2 Effect of sTLR2 on SES-induced NF-κB and STAT activation  
To further investigate the mechanism of sTLR2 modulatory activity in vivo, EMSA analysis of 
nuclear extracts from mouse peritoneal membranes was conducted to assess NF-κB and STAT 
activation during the initial phase of the inflammatory response. Strong NF-κB activation was 
observed at 1h and 2h following i.p. injection of SES, whereas the PBS- and sTLR2-injected 
mice showed very low levels of transcription factor activation (Fig 2.3.3A). The simultaneous 
inoculation of SES and sTLR2 resulted in reduced activation of NF-κB, with more than 50% 
reduction at 1h (Fig 2.3.3A). These findings mirrored those observed in HPMC in vitro (section 
2.2, Fig 2.2.1C) and were consistent with the reduction in CXCL1 levels and neutrophil 
recruitment observed in mice injected with SES + sTLR2 described previously (section 2.3.1). 
 
The activation of STAT (the main signalling intermediate downstream IL-6 receptor) was 
investigated next. SES-induced inflammation triggered STAT1/3 activation in the peritoneal 
membrane (Fig 2.3.3B). At the 1h time point, SES-induced STAT1/3 activation was increased 2-
fold above PBS, and further increased at 2h. The simultaneous inoculation of SES and sTLR2 
resulted in reduced STAT1/3 activation, at 1h and 2h (Fig 2.3.3B). These findings were 
consistent with the negative effect of sTLR2 on IL-6 and sIL-6R levels observed in mice 
inoculated with SES described previously (section 2.3.1 and Fig 2.3.2C). However, they 
contrasted with those in HPMC in vitro (section 2.2), as no effect of SES on STAT activation 
and, consequently, no effect of sTLR2 on STAT in SES-treated cells (section 2.2.4) was 
observed in the mesothelial cells. Clearly, the lack of IL-6R in HPMC explains these contrasting 
findings. 
2.3.3 Effect of sTLR2 on S. epi.-induced peritoneal infection 
The modulatory activity of sTLR2 observed in the SES in vivo model raised the question of 
whether such negative effect would be detrimental to bacterial clearance. To address this issue, 
the activity of sTLR2 was evaluated in an acute episode of peritonitis induced by i.p. inoculation 
of live S. epi. Mice were i.p. inoculated with S. epi. (5 x 108 cfu/mouse) in the absence or 
presence of increasing doses of sTLR2. As will be described in detail in the next section, this 
inoculum allowed a controlled and limited infection to develop and resolve, with the infection 
almost completely cleared by 48h (section 2.4, Figs 2.4.20 - 22). The S. epi.-induced peritoneal 
Figure 2.3.3. Effect of sTLR2 on NF-κB and STAT activation in the SES-induced inflammation model. 
(A and B) Mice were i.p. inoculated with SES, SES + 100 ng sTLR2 or PBS (controls). At the indicated time points, 
NF-κB (A) and STAT (B) activation was analysed by EMSA in nuclear extracts following protein extraction from 
samples of parietal peritoneal membrane. NF-κB and STAT fold induction relative to PBS-injected animals was 
calculated from densitometry analysis of the corresponding EMSA gels. Data shown are representative results of 
three experiments.  
NF-κB !!
+ sTLR2                                           + sTLR2 !
                  1h                                                          2h               !
PBS      sTLR2    SES      SES                    PBS        SES       SES !
                    1h                                                      2h               !
+ sTLR2                                    + sTLR2 !
PBS       sTLR2       SES        SES           PBS       SES          SES !
STAT !!
A!
B!
PBS!
sTLR2!
SES!
SES+sTLR2!
0!
1!
2!
3!
1h! 2h!
ST
AT
 fo
ld 
ind
uc
tio
n!
0!
2!
4!
6!
8!
1h! 2h!
NF
-k
B 
fo
ld 
ind
uc
tio
n!
PBS!
sTLR2!
SES!
SES+sTLR2!
 60 
inflammation and infection process was followed over 18h, the neutrophil, macrophage and 
lymphocyte numbers in the peritoneal lavages were determined by differential cell counting 
using cytospin, and bacterial numbers in the lavages and blood were determined on agar plates 
by using an automated spiral plater. The neutrophil recruitment kinetics and numbers differed 
from those in the SES in vivo model. Here, neutrophil influx peaked at 12h following injection, 
subsequently decreasing. In the presence of sTLR2, neutrophil numbers in the peritoneum were 
significantly reduced at the 12h peak time as well as 18h (Fig 2.3.4A, left panel). Mononuclear 
cells followed a similar recruitment profile to that in the SES model, and like in the SES model, 
their numbers were not significantly modified in the presence of any dose of sTLR2 (Fig 2.3.4A, 
right panel). These results, similar to those observed in vitro (section 2.2) and by using the SES 
in vivo model (section 2.3.2), highlighted the role of TLR2 in Gram-positive peritoneal 
inflammation and confirmed the negative regulatory capacity of sTLR2.  
 
The impact of sTLR2 on bacterial clearance was evaluated next. The bacterial load in the 
peritoneal cavity and in the blood peaked at 3h, and was followed by a steady decrease, with 
the bacteria cleared from the blood by 18h. The addition of sTLR2 to the inoculum - at any 
tested dose - did not significantly modify the bacterial count in the peritoneal cavity. In the 
peripheral circulation, although the mice treated with the highest dose of sTLR2 showed 
increased bacterial load at the earliest time (3h) post-injection (Fig 2.3.4B right), this effect does 
not appear to be physiologically significant, because none of the animals showed symptoms of 
shock, or died from the infection, and all animals had cleared the blood infection almost 
completely by 6h post-injection. Moreover, plasma levels of serum amyloid A (SAA), the acute 
phase reactant secreted by the liver in response to bacterial infection, were similar in control (S. 
epi. only) and sTLR2-treated mice at all time points examined (Fig 2.3.4C), indicating that the 
relatively small increase in bacterial load in the bloodstream of 1 µg of sTLR2-treated mice did 
not significantly impact on the level of the systemic acute phase response. 
 
To examine the mechanism of sTLR2 modulatory activity in this live bacteria in vivo model, 
EMSA analysis of nuclear extracts from the peritoneal membrane was conducted to assess NF-
κB and STAT activation during the initial phase of the inflammatory response. A substantial 
increase in NF-κB activation over the control levels (PBS) was observed at 3h and 6h following 
inoculation of S. epi. The simultaneous inoculation of S. epi. and sTLR2 resulted in reduced 
activation of NF-κB at 3h, but not at 6h, at all sTLR2 doses tested (Fig 2.3.5A). To assess the 
possible effect of sTLR2 on the IL-6 signalling pathway, STAT activation was investigated next. 
S. epi. induced STAT1/3 activation in the peritoneal membrane at 3h and 6h, with levels greatly 
increased above the control (PBS), whereas the simultaneous inoculation of S. epi. and sTLR2 
resulted in a substantial sTLR2 dose-dependent reduction in STAT1/3 activation levels at 3h 
and 6h (Fig 2.3.5B). 
S. epi. 5 x 108 cfu/mouse!
S. epi. + 10 ng sTLR2!
S. epi. + 100 ng sTLR2!
S. epi. + 1000 ng sTLR2!
PBS!
0!
2!
4!
6!
8!
10!
3! 6! 12! 18!
M
ac
ro
ph
ag
es
 (x
10
6 /m
l)!
Time (h)!
0.0!
0.2!
0.4!
0.6!
3! 6! 12! 18!
Ly
m
ph
oc
yte
s (
x1
06
/m
l)!
Time (h)!
0!
2!
4!
6!
8!
10!
12!
3! 6! 12! 18!
Ne
ut
ro
ph
ils
 (x
10
6 /m
l)!
Time (h)!
*!
*!
Figure 2.3.4. Effect of sTLR2 on S. epi.-induced peritoneal infection.  
Mice were i.p. inoculated with 5 x 108 cfu/mouse S. epi., in the presence or absence of the indicated doses of 
sTLR2. At the indicated time points mice were sacrificed, the peritoneal cavity was lavaged and neutrophil, 
macrophage and lymphocyte numbers were determined by differential cell counting using cytospin (A), bacteria in 
the peritoneal cavity and blood were counted using an automated spiral plater (B), and serum levels of Serum 
Amyloid A (SAA) were determined by ELISA (C). Values are expressed as the mean ± SEM (n=3-5/condition; *, p < 
0.05; S. epi. + sTLR2 (as indicated) vs. S. epi.).  
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2.3.4 Effect of IL-6 signalling on S. epi.-induced inflammation and infection 
The live bacteria in vivo model was also used to investigate the role of IL-6 and IL-6 signalling in 
bacterial-induced inflammation and bacterial clearance. To this end, S. epi. or PBS (control) 
was i.p. inoculated into WT and IL-6-deficient (IL-6KO) mice, and the induced inflammation was 
followed for 48h. As described in the next section (section 2.4), the mice body temperature was 
monitored throughout the time course as a parameter of the mice health status and as an index 
of bacterial infection.  
The temperature variations following PBS and S. epi. injection in IL-6KO mice were compared 
with those in WT animals (Fig 2.3.6A and section 2.4). Temperature fluctuations over the time 
course following PBS injection were observed in both WT and IL-6KO mice, reflecting the daily 
variations in body temperature as well as, most likely, the limited inflammation induced by the 
injection of PBS. The fluctuations were more pronounced in WT mice, whereas temperature 
changes in IL-6KO mice remained limited. Although the general pattern was similar in both 
strains, IL-6KO mice temperatures were generally higher than in WT and the increases were 
statistically significant at 0h, 1h, 6h and 18h (Fig 2.3.6A, left panel). Inoculation of WT mice with 
5 x 108 cfu/mouse of S. epi. resulted in a decrease in body temperature at 6h similar to that 
observed in the PBS inoculated mice, it was followed by a regular increase and reached its 
original level by 24-36h (Fig 2.3.6A, right panel). Despite showing an overall similar pattern, the 
body temperature changes in the IL-6KO mice were more severe, with significantly lower 
temperatures than the WT as early as 3h, reaching its lowest point at 6h, and subsequently 
increasing slowly and reaching similar levels to WT at 18h, and basal levels by 36-48h (Fig 
2.3.6A right panel).  
 
To monitor the inflammatory status and recovery of the mice, the serum levels of SAA, which is 
induced by the pro-inflammatory cytokines IL-1β, TNFα and IL-6, were quantified by ELISA. 
Systemic SAA levels increased slowly following bacterial injection, transiently peaking at 18h 
with significantly lower concentrations in the IL-6KO mice (Fig 2.3.6B), confirming the primordial 
role of IL-6 in the induction of the acute phase response to Gram-positive bacteria, as 
previously described (Kopf et al., 1994). 
 
Next, the effect of IL-6 deficiency on leukocyte recruitment was tested. As previously observed 
with the SES model (McLoughlin et al., 2003), and consistent with data from sterile models of 
inflammation (Xing et al., 1998), IL-6 deficiency resulted in a sustained increase in neutrophil 
influx in the peritoneal cavity (Fig 2.3.7A). In addition, the neutrophil influx in IL-6KO mice 
peaked earlier (6h) than in WT (12h), and their numbers were maintained at peak levels and 
higher than in WT up to 24h. IL-6 deficiency also resulted in a sustained increase in 
macrophage and modest in lymphocyte numbers (Fig 2.3.7A). Consistent with these findings, 
the levels of the neutrophil chemoattractant Cxcl1 mRNA, as measured by qRT-PCR, in one 
parietal peritoneal membrane per time point, and those of the macrophage chemoattractant 
Figure 2.3.6. Effect of IL-6 deficiency on sytemic parameters. 
WT and IL-6KO mice were i.p. inoculated with 5 x 108 cfu/mouse S. epi. or PBS. At the indicated time points, mice 
temperatures were measured using a rectal probe (A). Values represent the mean ±SEM (n=6-12/time point). At the 
same time points mice were sacrificed and serum levels of Serum Amyloid A (SAA) were determined by ELISA (B). 
Values represent the mean ±SEM (n=3-6/time point; *, p < 0.05; **, p < 0.01; WT vs. IL-6KO).  
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Figure 2.3.7. Effect of IL-6 deficiency on pro-inflammatory responses to S. epi. infection. 
WT and IL-6KO mice were i.p. inoculated with 5 x 108 cfu/mouse S. epi. At the indicated time points mice were 
sacrificed, the peritoneal cavity was lavaged and neutrophil, macrophage and lymphocyte numbers were 
determined by differential cell counting using cytospin (A), levels of CCL2 expression were determined by ELISA (B, 
right panel), and bacteria in the peritoneal cavity and blood were counted using an automated spiral plater (C). 
Values are expressed as the mean ± SEM (n=6-12/time point for WT and n=6-16/time point for IL-6KO; *, p < 0.05; 
**, p < 0.01; ***, p < 0.001; WT vs. IL-6KO). At the indicated time points, Cxcl1 mRNA expression levels were 
quantified by qRT-PCR following total RNA extraction from biopsies of the parietal peritoneal membrane (B, left 
panel). Data represents the results of one experiment. 
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CCL2, measured by ELISA in the peritoneal cavity, were found increased in IL-6KO mice (Fig 
2.3.7B).  
To evaluate the impact of IL-6 on bacterial clearance, viable bacterial counts were determined 
in peritoneal lavages and whole blood at every time point. While both strains resolved this level 
of infection, Staphylococcal infection in WT mice was more rapidly resolved and brought under 
control within the first 18-24 hours, whereas IL-6KO mice showed impaired bacterial clearance 
and increased dissemination of infection into the bloodstream (Fig 2.3.7C). 
 
EMSA analysis of nuclear extracts from the peritoneal membrane of mice was conducted next 
to assess and compare STAT1/3 activation in WT vs. IL-6KO mice. WT mice showed an early 
and transient STAT1/3 activation, peaking at 3h and decreasing subsequently, with only a 
residual level up to 48h. STAT1/3 activation in IL-6KO mice was found delayed, peaking at 6h, 
and reduced in intensity (Fig 2.3.8A). To determine the STAT family members involved, 
supershift EMSA experiments were conducted using a STAT1 antibody, which causes a loss of 
DNA binding, and a STAT3 antibody, which induces a classical supershift in electrophoresis 
mobility.  STAT3 supershift was observed, as well as the disappearance of the STAT1 band, 
which identified STAT3, and to a lower extent STAT1, in both WT and IL-6KO mice (Fig 2.3.8B). 
Of note, unlike peritoneal stromal cells, SES-induced HPMC activation did not show STAT1 
activation (Fig 2.2.5D), suggesting that other cell types, in addition to mesothelial cells, may be 
involved and/or that S. epi., as opposed to SES, may induce the activation of STAT1 as well as 
STAT3. 
NF-κB activation was next investigated in both strains. IL-6KO mice showed higher basal levels 
of NF-κB activation, and while in WT mice NF-κB activation appeared to be induced earlier (at 
the 1h time point) than in IL-6KO, the latter showed a sustained level of activation over the 48h 
period (Fig 2.3.8C).  
Notably, qRT-PCR analysis of RNA extracted from the peritoneal membrane of one IL-6-
deficient mouse showed increased Tlr2 mRNA expression at 3h compared to that observed in a 
WT mouse (Fig 2.3.8D). 
 
To examine in more detail the role of IL-6 signalling, IL-6 trans-signalling was reconstituted in 
the IL-6KO mice by using a genetically engineered sIL-6R-IL-6 fusion protein (IL-6 is covalently 
linked to sIL-6R) called HYPER-DS-sIL-6R (HDS). IL-6KO mice were i.p. inoculated with S. epi. 
(5 x 108 cfu/mouse) in the absence or presence of increasing doses of HDS. SAA serum 
concentrations were quantified by ELISA. As described in the previous experiment with WT and 
IL-6KO mice, SAA levels were greatly impaired in the absence of IL-6 (Fig 2.3.6B), indicating 
that alterations of systemic activation events is a prominent feature of localised episodes of 
infection. Following the simultaneous administration of S. epi. + HDS, SAA levels were reduced 
in the presence of HDS, suggesting an increased resolution of the acute phase response (Fig 
2.3.9A). The effect of HDS on leukocyte recruitment was examined, and no significant change 
in neutrophil influx was observed. In comparison, HDS seemed to slightly increase the 
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Figure 2.3.8. Effect of IL-6 deficiency on STAT and NF-κB activation, and Tlr2 expression following S. epi. 
infection. 
WT and IL-6KO mice were i.p. inoculated with 5 x 108 cfu/mouse S. epi. At the indicated time points, STAT (A) and 
NF-κB (C) activation was analysed by EMSA in nuclear extracts following protein extraction from samples of parietal 
peritoneal membrane. STAT and NF-κB fold induction relative to PBS-injected animals was calculated from 
densitometry analysis of the corresponding EMSA gels. Data shown are representative results of three experiments. 
The composition of the STAT DNA binding complexes was studied by supershift analysis of the nuclear extracts (B). 
Data shown are results of one experiment. (D) At the indicated time points, Tlr2 mRNA expression levels were 
quantified by qRT-PCR following total RNA extraction from biopsies of the parietal peritoneal membrane. The data 
shown is the result of one experiment.  
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mononuclear cell numbers in the peritoneal cavity at the later time points (Fig 2.3.9B). To 
evaluate the impact of IL-6 trans-signalling on bacterial clearance and dissemination, viable 
bacterial counts were determined in peritoneal lavage and whole blood. Addition of HDS in the 
peritoneal cavity significantly improved bacterial clearance, in a dose-dependent manner, and 
reduced bacterial dissemination in the bloodstream, with an indication of increased 
improvement over the amounts of bacteria in WT mice at the highest doses tested (Fig 2.3.9C). 
2.3.5 Discussion 
In this section, the role of TLR2 in peritoneal responses to Gram-positive infection and the 
consequent negative modulatory activity of sTLR2 and its underlying mechanism, via inhibition 
of NF-κB activation, observed in vitro, were confirmed by using in vivo models of inflammation 
(SES) and infection (S. epi.). sTLR2 did not show however a negative effect on bacterial 
clearance, despite its negative effect on chemokine production and neutrophil recruitment. By 
contrast, IL-6 signalling seemed to improve clearance and reduce dissemination of bacteria as 
well as counteract TLR2-mediated responses by reducing peritoneal leukocyte recruitment and 
chemokine production. The results also suggest that in addition to leukocytes, non-
hematopoietic stromal cells of the peritoneal membrane may be targets for TLR2- and IL-6-
mediated activation during acute infection. 
 
sTLR2’s negative modulatory effect on NF-κB activation and neutrophil chemoattractant CXCL1 
release was demonstrated and correlated with a reduction in neutrophil recruitment, confirming 
sTLR2 anti-inflammatory capacity. The negative modulatory effect of sTLR2 on NF-κB 
activation has the potential to affect the expression of many genes coding for 
immunomodulatory molecules, as observed with the reduced expression of IL-6 and sIL-6R 
mRNA levels at the peak of neutrophil recruitment. This in turn may explain sTLR2’s negative 
effect on SES- and S. epi-induced STAT activation.  
Notably, sTLR2 did not affect mononuclear cell trafficking, thus allowing the resolution phase of 
inflammation to take place. Indeed, the differential effect of sTLR2 on early and late leukocyte 
recruitment (positive on neutrophils and no effect on monocytes, respectively) and the 
consequent skewing of the leukocyte influx in favour of mononuclear cells 
(monocytes/macrophages) may promote efficient removal of senescent neutrophils, allowing the 
resolution of infection while avoiding the detrimental role of a sustained and high level of 
neutrophils at the inflammatory site (Raby et al., 2009). 
An additional modulatory effect of sTLR2 was observed, its capacity to reduce TLR2 expression 
levels. This might represent an alternative mechanism used by sTLR2 to modulate TLR2-
mediated inflammatory responses. Additional experiments will be required to understand how 
this effect on TLR2 expression takes place; a positive effect of sTLR2 on the activation or over-
expression of molecules involved in protein degradation such as ubiquitination may be worth 
testing, as they have been described to be responsible for a reduced expression of some TLRs, 
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although the available data regarding TLR2 is limited and contradictory (Flo et al., 2001; Kurt-
Jones et al., 2002).  
Despite its anti-inflammatory capacity, sTLR2 did not affect bacterial clearance or the acute 
phase response in the model tested. The maintenance of efficient peritoneal removal of bacteria 
in the face of sTLR2 modulation is likely to be due in part to the following: 1) the fact that 
modulation of neutrophil recruitment by sTLR2 was significant at 12h, the peak of neutrophil 
influx, when the animals had cleared the infection almost completely, and 2) the activity of a 
number of other humoral pathway that mediate bacterial clearance and killing, e.g. complement, 
mannose-binding lectin, Igs as well as cell surface Fc and scavenger receptors. Clearly, in vivo, 
other immune components in addition to sTLR2 make a substantial contribution to bacterial 
clearance. It is also worth noting that although this study and others confirmed the critical role of 
TLR2 in the inflammatory response, to Gram-positive bacteria in particular, a number of studies 
on the potential role of TLR2 in bacterial clearance have led to contradictory results and 
interpretations. Initial work with TLR2- and MyD88-deficient mice indicated a positive role of 
TLR2 in bacterial clearance following i.v. Gram-positive infection, potentially only at high 
bacterial dose (107 cfu/mouse), and suggested a role for other TLRs (Takeuchi et al., 2000). 
Other studies using i.p. inoculated S. aureus implicated other receptors as playing more 
prominent roles, notably the complement receptor C5aR (Mullaly and Kubes, 2006). A more 
recent and extensive study however identified TLR2 as the main receptor involved in S. epi. 
clearance, but noted a possible TLR2-independent mechanism of TNFα production by 
peritoneal murine macrophages at high bacterial doses (107-108 cfu/ml) (Strunk et al., 2010). 
Conversely, a detrimental role of TLR2 in a polymicrobial sepsis model has been reported, 
through the inhibition of neutrophil migration towards the site of infection, with an improved 
survival in TLR2KO mice. This study also showed a differential role of TLR2 depending on the 
level of infection (Alves-Filho et al., 2009). The type of infecting microorganism(s), the level and 
route of infection as well as the strain of mice used in the studies may explain, at least in part, 
the controversial findings. Furthermore, for many organisms studied, several TLRs are activated 
and can co-operate, as TLR2 and TLR9 in response to Mycobacterium tuberculosis, and co-
operation with other PRRs such as NOD1 and NOD2 has been implicated in bacterial 
clearance, but these co-operations still remain to be fully assessed (Gerold et al., 2007; Philpott 
et al., 2014). Therefore, compensatory mechanisms can exist, rendering it more complex to 
identify the exact role of a single receptor.  
 
At the onset of S. epi. infection and TLR2-driven inflammatory response, many molecules are 
released and act in parallel, notably cytokines, including IL-6, which possesses pleiotropic roles. 
IL-6 is implicated in the regulation of body temperature by inducing fever early in the acute 
phase response - along with IL-1β and TNFα - via prostaglandin E2 generation in the brain 
(Dinarello et al., 1991). However, in some animals, and notably in mice, hypothermia is a 
feature of disease or infection and predictive of survival (Olfert and Godson, 2000; Soothill et 
al., 1992). Even though IL-6-deficiency did not greatly affect the body temperature of non-
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infected animals, it is not surprising that it should produce a deregulated temperature pattern 
following infection, as was observed.  
Comparative analysis between WT and IL-6KO mice showed that bacterial clearance from the 
peritoneal cavity was significantly impaired in IL-6KO mice, despite a heightened and more 
sustained neutrophil infiltration, whilst dissemination into the bloodstream was also increased, 
demonstrating that the absence of IL-6 was associated with a reduced capacity to fight 
infection. The increase in neutrophil and macrophage influx correlated with an increased NF-κB 
activation in the stromal cells of the peritoneal membrane, which was sustained over the 48h 
time course, as well as with the corresponding increased Cxcl1 mRNA levels and CCL2 
secretion. These findings indicate the involvement of peritoneal stromal cells, including 
mesothelial cells, in leukocyte trafficking through IL-6 trans-signalling, via inhibition of NF-κB 
activation, which was demonstrated in the previous section (section 2.2). These results 
correlated with previous investigations in various models of pneumonia, sepsis and intracellular 
microbial infection, which have documented links between IL-6 and host defence against Gram-
positive and Gram-negative pathogens, where neutrophil function was affected, whereas 
mononuclear cell and NK population did not seem impaired (Dalrymple et al., 1995; Dalrymple 
et al., 1996; Sutherland et al., 2008). 
The reduced bacterial clearance in IL-6KO mice, despite the significantly higher number of 
neutrophils observed in this study, suggested that the anti-microbial neutrophil function was 
impaired. In this regard, a study using a S. aureus septic model in vivo, showed that the 
administration of a recombinant IL-6R improved neutrophil phagocytic function, bacterial 
clearance and survival, through a STAT3-dependent mechanism (Onogawa et al., 2013). 
Although delayed and reduced, STAT3 activation was not abolished, as it is triggered by other 
IL-6 family members, cytokines, hormones and growth factors, but coincided with the early and 
increased neutrophil infiltration. A protective role of STAT3 in endotoxin-induced inflammation 
has previously been described, where genetic deficiency of STAT3 demonstrated an impaired 
cytokine signalling, enhanced NF-κB activation and increased susceptibility to bacterial 
infections (Welte et al., 2003), as observed in this study. 
 
Following reconstitution of IL-6 signalling in the peritoneal cavity of IL-6-deficient mice, HDS did 
not seem to influence the neutrophil influx, despite demonstrating an inhibitory effect on 
neutrophil recruitment in the SES model in other studies conducted in our laboratory. This may 
be due to the presence of an overwhelming amount of bacteria in a context where the neutrophil 
chemoattractant CXCL1 is greatly increased. However, when IL-6 signalling was re-established 
in IL-6-deficient mice, bacterial clearance improved significantly and in a dose-dependent 
manner, and was also associated with an increased resolution of the acute phase response 
(SAA), suggesting that increased bacterial killing at the infection site helps to stem development 
of systemic inflammatory events. This would indicate that IL-6 triggers responses early in the 
inflammatory cascade that facilitate anti-microbial host defense or the containment of acute 
resolving infection. 
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The SES in vivo model, described and used in the previous sections, has allowed to study acute 
inflammation and inflammation-related tissue damage but is restricted in its scope and do not 
permit to examine certain aspects such as anti microbial activities. This is the reason why the 
establishment of a new in vivo model, using live bacteria, which generated some of the results 
described in this section, was undertaken in the laboratory and will be described in the following 
section. 
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2.4 Development of an in vivo model of bacterial peritonitis 
 
There is a need for an improved diagnostic approach to bacterial peritonitis, as this common 
infectious complication observed in PD may lead to fibrosis and treatment failure. This need 
requires a better understanding of how the immune response unravels for each specific type of 
infection (culture negative vs. positive and Gram-negative vs. Gram-positive infection) (Krediet, 
2007; Mactier, 2009). Subsequently, novel therapies could be defined for PD patients with 
peritonitis. In these patients, Gram-positive bacteria are the main cause of peritonitis and 
coagulase-negative Staphylococcus represent almost half of all Gram-positive cases. However, 
Gram-negative bacteria are now responsible for 20 to 30% of all PD-related peritonitis and also 
a major cause of mortality (Szeto and Chow, 2007; Szeto et al., 2008). The treatment strategy 
for these organisms is still disputed (Szeto et al., 2008; Szeto et al., 2005), and the need to fully 
understand the course of immunological events occurring during infection still remains. 
 
In order to better understand the immunological processes taking place during bacterial 
peritonitis, in our laboratory we have used an in vivo model of peritonitis, the SES model (Hurst 
et al., 2001; McLoughlin et al., 2003). Other in vivo models of peritonitis and sepsis have been 
described such as cecal ligation and puncture model of peritonitis/sepsis (Spight et al., 2008), 
zymosan-induced peritonitis (Kolaczkowska et al., 2006) and polymicrobial peritonitis (Celik et 
al., 2001). However, some of them are only used as a mean to study the inflammatory response 
in the peritoneal cavity and systemically in the blood (Celik et al., 2001). Consequently, they do 
not provide a representation of what is observed in PD patients (Kolaczkowska et al., 2006). 
Therefore, these models remain limited and inappropriate in the study of PD. As a 
consequence, the need for a more clinically relevant peritonitis model arose, which aimed at 
recreating the specific clinical situation of PD patients. This explains why in the present study in 
vivo models using an intraperitoneal route of infection/inflammation were chosen, as the 
inflammation in these patients occurs first in the peritoneal cavity, remaining local or spreading 
to other organs subsequently.  
 
In this section, the development of a model that reflects an acute resolving bacterial peritonitis, 
and which allows a close inspection of both local and disseminated infection is described. This 
model has been used in a number of experiments described in the previous sections. The 
organisms chosen for this model are representative of the most common bacteria encountered 
in PD-related peritonitis: Gram-positive bacteria coagulase-negative Staphylococcus 
epidermidis and Staphylococcus aureus and Gram-negative Escherichia coli. Based on the SES 
in vivo model, which has been used and refined over several years, a new model using live 
bacteria was developed. The existing model needed technical adaptation from the SES model 
to address the differences due to the use of live organisms, and a specific design and 
refinement to reach the level of infection desired. It also required to be controlled, with the 
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infection spreading moderately and resolving, unlike some existing models of sepsis, which are 
systemic and often have death as an end point. 
2.4.1 Method 
2.4.1.1 Reagents and Equipment 
See Chapter 4, Material and Methods. 
 
2.4.1.2 Animals 
WT C57BL/6 mice were provided by Charles River and Harlan. Following the establishment of 
the model in mice from Charles River, it was then tested on mice from Harlan, as mice from the 
latter provider had been used previously in some other experiments and gave different results. 
The model established using Harlan mice was however consistent with that using Charles 
River’s, showing similar patterns of temperature variation, leukocytes recruitment and bacterial 
dissemination. For consistency, we selected Charles River mice to carry out the experiments 
described in this thesis. Whenever possible, each experiment was conducted with 50% males 
and 50% females. 
 
2.4.1.3 General aseptic technique 
Before and after any procedure was carried out, work surfaces were thoroughly cleaned with 
1% (v:v) hypochlorite and gloved hands sprayed with 70% (v:v) ethanol. All waste was disposed 
of in autoclavable bags. 
 
2.4.1.4 Bacteria 
The different strain of bacteria used for this model were kept in a dormant state at -80oC as 50% 
glycerol stocks, and experimental batches maintained at room temperature on agar slopes. 
 
2.4.1.5 Agar plate inoculation and incubation  
Using a flame-sterilised loop, bacteria were aseptically transferred to an agar plate, which was 
streaked to isolate single colonies. The plate was incubated at 37oC for 48h, with a check for 
growth after 24h. 
 
2.4.1.6 First and second broth inoculation and incubation  
A single colony of S. epi collected from an agar plate with a flame-sterilised loop was aseptically 
inoculated in 10 ml of liquid broth (see Material and Methods, section 4.1) and incubated 24h at 
37oC in a shaking incubator. This bacteria culture was then used to inoculate nutrient broth for 
each specific experiment (100 µl/10 ml broth) and left initially for 18h, and later reduced to 15h, 
in the shaking incubator. This overnight bacterial culture consistently grew to approximately 1 x 
109 cfu/ml following 15h incubation (see section 2.4.2.1a), consistent with previous reports 
(Masuda and Tomioka, 1978) and with the reported doubling time of 25-30 min (Irwin et al., 
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2010). Consequently, calculations of bacteria preparations for injection were made assuming 
this estimated concentration, verified by OD reading, agar plate count and ATP measurement 
for each individual experiment (see section 2.4.1.8). Using the same protocol, Staphylococcus 
aureus (S. aureus) reached 5 x109 cfu/ml following 15h incubation (see section 2.4.2.1b) and 
Escherichia coli (E. coli) 2 x 109 cfu/ml (see section 2.4.2.1c). All inoculums were prepared 
according to the procedure described for S. epi., and the protocol described in the following 
subsections is based on the use of S. epi. 
 
2.4.1.7 Bacteria preparation for inoculation 
Bacteria were harvested during their log phase growth after 15h incubation and spun down for 
10 min at 4,000 x g at room temperature. The supernatant was carefully removed, avoiding 
disturbing the pellet, which was washed in sterile PBS. The bacteria were spun again and 
resuspended in PBS for a total of 3 times. A final centrifugation at 4,000 x g for 10 min at room 
temperature was done before resuspending the pellet in the volume of sterile PBS calculated for 
each specific experiment. Bacterial suspensions were then left on ice in readiness for 
immediate i.p. administration. 
 
2.4.1.8 Inoculum verification 
a. OD measurement 
     Assuming a concentration at 1 x 109 cfu/ml following 15h incubation, serial dilutions were 
prepared (1 x 109 to 1 x 104 cfu/ml) in PBS, the OD were measured in a spectrophotometer set 
at 600 nm and compared with the counts obtained by agar plate reading (see section 2.4.1.8b). 
Table 2.4.1 below shows representative OD values obtained. 
 
Table 2.4.1 Representative OD values of overnight bacterial cultures 
cfu/ml OD OD OD OD OD 
1 x 109 1.44 1.575 1.121 1.016 1.117 
1 x 108 0.164 0.197 0.126 0.132 0.158 
1 x 107 0.023 0.023 0.006 0.003 0.015 
1 x 106 0.004 0.006 0.003 0.001 0.001 
1 x 105 0.001 0.004 0 0.0015 0 
1 x 104 0 0.005 0 0 0 
 
b. Bacterial counts on agar plate 
     Assuming a concentration at 1 x 109 cfu/ml following 15h incubation, the specific dilution 
used for each experiment was manually or spiral plated on an agar plate to confirm the exact 
concentration obtained. The plate was incubated at 37oC overnight or up to 24h, until colonies 
were big enough to be counted. 
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c. ATP bioassay 
     An alternative technique used for assessing the amount of bacteria to be injected was the 
determination of ATP levels of overnight bacterial cultures. One millilitre of each bacterial 
dilution (1 x 109 - 1 x 104 cfu/ml) was used for ATP assays. All samples were centrifuged at 
17,900 x g for 10 min, the supernatants were discarded, and 100 µl of Benzalkonium Chloride-
extract/EDTA were added to the pellets followed by 100 µl of 25 mM Hepes/10mM EDTA. The 
samples were then stored at -20oC until analysis using the ATP Bioluminescence Assay Kit CLS 
II (Roche Diagnostics).  
 
2.4.1.9 Preparation of injection 
a. Mice body temperature readings 
     According to the Home Office and animal license regulations, if the mice become 
hypothermic (<32oC) for prolonged periods (over 12h), they should be culled and excluded from 
the study. Body temperature readings were carried out on scruffed animals using a 
thermometer probe, previously cleaned with 70% (v:v) ethanol and coated with lubricating gel, 
which was inserted rectally and hold until the reading was stable. The probe was cleaned 
between each animal. Before injecting the mice with bacteria, their body temperature was 
recorded and monitored at indicated time points throughout the procedure, as a measure of 
animal health status. 
 
b. Anaesthetisation of mice 
     A group of 5 to 6 mice was anaesthetised with isoflurane in an anaesthetic chamber with an 
oxygen flow of 2.5 to 3 l/min, following the local animal house regulations. Once unconscious 
and their breathing rate had slightly decreased, the isoflurane level was lowered to maintain the 
mice in an unconscious state. 
 
2.4.1.10 Intra peritoneal injection of anaesthetised mice 
As soon as the mice were unconscious, they were taken one at a time out of the anaesthetic 
chamber, their lower abdomen was sprayed with 70% (v:v) ethanol, and they were injected with 
the indicated bacterial inoculum via the intraperitoneal route. Mice were then put in their 
respective experimental cage and monitored for full recovery from anaesthesia. 
 
2.4.1.11 Mice body temperature readings and culling process 
At designated end time points, the body temperature of each mouse was taken as described 
above (section 2.4.1.9a). They were put in a CO2 chamber to be culled in batches of 2 to 3 mice 
with a CO2 flow rate of 2 to 2.5 l/min.  
 
2.4.1.12 Blood retrieval by cardiac puncture 
Mice were sprayed with 70% (v:v) ethanol prior to proceeding to cardiac puncture. A needle 
coated with heparin to prevent adverse clotting was inserted in the heart and up to 0.6 ml of 
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blood drawn. The volume obtained was recorded, to allow for dilution volumes to be considered 
when calculating bacterial counts. Blood was kept on ice until further processing. 
 
2.4.1.13 Peritoneal lavages  
An incision was made in the abdominal skin, which was pulled away to completely expose the 
peritoneal membrane. Two millilitres of cold PBS was injected in the peritoneal cavity with a 
syringe via a flexible catheter, and the membrane was massaged to ensure sufficient flushing of 
the cavity. The liquid in the cavity was carefully aspirated to collect the cell suspension, and the 
recovered volume recorded. Lavages were kept on ice for further processing. 
 
2.4.1.14 Peritoneal membrane recovery for bacterial count   
About 2 cm2 of membrane was cut out and placed in 1 ml of sterile ice cold PBS, homogenised, 
then spread on an agar plate and incubated at 37oC for 24h to quantify bacterial growth. 
 
2.4.1.15 Kidney recovery for bacterial count 
The mice’s kidneys were carefully cut out and the renal capsule, ureter and blood vessels 
removed. They were then placed in 1 ml of sterile ice cold PBS and kept on ice and 
homogenised. Subsequently, the kidney homogenate was spread on an agar plate to quantify 
bacterial levels following 24h growth at 37oC. 
 
2.4.1.16 Sample processing 
The various samples collected (blood, peritoneal lavages, kidneys and peritoneal membrane) 
were then processed for leukocyte and bacterial counts and storage. 
Before establishing the appropriate dose of bacteria to use and refine the model to suit the 
requirements, the most adequate techniques to measure the different outputs in this model had 
to be determined. 
 
a. Technical issue: haemocytometer vs. cell counter counts 
     First, two different techniques to count the cells from the peritoneal lavage were compared. 
Fig 2.4.1, Fig 2.4.2 and Fig 2.4.3 illustrate the results obtained after counting with a 
haemocytometer or by using a Coulter counter. As shown in Fig 2.4.1A and C, Fig 2.4.2A and C 
and Fig 2.4.3A and B, following injection of increasing numbers of bacteria, the counts with the 
haemocytometer were consistently lower than those obtained with the Coulter counter, when 
looking at total cell counts or a specific cell type. Statistical analysis of the data was conducted 
by using the Bland-Altman test, which assesses the agreement between two methods of 
measurement. Fig 2.4.1B and D, Fig 2.4.2B and D show that the two methods are not 
equivalent, as there is an imbalance between them, indicated by the % of difference 
concentrated on only one side of the x axis. It was difficult to assess exactly how the differences 
between the two methods originated, but despite these divergences, the overall results with 
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Figure 2.4.1. Comparison of two methods for cell counting. 
Mice (n=3/condition) were i.p. injected with the indicated doses of S. epi. At the indicated time points, mice were 
sacrificed, the peritoneal cavity was lavaged and leukocyte numbers were counted using a Coulter counter or a 
heamocytometer (A,C). A Bland-Altman statistical test was used to analyse the data (B,D). 
Figure 2.4.2. Optimisation of cell counting. 
Following a time course of infection with S. epi. (1 x 108 cfu/mouse), total cell (A) and neutrophil (C) numbers were 
determined using the two indicated methods. A Bland-Altman statistical test was used to analyse the data (B and D) 
(n=5/condition). 
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Figure 2.4.3. Determination of neutrophil numbers using two counting methods. 
Mice were i.p. inoculated with the indicated doses of S. epi. At the indicated time points, mice were sacrificed, the 
peritoneal cavity was lavaged and total leukocyte numbers were determined by using a Coulter counter or a 
heamocytometer as indicated. Neutrophils in the preparation were identified by differential cell counting on 
cytospined slides. Their numbers were estimated according to the corresponding leukocyte counts. Values 
represent the mean ±SEM (n=5/time point).  
Figure 2.4.4. Comparison of two methods to differentiate leukocyte populations. 
Mice were i.p. inoculated with S. epi. (5 x 107 cfu/mouse). At the indicated time points, mice were sacrificed, the 
peritoneal cavity was lavaged and neutrophil numbers were determined by differential cell counting using cytospin or 
flow cytometry. Left and right panels show the results of two independent experiments. Values represent the mean 
±SEM (n=2-4/time point). 
Figure 2.4.5. Comparison of two methods to determine bacterial dissemination. 
Mice (n=3/condition) were i.p. inoculated with S. epi. (1 x 107 cfu/mouse). Subsequently, mice were sacrificed and 
bacteria were counted in the indicated organs by manual spreading on agar plates or using an automated spiral 
plater. 
Coulter counter Heamocytometer
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both methods were similar, as shown in Fig 2.4.2C or by the comparison of neutrophil 
recruitment in Fig 2.4.3A and B. Subsequent to this comparison, we used the Coulter counter to 
determine cell numbers, as this was a faster method, more appropriate to the setting of our 
protocol and time constrictions. 
 
b. Technical issue: Differential cell counting by cytospin vs. flow cytometry  
     To distinguish leukocyte populations in the peritoneal lavages, differential cell counting 
(DCC) following cytospin or using flow cytometry may be performed. Fig 2.4.4 shows the results 
of two experiments where the two techniques were used and compared. At the indicated times 
points in each experiment, peritoneal lavages were divided in half and neutrophil, macrophage 
and lymphocyte numbers were determined using either technique. Comparison of results in Fig 
2.4.4 (left and right panels) shows that lower counts were obtained by using flow cytometry than 
cytospin. One reason might be that some cells had been lost during staining in preparation for 
flow cytometry. Given these results, and considering the cost of flow cytometry and time 
necessary to stain the cells, as well as the long time courses of the experiments (involving 
overnight work), it was decided to determine cell numbers by the cytospin method. 
 
c. Technical issue: manual vs. spiral plating of bacteria 
     In order to determine the bacterial load in the different tissues over the time during infection, 
the organs were homogenised and spread manually on agar plates. A spiral plater was acquired 
later (Whitley Automated Spiral Plater II, Don Whitley Scientific Limited, UK), which 
automatically spreads the liquid in a concentric and decreasing manner, facilitating counting 
(high counts in particular). Fig 2.4.5 shows the result of using the manual and automated 
techniques on the same experiment. Although the counts are comparable, manual spreading 
resulted in slightly lower counts than spiral spreading, which might be due to an increased 
difficulty to identify separate colonies when spreading manually and thus less evenly. Spreading 
the cells manually is also a lengthier and less accurate technique, while spiral plating 
standardises counting methods and decreases consumables costs. Hence spiral plating was 
used in all subsequent experiments. 
 
2.4.1.17 Microbiology, dilutions, plating, incubation and counting 
In most experiments only lavages and blood were assessed for bacterial load. For spiral plating, 
50 µl of neat sample were used. Plates were incubated at 37oC for 24h to 48h before storage at 
4oC prior to cell counting using a specified template and counts converted with appropriate 
counting tables from the spiral plater user manual (Don Whitley Scientific Limited, WASP II user 
manual). Later on, this process was done using a plate counter (Don Whitley Acolyte plate 
counter) and software set for counting pour plates with the appropriate dilutions factored into the 
program. The calculations were also averaged for duplicate samples. Remaining samples of 
peritoneal lavages were centrifuged, rendered cell-free and supernatants stored at -80oC for 
further analysis by ELISA (see Material and Methods, section 4.13). Leukocyte pellets were 
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resuspended in PBS prior to analysis by flow cytometry (see Material and Methods, section 
4.13). Blood samples were centrifuged. The serum (cell-free supernatant) was stored at -80oC 
for further analysis by ELISA. For DCC following cytospin, slides were let to dry at room 
temperature following centrifugation, and later stained with modified Wright-Giemsa for 30 sec, 
followed by a 5 min wash in water. Neutrophils, macrophages and lymphocytes in the 
preparations were identified according to their morphology and staining pattern and counted 
under a phase constrast microscope. Fig 2.4.6 shows a representative slide used for DCC by 
the cytospin technique. 
2.4.2 Results 
Fig 2.4.7 recapitulates the protocol followed to develop the new in vivo model. 
 
2.4.2.1 Standardisation-Bacterial growth 
a. Staphylococcus epidermidis 
     One bacterium focus of the present study was S. epi., since amongst coagulase-negative 
staphylococcus organisms, it remains a predominant cause of peritonitis in PD patients (Li et 
al., 2010). Initially, an overnight culture of 1 x 109 cfu/ml was established in liquid broth and the 
OD at 600 nm was measured. Dilutions of 1 x 105, 1 x 106 and 1 x 108 cfu/ml were prepared in 
10 ml broth and the OD measured. Each of these cultures was returned to a shaking incubator 
at 37oC and the OD measured every hour for 7h and then at 24h. Fig 2.4.8 (left panel) shows 
that only the 1 x 108 cfu/ml culture grew from the start in a linear fashion up to 24h, whereas the 
1 x 105 and 1 x 106 cfu/ml cultures took 5h to 6h to start growing. At 24h, the bacterial counts of 
these cultures suggested that they had stopped growing in a linear fashion. Subsequently, 1 x 
106 and 1 x 108 cfu/ml dilutions of the overnight 1 x 109 cfu/ml culture were prepared and the OD 
monitored every hour over a 10h period (Fig 2.4.8 right panel). As in the previous experiment, 
the 1 x 106 cfu/ml culture took 4h to start growing, whereas the 1 x 108 cfu/ml culture grew from 
the start. Both cultures showed a linear growth for about 7h. From the overnight culture, an 
additional 1 x 104 cfu/ml dilution was prepared and 1, 10 and 100 µl aliquots were plated on 
agar and the bacterial numbers counted following overnight incubation (Table 2.4.2 ).  
 
Table 2.4.2 Correlation between nominal bacterial numbers and counts on 
 plates following overnight growth. 
Volume of 1 x 104 cfu/ml 
dilution 
Expected bacterial 
numbers  
Actual bacterial 
counts on plate 
1 µl 10 16 
10 µl 100 94 
100 µl 1000 624 
 
The counts were similar to the numbers expected from a 1 x 104 cfu/ml culture, indicating that 
the estimated concentration of the starting dilution (1 x 109 cfu/ml) was accurate. Following two 
additional experiments that confirmed the correlation between OD readings and bacterial 
Figure 2.4.7. Summary of the process followed for setting up a live bacteria infection model using S. epi., S. 
aureus and E. coli. 
Figure 2.4.6. Leukocytes on cytospin preparations. 
Neutrophils, macrophages and lymphocytes (indicated by black arrows) were identified according to their 
morphology and staining (Wright-Giemsa) pattern in cytospin preparations from peritoneal lavages of mice i.p. 
injected with S. epi., S. aureus or E. coli. 
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Fig 3.2.9. S. aureus (ATCC 25923) growth curve. 
Bacterial cultures of S. aureus with defined ODs measured at the indicated time points (left panel) were grown on 
agarose in triplicate for 24h and bacterial numbers were determined (right panel). 
Figure 2.4.10. E. coli (ATCC 25922)  growth curve. 
Bacterial cultures of E. coli with defined ODs measured at the indicated time points (left panel) were grown on 
agarose in triplicate for 24h and bacterial numbers were determined (right panel). 
Figure 2.4.8. S. epi. (ATCC 12228) growth curve.  
From an overnight S. epi. 1 x 109 cfu/ml culture, several dilutions were prepared as indicated, and at the indicated 
time points the growth of the cultures was monitored by OD reading. Results shown in left and right panels 
correspond to two independent experiments. 
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numbers, bacteria was taken from an agar slope and cultured for 15h. This protocol was 
adopted as part of the final setting of the in vivo model and used in the methodology described 
under sections 2.4.1.5 and 2.4.1.6.    
 
b. Staphylococcus aureus 
     S. aureus is another leading Gram-positive bacteria responsible for peritoneal infection and 
represents a serious complication in PD (Szeto et al., 2007). Understanding S. aureus-triggered 
peritonitis is a prority, as its clinical course has not yet been fully clarified. Following 
establishment of the S. epi. infection model, the same procedure was used to establish a 
corresponding model with S. aureus (ATCC 25923), choosing a mild and commonly used strain 
for quality control and positive control in the evaluation of specific agar plates. Bacteria were 
cultured as indicated previously in section 2.4.1.5 and adapted section 2.4.1.6. To study 
bacterial growth over time, an overnight growth between 1 x 108 and 1 x 109 cfu/ml was 
assumed, and a 1:10 dilution was prepared, cultured and growth monitored over 18h with the 
OD measured every hour (Fig 2.4.9 left panel). The culture grew from the start, with a sharp 
increase in concentration in the first 4h, followed by a slower growth during the next 10h and a 
plateau in the last 4h. At defined time points, a sample of the culture was taken and plated in 
triplicate to determine the bacterial concentration (Fig 2.4.9 right panel). The results indicated 
that the culture reached about 1 x 109 cfu/ml by 12h, subsequently, the concentration 
decreased slightly. Five liquid broth cultures were established, the OD of the overnight (last 
15h) culture was measured, and a sample of the culture was plated in triplicate to verify the 
bacterial concentration. Table 2.4.3 shows the results obtained: 
 
 Table 2.4.3 OD values and bacterial counts of a 15h S. aureus culture 
OD  counts (cfu/ml) 
counts 
(cfu/ml) 
counts 
(cfu/ml) 
Average counts 
(cfu/ml) 
1.144 
144 
4.23 x 109 4.45 x 109 5.77 x 109 4.82 x109 
 1.153 4.43 x 109 5.26 x 109 5.47 x 109 5.05 x109 
 1.192 6.64 x 109 5.99 x 109 4.13 x 109 5.59 x109 
 1.153 4.23 x 109 4.16 x 109 5.18 x 109 4.52 x109 
 1.192 5.55 x 109 5.52 x 109 5.62 x 109 5.56 x109 
    Total average 
5.11 x109 
 
 
 
Based on these results, it was concluded that a 15h culture reached approximately 5 x 109 
cfu/ml. ATCC documentation indicated that the culture protocol followed for S. epi. preparation 
was also appropriate for S. aureus, which was confirmed by the results of bacterial growth.  
 
Of note, OD measurements of bacterial growth were initially complemented with ATP 
measurements of serial dilutions of bacteria, as described in section 2.4.1.8c. However, 
following measurements of ATP activity in more than 10 experiments, this technique proved to 
be unreliable and it was abandoned. 
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c. Escherichia coli 
     PD-related peritonitis and its severe complications are also caused by Gram-negative 
bacteria, with E. coli alone being responsible for almost 7% of culture positive episodes (Szeto 
and Chow, 2007). As previously described for the two other strains of bacteria tested, a growth 
curve of E. coli (ATCC 25922) was established. A bacterial culture was prepared as indicated in 
section 2.4.1.5 and adapted section 2.4.1.6. To study the bacterial growth over time, a 1:100 
dilution of an overnight culture was prepared. The new culture was monitored over a 12h period, 
and the OD measured every hour (Fig 2.4.10 left panel). The culture grew from the start, with a 
regular increase in concentration for about 6h, followed by a slower growth during the 
subsequent 6h. At defined time points, a sample of the culture was plated and checked for the 
bacterial concentration (Fig 2.4.10 right panel). The results showed that the culture reached a 
growth peak of about 2 x 109 cfu/ml after 11h-12h, This concentration is consistent with what 
has been reported in the literature (Masuda and Tomioka, 1978). 
 
2.4.2.2 Staphylococcus epidermidis infection 
A series of experiments were conducted to develop a model of acute peritonitis. In defining the 
appropriate dose of bacteria, it was taken into consideration that a substantial level of 
inflammation should be induced without being lethal, and that the dissemination in other organs 
and blood should be kept limited.  
 
a. Pilot study 1: Aseptic techniques and bacterial dissemination 
     Pilot study 1 was designed to ascertain the optimal aseptic technique for injections and 
evaluate bacterial dissemination. Two groups of five animals were i.p. injected with PBS, with 
the injection site either swabbed or sprayed with 70% (v:v) ethanol before injection. The body 
temperature (rectal probe) and leukocyte counts in the peritoneal cavity (peritoneal lavages) 
were monitored over a 24h and 48h period, respectively. As shown in Fig 2.4.11A, the baseline 
temperature (pre-inoculation) for the two PBS groups differed significantly, with the swabbed 
group showing lower temperatures. The cause of this discrepancy is not clear. However, at 6h 
and 24h both groups showed similar values. Leukocyte numbers were similar after 48h, with no 
sign of inflammation in the lavages (Fig 2.4.11B). Given these similar results, the mice abdomen 
was sprayed with ethanol in subsequent experiments.  
In order to determine the appropriate dose of bacteria to inject that reflects the clinical setting of 
PD-related peritonitis, and to assess the level of dissemination in different organs, 1 x 107 or 1 x 
108 cfu of S. epi./mouse were injected. Similar body temperature was observed in both groups 
(5 mice/group) over the time course (Fig 2.4.12A). As expected, the peritoneal leukocyte counts 
show more inflammation i.e., higher neutrophil and macrophage numbers after 48h, when 1 x 
108 cfu/mouse were injected (Fig 2.4.12B). Blood, peritoneal lavages, peritoneal membrane and 
kidney samples were collected. All material retrieved was spread on agar plates to assess 
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Figure 2.4.11. Evaluation of two aseptic techniques. 
Before i.p. injection of PBS, mice abdomen were swabbed or sprayed with ethanol as indicated. At the indicated 
time points, mice temperatures were measured using a rectal probe (*, p <0.05) (A). At 48h, mice were sacrificed, 
the peritoneal cavity was lavaged and leukocyte numbers were determined by differential cell counting using 
cytospin (B). Values represent the mean ±SEM (n=5/condition).  
Figure 2.4.12. Comparison of body temperatures and leukocyte recruitment following infection with two S. 
epi. doses.  
Mice were i.p. inoculated with the indicated doses of S. epi. At the indicated time points, mice temperatures were 
measured using a rectal probe (A). At 48h, mice were sacrificed, the peritoneal cavity was lavaged and leukocyte 
numbers were determined by differential cell counting using cytospin (B). Values represent the mean ±SEM (n=5/
condition) (*, p <0.05; **, p <0.01).  
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bacterial dissemination (as described in section 2.4.1.16c). Only one colony was found in the 
neat lavage for each group, and all other samples showed no bacterial growth. 
 
b. Pilot study 2: Dose determination 
     Pilot study 2 was conducted to determine the optimal dose of bacteria to use in the 
experiments. To better study the inflammation process and bacterial dissemination, an 
additional time point was included to understand initial immunological events. The baseline 
body temperature was well below the 32oC threshold (lowest body temperature accepted by the 
regulatory body), and remained under that level throughout the procedure, increasing slightly at 
5h and 18h, and decreasing significantly at 24h (Fig 2.4.13). These low body temperature 
values might have resulted from a technical artefact, the probe might not have been used 
appropriately to record actual values (accurate depth and adequate time for temperature 
stabilisation).  
In the next set of experiments, mice (n=3/group) were i.p. injected with S. epi. at 1 x 107 or 1 x 
108 cfu/mouse, and after 18h and 24h, leukocyte numbers in the peritoneal lavages were 
determined (2.3.14A–C). As expected, the higher dose of bacteria (1 x 108 cfu/mouse) induced 
larger peritoneal influx of neutrophils and macrophages, the latter after 24h, which is consistent 
with their later recruitment (Fig 2.4.14A and B). Following the injection of 1 x 107 cfu/mouse, the 
inflammation was in its resolution phase after 24h, with decreasing neutrophil and macrophage 
numbers (Fig 2.4.14A and B), whereas injection of S. epi. at 1 x 108 cfu/mouse prolonged the 
inflammation process, with as many neutrophils at 24h as at 18h (Fig 2.4.14A) and still 
increasing numbers of macrophages and lymphocytes at 24h (Fig 2.4.14B and C). This was 
confirmed by the microbiology counts, which showed approximately 5 times more bacteria after 
24h in the peritoneal membranes of the 1 x 108 cfu-inoculated mice than in those from 1 x 107 
cfu/mouse (Fig 2.4.15 left and right). Of note, Fig 2.4.15B also shows the resolution of 
inflammation, as there are almost no remaining bacteria in the lavages after 18h and 24h.  
 
c. Pilot study 3: Toxicity-survival 
     The previous pilot studies showed that the mice were in good health throughout the time 
course of the experiments and showed mild inflammation (no sign of distress, pain or suffering, 
leukocytes numbers returning to baseline levels, no extensive bacterial dissemination). 
Therefore, the pilot study 3 was designed to explore whether a controlled dissemination and 
resolution of the infection may still be achieved when a higher dose of bacteria is used. To this 
end, S. epi. at 1 x 109 or 1 x 1010 cfu/mouse or PBS (control injection) were i.p. injected, and the 
infection was monitored over a 24h period. At 3h, the mice body temperature was measured. 
Mice injected with 1 x 109 cfu showed diminished activity and looked poorly (piloerection and 
slightly hunched), but their temperature remained at the basal level (Fig 2.4.16A) and similar to 
that of the PBS group (Fig 2.4.16C). The mice injected with 1 x 1010 cfu looked extremely poor 
after 3h with severe signs of sickness, such as piloerection, were slow and hunched, and their 
temperature started to drop (Fig 2.4.16B). This group of mice were considered too poorly, and 
Figure 2.4.13. Body temperature patterns over a 24h time course. 
Mice were i.p. inoculated with the indicated doses of S. epi. At the indicated time points, mice temperatures were 
measured using a rectal probe (**, p <0.01). (n=3-6/time point). 
Figure 2.4.15. Bacterial dissemination following S. epi. infection. 
Mice were i.p. inoculated with the indicated doses of S. epi. At the indicated time points, mice were sacrificed and 
bacteria were counted in the indicated organs by manual spreading on agar plates (n=3/time point). 
Figure 2.4.14. Leukocytes recruitment following S. epi. infection. 
Mice were i.p. inoculated with the indicated doses of S. epi. At the indicated time points, the peritoneal cavity was 
lavaged and neutrophil (A), macrophage (B) and lymphocyte (C) numbers were determined by differential cell 
counting using cytospin. Values represent the mean ±SEM (n=3/time point). 
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thus they were culled and no more data was collected. The mice of the 1 x 109 cfu/mouse group 
were kept over the 24h period, but their temperature dropped significantly at 18h and 24h when 
compared with that at 3h and pre-inoculation (Fig 2.4.16A). The PBS group remained stable 
throughout the experiment (Fig 2.4.16C).  
With regard to bacterial dissemination, too many bacteria were present in the different samples 
collected from the 1 x 109 cfu/mouse group at either 18h or 24h, and could not be counted. Fig 
2.4.16D shows however that there was some bacterial clearance at 24h, as some mice had no 
bacteria in their blood, peritoneal lavage or kidney. Leukocyte numbers could not be 
determined, as the slides presented debris and necrotic cells extremely difficult to identify. It 
was concluded that both inoculums, the 1 x 109 and 1 x 1010 cfu/mouse, resulted in an 
inflammatory episode more severe than that required for the planned experiments of this thesis 
and additional experiments of our laboratory. Overall it would not reflect what was observed in 
most PD patients with peritonitis. 
 
d. Pilot study 4: Bacterial dose optimisation for a 24h study 
     Following the standardisation of bacterial growth described in section 2.4.2.1a, a pilot study 
was conducted to further refine the dose of bacteria to be used in the in vivo model. This study 
aimed at increasing the inflammation process, although slightly, compared with what was 
observed using the doses described in the pilot study 2. To this end, S. epi. at 2.5 x 108 and 5 x 
108 cfu/mouse were injected (n=5/group), and the infection was monitored over a 24h period. To 
confirm the dose of the inoculum, the OD of the two different doses was measured and serial 
dilutions were made, down to 1 x 104 cfu/ml, plated overnight and counted. Table 2.4.4 shows 
the results obtained. 
 
Table 2.4.4 Summary of checks to verify bacterial doses 
Dose 
(cfu/mouse) 
Expected 
bacterial 
numbers 
in 1 µl 
Actual 
counts 
in 1 µl  
Expected 
bacterial 
numbers 
in 10 µl 
Actual 
counts 
in 10 µl  
Expected 
bacterial 
numbers 
in 100 µl 
Actual 
counts 
in 100 µl 
OD 
S. epi. 2.5 x 108 10 26 100 324 1000 1776 0.691 
S. epi. 5 x 108 10 28 100 195 1000 1248 1.245 
 
The bacterial counts indicated that the dose of bacteria injected was higher (up to 2 fold) than 
expected.  
The baseline temperatures were around 36oC, showing a drop of 2 to 3oC (depending on the 
bacterial dose) after 6h and an increase to slightly above baseline levels at 18h, which was 
maintained up to 24h (Fig 2.4.17A and B). Leukocyte counts indicated that the inflammation 
was not resolved in 24h, as expected from the results of pilot study 2. Indeed, neutrophil 
numbers (Fig 2.4.17C) were not yet decreasing, while macrophage and lymphocyte numbers 
(Fig 2.4.17D and E, respectively) were still increasing by 24h, reflecting the initial events of the 
inflammatory process. The bacterial counts from the retrieved organ samples provided 
additional information about the inflammatory process. With the exception of blood, significantly 
Figure 2.4.16. Toxicity and survival study. 
Mice were i.p. inoculated with S. epi. (1 x 109 (A) and 1 x 1010 (B) cfu/mouse) (n=5/time point) and PBS (n=3/time 
point) (C) (n=3-10/condition). At the indicated time points, mice temperatures were measured using a rectal probe 
(***, p <0.001 0h vs. indicated time points). At the indicated time points, mice were sacrificed and bacteria presence 
was determined in the indicated organs (n=5/condition) (D). 
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Figure 2.4.17. Body temperatures and leukocyte recruitment following S. epi. infection. 
Mice were i.p. inoculated with the indicated doses of S. epi. At the indicated time points, mice temperatures were 
measured using a rectal probe (A, B) (n=5-10/time point). At the indicated time points, the peritoneal cavity was 
lavaged and neutrophil (C), macrophage (D) and lymphocyte (E) numbers were determined by differential cell 
counting using cytospin. Values represent the mean ±SEM (n=5/time point). 
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higher counts were always observed with a higher bacterial dose injected (Fig 2.4.18). At 24h 
following injection with S. epi. 2.5 x 108 cfu/mouse, there were almost no remaining bacteria in 
the blood and kidney (Fig 2.4.18A and C), while the numbers were decreasing in the peritoneal 
lavage and membrane (Fig 2.4.18E and G), indicating resolution of inflammation. By contrast, 
the numbers of bacteria were very high in the organs following the injection of S. epi. at 5 x 108 
cfu/mouse, and while decreasing in the kidney (Fig 2.4.18D), they were still increasing at 24h in 
the blood (Fig 2.4.18B), lavage and peritoneal membrane (Fig 2.4.18F and H), thus reflecting an 
ongoing inflammatory process, with dissemination and lack of containment by anti-microbial 
mechanisms. 
 
e. Pilot study 5: Bacterial dose optimisation for a 96h study  
     As the experiments so far have been performed over a 24h period, and with some doses of 
bacteria resulting in an unresolved inflammatory process at the end of the study, the pilot study 
5 was conducted over a longer time course, to ensure complete resolution of the infection and 
facilitate interpretation of the findings. For this experiment, PBS was injected as control, along 
with S. epi. at 1 x 108, 2.5 x 108 and 5 x 108 cfu/mouse over a 96h period. To confirm the 
inoculum doses, dilutions of a theoretical 1 x 104 cfu/ml dose were prepared, plated and 
counted. Table 2.4.5 shows the results obtained. 
 
     Table 2.4.5 Summary of checks to verify bacterial doses 
Dose 
(cfu/mouse) 
Expected 
bacterial 
numbers 
in 1 µl 
Actual 
counts 
in 1 µl 
Expected 
bacterial 
numbers 
in 10 µl 
Actual 
counts 
in 10 µl 
Expected 
bacterial 
numbers 
in 100 µl 
Actual 
counts 
in 100 µl 
S. epi. 1 x 108 10 18 100 172 1000 1584 
S. epi. 2.5 x 108 10 23 100 168 1000 1184 
S. epi. 5 x 108 10 20 100 165 1000 1202 
 
 
The bacterial counts indicated that the doses of bacteria to be injected were higher (up to 1.7 
fold) than estimated. For all subsequent experiments the OD of each dose was measured and 
the concentration checked on agar plates. The bacterial concentrations were then adjusted to 
correspond to the appropriate OD, and thus a dose closer to the one required was prepared.  
For all doses of bacteria injected the pattern of mouse body temperature over time was similar 
(Fig 2.4.19A-C). Indeed, temperature levels at 6h were similar to basal levels, dropped by 3oC - 
4oC at 10h, increased slightly above the basal levels by 18h, and remained at this level up to 
96h. Leukocytes counts in the peritoneal cavity were only monitored from 18h to 96h, as the 
early time points had been studied in pilot studies 2 and 3. The highest neutrophil numbers 
were found at 18h, corresponding to the 1 x 108 and 2.5 x 108 cfu/mouse doses (Fig 2.4.20A). 
The numbers decreased by 24h and remained relatively low. The 5 x 108 cfu/mouse showed a 
different pattern, with a comparatively lower number of neutrophils at 18h, the number 
decreased by 24h but went back up at 36h, decreasing again by 48h and remaining at this level 
until 96h (Fig 2.4.20A). As expected, the overall number of neutrophils over the course of the 
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Figure 2.4.18. Bacterial dissemination following S. epi. infection. 
Mice were i.p. inoculated with the indicated doses of S. epi. At the indicated time points, mice were sacrificed and 
bacteria were counted in the indicated organs by manual spreading on agar plates (n=5/time point). 
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Figure 2.4.19. Body temperature patterns over a 96h time course following S. epi. infection. 
Mice were i.p. inoculated with the indicated doses of S. epi. (A, B, C) or with PBS (D) (n=3/time point). At the 
indicated time points, mice temperatures were measured using a rectal probe (n=5-30/time point (A), n=5-30/time 
point (B), n=5-25/time point (C) and (n=3/time point (D)) (*, p <0.05; **, p <0.01; ***, p <0.001 0h vs.indicated time 
points).  
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Figure 2.4.20. Leukocyte recruitment pattern over a 96h time course following S. epi. infection. 
Mice were i.p. inoculated with the indicated dsoses of S. epi. At the indicated time points, mice were sacrificed, the 
peritoneal cavity was lavaged and neutrophil (A), macrophage (B) and lymphocyte (C) numbers were determined by 
differential cell counting using cytospin (B). Values represent the mean ±SEM (n=5/time point).  
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study was slightly higher with the highest dose of bacteria. Unlike the neutrophil counts, the 
pattern of macrophage and lymphocyte numbers over the time were similar (Fig 2.4.20B and C), 
with no major differences between the different doses of bacteria injected. As previously 
established with the SES model, these two leukocyte populations peaked later than the 
neutrophils (at 36h-48h for macrophages and 48h-72h for lymphocytes; Fig 2.4.20B and C). 
Surprisingly, the lowest dose showed an overall slightly higher number of macrophages and 
lymphocytes than the two other doses.  
Examination of the bacterial counts in the blood, kidney, peritoneal lavage and membrane (Fig 
2.4.21 and 2.4.22) showed, except for the lavages, no remaining bacteria by the end of the 
experiment. Overall, apart from the occasional outliers, a higher bacterial dose resulted in an 
increased bacterial count in the organs, and a longer bacterial clearance. With a regular 
decrease, no bacteria remained in the blood later than 48h (Fig 2.4.21A, C and E), whereas the 
kidney showed some viable bacteria over the time. (Fig 2.4.21B, D and F). The peritoneal 
lavages and peritoneal membrane (Fig 2.4.22A-F) showed a considerable number of viable 
bacteria over the course of the study at any dose used, with the highest dose showing the 
highest bacterial numbers. The lower bacterial dose showed an initial increase in the peritoneal 
lavages, which was sustained until 72h, followed by an abrupt decline by 96h. By contrast, the 
intermediate dose showed a regular decline of bacterial numbers over the time course (Fig 
2.4.22A and C). In the peritoneal membrane bacterial dissemination initially increased from 18h, 
followed by a decrease, peaking at later time points with increasing bacterial doses (Fig 2.4.22 
B, D and F). 
These pilot studies demonstrated the establishment of a controlled model of peritoneal 
inflammation and infection, acute, non lethal, and with a resolving infection manifested by 
moderate temperature variations, leukocyte numbers returning to baseline, and clearance of 
bacteria. 5 x 108 cfu/mouse of S. epi. was determined as the highest appropriate dose for this 
model. 
 
2.4.2.3 Pilot study to establish a mild peritonitis model with S. aureus 
A literature search showed that up to 3 x 109 cfu/mouse were used as sub-lethal doses of S. 
aureus to induce peritoneal inflammation over at least a 24h time course (Crosara-Alberto et al., 
2002; Mullaly and Kubes, 2006). In the first pilot study, three different bacterial doses were 
injected, 1 x 108, 5 x 108 and 1 x 109 cfu/mouse, (n=3/group), with 5 time points over a 24h 
period for testing body temperature levels, leukocyte numbers and bacterial numbers in tissue 
samples.  
The body temperature pattern showed an initial decrease reaching the lowest level at 
approximately 6h. Subsequently, mice injected with the lowest and intermediate bacterial doses 
showed an increased in temperature levels with values closer to basal by 18h, and decreasing 
again by 24h (Fig 2.4.23A and B). The mice injected with the highest bacterial dose showed a 
more important decrease in body temperature (Fig 2.4.23C), probably reflecting a more severe 
infection. This was consistent with the findings on leukocytes recruited to the peritoneal cavity, 
Figure 2.4.21. Bacterial dissemination over a 96h time course following S. epi. infection. 
Mice were i.p. inoculated with the indicated doses of S. epi. At the indicated time points, mice were sacrificed and 
bacteria were counted in the indicated organs by manual spreading on agar plates (n=5/time point). 
A B
C D
E F
S. epi. 2.5 x 108 cfu/mouse
S. epi. 5 x 108 cfu/mouse
S. epi. 1 x 108 cfu/mouse
S. epi. 2.5 x 108 cfu/mouse
S. epi. 5 x 108 cfu/mouse
S. epi. 1 x 108 cfu/mouse
Figure 2.4.22. Bacterial dissemination over a 96h time course following S. epi. infection. 
Mice were i.p. inoculated with the indicated doses of S. epi. At the indicated time points, mice were sacrificed and 
bacteria were counted in the indicated organs by manual spreading on agar plates (n=5/time point). 
Fig 3.2.23. Body temperature patterns over a 24h time course following S. aureus infection. 
Mice were i.p. inoculated with the indicated doses of S.aureus. At the indicated time points, mice temperatures were 
measured using a rectal probe  (n=3-46/time point (A), n=3-46/time point (B) and n=2-46/time point (C)) (**, p <0.01; 
***, p <0.001 0h vs.indicated time points). 
Figure 2.4.24. Leukocyte recruitment patterns over a 24h time course following S. aureus infection. 
Mice were i.p. inoculated with the indicated doses of S.aureus. At the indicated time points, mice were sacrificed, 
the peritoneal cavity was lavaged and neutrophil (A), macrophage (B) and lymphocyte (C) numbers were 
determined by differential cell counting using cytospin. Values represent the mean ±SEM (n=3/time point).  
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with faster neutrophil, macrophage and lymphocyte influxes when 5 x 108 and 1 x 109 
cfu/mouse were injected (Fig 2.4.24A-C), and mostly higher leukocyte numbers recruited when 
more bacteria were injected. Of note, by 24h neutrophil numbers remained relatively high (Fig 
2.4.24A), indicating that the inflammation was not totally resolved. The bacterial load data (Fig 
2.4.25) showed that most mice have cleared bacteria from the blood and peritoneal lavage by 
24h, but there were a few outliers with some bacteria remaining in the blood (Fig 2.4.25A and E) 
as well as the lavage (Fig 2.4.25F). This data suggests that although the bacteria have mostly 
been cleared by 24h, the inflammation process is prolonged with neutrophils remaining in the 
peritoneal cavity for longer and the resolution phase occurring later. Increasing the inoculum of 
bacteria increased the severity of the infection, as shown in Fig 2.4.25 and by inspecting the 
mice. Indeed, all groups were doing poorly between 6h and 18h, with mice moving slowly and 
presenting some piloerection and infected eyes. While 1 x 108 and 5 x 108 cfu/mouse groups 
also presented these signs of sickness, they were less severe and the mice were recovering by 
24h. The 1 x 109 cfu/mouse group showed signs of sickness as early as 6h, and were still poor 
at 24h. An inoculum of 5 x 108 cfu/mouse of S. aureus was deemed appropriate for subsequent 
studies. 
 
2.4.2.4 Pilot study of E. coli - induced peritonitis 
Aiming for a moderate model of E. coli peritonitis, a literature search was conducted and 
showed that sub-lethal doses of E. coli up to 2 x 108 cfu/mouse have been used to induce 
peritoneal inflammation (Demir et al., 2007; Hemmi et al., 2002). The pilot study consisted of 
three different inoculums, 1 x 107, 5 x 107 and 1 x 108 cfu/mouse (n=4/group) to be followed for 
48h, with several time points to test infection/inflammation parameters. The mice injected with 1 
x 107 cfu/mouse showed a body temperature pattern different from that observed with the 
previous strains of bacteria, no significant changes throughout the time course were observed 
(Fig 2.4.26A), even though they showed signs of sickness between 12h and 18h, recovering 
thereafter. The groups injected with the intermediate and higher doses showed a body 
temperature pattern previously observed, a decrease in temperature between 3h and 6h and a 
subsequent increase (Fig 2.4.26B and C). As early as 6h, however, some mice of these two 
groups showed severe signs of sickness, and a few were found dead. At this point, it was 
decided to cull the remaining mice of the 1 x 108 cfu/mouse group except for one, and most of 
the 5 x 107 cfu/mouse ones, keeping only those that appeared to be well and with a temperature 
above 34ºC. For this reason, the experiment was stopped at the 26h time point. The leukocyte 
counts were incomplete, as many slides proved very difficult to count (dead cells, cell debris). 
The data obtained however reflected the severity of the infection (Fig 2.4.27), with neutrophils at 
their highest levels at 24h-26h (Fig 2.4.27A). Macrophage and lymphocyte levels were still rising 
after 24h (Fig 2.4.27B and C). The bacterial counts were also much higher than those 
previously observed with the other strain of bacteria, still very high at 24h for the lowest 
inoculum (Fig 2.4.28A and B). Most of the mice of the 5 x 107 and 1 x 108 cfu/mouse groups had 
Figure 2.4.25. Bacterial dissemination over a 24h time course following S. aureus infection. 
Mice were i.p. inoculated with the indicated doses of S.aureus. At the indicated time points, mice were sacrificed 
and bacteria were counted in the indicated organs using an automated spiral plater (n=3/time point). 
A B
C D
E F
Figure 2.4.26. Body temperature patterns following infection with increasing doses of E. coli. 
Mice were i.p. inoculated with the indicated doses of E. coli. At the indicated time points, mice temperatures were 
measured using a rectal probe (n=10-24/time point (A), n=2-21/time point (B), n=8-20/time point (C)) (**, p <0.01; 
***, p <0.001 0h vs.indicated time points). 
Figure 2.4.27. Leukocyte recruitment patterns following infection with increasing doses of E. coli. 
Mice were i.p. inoculated with the indicated doses of E. coli. At the indicated time points, mice were sacrificed, the 
peritoneal cavity was lavaged and neutrophil (A), macrophage (B) and lymphocyte (C) numbers were determined by 
differential cell counting using cytospin. Values represent the mean ±SEM (n=5-21/time point).  
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to be culled at 6h, as explained previously, and at this time point the bacterial load was still high 
(Fig 2.4.28C, D, E and F).  
This experiment demonstrated that the levels of infection attained with these inoculums were 
much higher than anticipated, and sepsis was observed in many animals. E. coli was not 
extensively used in our laboratory and further setting up and revision of the model using this 
bacterium was subsequently conducted by others. 
2.4.3 Discussion 
The clinical outcomes of Gram-positive and Gram-negative peritonitis in PD patients are 
markedly different when considering hospital admission, catheter removal or relapse, which 
underlines the relevance of studying both types of organisms in our in vivo models. In order to 
obtain a more controllable process, the initial set up of this model was limited to the use of three 
relatively attenuated organisms, although the ultimate aim was to study all the varying strains as 
well as events encountered in the clinical setting by using more virulent organisms.  
 
The setting up of the in vivo model started with relatively small experiments, with limited number 
of mice and time points to assess the severity of the inflammation process induced with lower 
doses of bacteria. The model then increased in complexity by increasing the concentration of 
the bacterial inoculum to adjust the doses to the level of inflammation required, before 
extending the time frame for a better understanding of the inflammation/infection process. As 
the dose of bacteria injected increased, the intensity of the inflammation heightened with 
extended bacterial dissemination and systemic activation. This was reflected in more marked 
body temperature changes. Furthermore, a larger leukocyte recruitment and new patterns of 
recruitment and dissemination were observed, reflecting different time frames of immunological 
events and possibly leukocyte subpopulations activation status. The temporal evaluation of the 
body temperature, leukocyte influx, bacterial clearance from the peritoneal cavity and bacterial 
dissemination into blood, allowed a refinement of animal use in the experiments and facilitated 
the interpretation of the regulation of peritoneal infection. The use of more mice in the 
experiments may have resulted in an increase in the reliability and accuracy of the data, given 
that the variability between animals and genders is quite important. However, it was planned to 
use a limited number of mice in the experiments, and thus animals used were kept to a 
minimum compatible with valid data. 
 
Before establishing the in vivo model in our laboratory, a preliminary experiment was conducted 
in Boston (USA) under the expert supervision of Dr Arthur Tzianabos and staff from his 
laboratory, where another live S. epi. in vivo model for intra-abdominal abscess formation 
studies had already been established. The aim was to determine the pattern of leukocyte 
recruitment and measure chemokine secretion following i.p. injection of S. epi. and to compare 
them with the SES model. Overall, the results were similar to those obtained by using the SES 
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model. This preliminary experiment confirmed the possibility to reproduce with live bacteria what 
is observed in PD patients.  
 
In addition to the SES model, the in vivo model established in our laboratory and described here 
recreated more accurately the infections occurring in PD patients, thus allowing studies on 
acute inflammation, infection, inflammation-induced tissue damage and anti-microbial immunity 
as well as their control mechanisms.  
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Chapter 3 
GENERAL DISCUSSION AND FUTURE WORK 
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A number of studies have demonstrated the capacity of epithelial, endothelial and various other 
cell types lining body cavities to contribute to immune defences (Card et al., 2014; Peterson and 
Artis, 2014). Notably, in the last thirty years the development of PD as an alternative treatment 
for ESRD patients has brought substantial interest in the immunobiology of peritoneal 
mesothelial cells and their role in inflammation (Muijsken et al., 1991; Topley and Williams, 
1994; Valle et al., 1995). The capacity of HPMC to ingest bacteria has been described (Visser 
et al., 1996), and TLRs’ critical ability to detect and initiate inflammatory responses to various 
types of pathogens has been amply demonstrated, in particular in leukocytes (Akira et al., 
2006). However, the pathogen recognition ability of HPMC, the potential role of TLRs in this 
activity, the specific role of HPMC in the early stages of the inflammatory response and the 
regulation of the putative pathogen recognition by HPMC have not been fully investigated. 
 
The aims of the present study were to characterise TLR expression and responses in HPMC, 
and evaluate the capacity of known modulators of pro-inflammatory responses, namely sTLR2 
and IL-6/sIL-6R, to regulate TLR-mediated HPMC and peritoneal responses in vitro and in vivo. 
This study demonstrated the capacity of HPMC to recognise and respond to a vast array of 
bacterial pathogens via expression and function of a specific set of TLRs and NOD receptors. 
Although HPMC did not appear to be able to release sTLR2 and sIL-6R, which are known to be 
secreted during the course of an inflammatory response, they were able to respond to both 
soluble modulators, leading to modulation of the inflammatory response in a timely manner. In 
vivo, sTLR2 and IL-6/sIL-6R showed the capacity to reduce neutrophil influx, at least in part via 
modulating signalling in the mesothelial/stromal cells of the peritoneal membrane. Notably, 
following the establishment of a mouse model of peritoneal bacterial infection, IL-6 signalling 
was confirmed to be beneficial to bacterial clearance. The proposed role of TLRs and IL-6/sIL-
6R in HPMC and their early involvement in inflammation is recapitulated in Figure 3.1. 
 
Primary HPMC, as opposed to an established cell line, were used in part to account for human 
inter-individual variability. Indeed, variability has been well documented in biological systems 
(Endres et al., 1989; Raby et al., 2011; Shikotra et al., 2012), and notably in response to drugs, 
leading to tailored treatment in modern medicine (Rocca et al., 2013; Rosenbaum and Lipton, 
2012). It is important to account for variability when trying to understand a molecular 
mechanism. Variability was observed in TLR2 cell-surface expression (Fig 2.1.2), as well as in 
the basal levels of chemokine secretion, notably with up to 40 fold difference in basal CXCL8 
secretion between various primary cell preparations. These differences may account for inter-
subject variations in the observed response to a particular stimulus, as cells isolated from a 
particular donor might have a different sensitivity to a stimulus as the result of a different 
threshold to trigger a response. The interpretation of cellular responses are particularly 
challenging when a complex stimulus such as SES is used, as opposed to a single stimulus e.g. 
Pam3Cys, as SES probably triggers responses via several signalling pathways in addition to 
TLR2, whereas Pam3Cys signals through TLR2 only. The multiplicity and nature of ligands in 
Bacterial insult 
 (e.g. SES, S. epi.) 
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IL-6 
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IL-6/sIL-6R 
Figure 3.1. Proposed role of TLRs, sTLR2 and IL-6 trans-signalling in TLR-mediated peritoneal responses. 
(A) Bacterial insult triggers cytokine and chemokine secretion by resident macrophages and stromal cells (shown, 
mesothelial cells) from the peritoneal membrane, inducing neutrophil influx into the peritoneal cavity. Upon activation 
by a variety of modulators present at the onset of infection, particularly SES and IFNγ, TLR2 expression on HPMC is 
temporarily increased. This results in an increased production of various chemokines and cytokines dependent on 
NF-κB activation - such as CXCL8, IL-6 and TNFα - that contributes to the peritoneal cytokine network. (B) sTLR2, 
released into the peritoneal cavity during inflammation (most likely by myeloid cells), contributes to a negative 
feedback by inhibiting CXC chemokines (CXCL8/CXCL1), IL-6 and sIL-6R production, neutrophil infiltration as well 
as modulating TLR2 cell-surface expression. (C) Subsequent to peritoneal infection and upon migration and 
activation, neutrophils (and macrophages) shed sIL-6R, which combines with IL-6 - produced by mesothelial cells 
and macrophages - to form the IL-6/sIL-6R complex. (D) This complex inhibits CXC chemokine secretion, neutrophil 
infiltration, TLR2 cell-surface expression and increases bacterial clearance. At the systemic level, IL-6 triggers the 
acute phase reactant serum amyloid A (SAA) secretion whereas the IL-6/sIL-6R complex increases acute phase 
response resolution. 
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preparations like SES clearly contribute to the inter-individual variability observed. A number of 
parameters are responsible for this variability such as age, gender, co-morbidities and genetic 
characteristics. Examining the response in enough individuals to observe a trend or a definite 
response, although not always achievable, may circumvent it. A potential consequence of the 
variability in TLR expression and sTLR2 secretion for pro- vs. anti-inflammatory mediator 
response between individuals might be a differing capacity to clear infection efficiently and 
successfully resolve inflammation. Amongst the parameters responsible for variability, an 
important one to consider is age, as there is evidence that immunological responses are greatly 
affected by it - both in terms of cell population numbers and functions - which led to the creation 
of the new separate research area that is immunoscenescence (Solana et al., 2012). This is 
particularly important when considering an aging population, like PD patients who are often 
elderly. For example, preliminary work by Witowski’s group showed that HPMC seem to behave 
differently when stimulated at early and late (senescent cells) passages, with a heightened 
basal level of IL-6 secretion and lack of response to stimulation by PD effluent by the latter 
when compared to “younger” cells (Rudolf and Witowski, 2013). In addition, it has been shown 
that breast cancer cells, naturally unresponsive to IL-6 stimulation, increase their IL-6R 
expression during cellular senescence, rendering them responsive to classic IL-6 signalling, 
whereas they were previously only responsive to trans-signalling (Garbers et al., 2013), 
potentially triggering a detrimental cascade of events. This will be important to consider when 
exploring new therapeutic avenues. 
 
Despite the mentioned variability, the data presented in this study adds further evidence of the 
role of the mesothelium in the regulation of inflammation in the peritoneal cavity, and emphasise 
the importance and relevance of cell-type/organ specific studies, as conflicting data often arise 
from different experimental model systems. In addition, experiments done with KO mice 
replenished with the missing protein/molecule do not necessarily recapitulate the observations 
in WT animals, implying the existence of underlying mechanisms better understood at a specific 
cell-type/organ level. Indeed, in CAPD, increased local IL-6 levels in the peritoneal cavity are 
associated with lower membrane function but not with survival, whereas systemic levels 
correlate with survival (Lambie et al., 2013). In addition, since individual pathologies may 
possess unique aetiologies, it is critical that changes in the immune response are monitored 
within a defined clinical context.  
 
The critical role played by the mesothelium in inflammation is further demonstrated by the 
capacity of human peritoneal fibroblasts to secrete CXC and CC chemokines - notably CXCL8, 
CXCL1, IL-6, CCL2 - in response to inflammatory mediators secreted by macrophages, 
demonstrating the fibroblasts’ contribution to leukocyte trafficking into the peritoneal cavity 
(Jorres et al., 1996; Witowski et al., 2009; Witowski et al., 2001). 
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SES- and S. epi.-induced TLR2 stimulation leading to NF-κB activation, chemokine secretion 
and leukocyte recruitment, and the modulatory effect of sTLR2 demonstrated in this study are 
convincing evidence that TLR2 is involved in peritoneal responses to Gram-positive bacterial 
infection. Notably, in addition to the well-documented observations of the activity of TLR2 in 
leukocyte populations (Zarember and Godowski, 2002) confirmed here, the present results 
demonstrate the activity of TLR2 in stromal cells of the peritoneal membrane.  
 
This study also demonstrated that sTLR2 regulates peritoneal TLR2-mediated pro-inflammatory 
responses induced by microbial components from Gram-positive bacteria in vitro and in vivo. In 
addition, a role of sTLR2 in macrophage and neutrophil functions has been shown, with a 
modest inhibitory effect on the phagocytic capacity of macrophages, but a significant reduction 
in superoxide production by neutrophils (Raby et al., 2009), thus showing sTLR2 potential to 
modulate critical effector functions. The presence of sTLR2 in non-infected and infected 
effluents of PD patients points at a role of sTLR2 as part of a negative feedback mechanism to 
control peritoneal inflammation and therefore limit the potential damage to peritoneal tissues 
that may result from a prolonged response to infection. Considering that inflammation is an 
aggravating factor in PD and increases treatment failure, it would be of interest to monitor 
sTLR2 levels over the course of PD therapy and evaluate the potential as marker of treatment 
outcomes by linking sTLR2 levels to membrane function and survival. Given that HPMC are 
known to play an important role during the early phase of peritoneal inflammation, notably in 
leukocyte trafficking into the peritoneal cavity (Douvdevani et al., 1994; Topley et al., 1993a; 
Topley and Williams, 1994), their ability to respond to sTLR2 demonstrated in this study 
supports an additional role of this cell type, as critical player in the modulation of the 
inflammatory response.  
 
Beside a role in processes such as metabolism, embryonic development and memory 
consolidation, IL-6 and its receptors are involved in inflammation by controlling differentiation, 
proliferation, migration and apoptosis of target cells (Scheller et al., 2013). Previous studies 
demonstrated the involvement of IL-6 signalling in the resolution of inflammation (Hurst et al., 
2001; McLoughlin et al., 2005; Xing et al., 1998) and the data presented here further 
substantiate this role. Unpublished data from our laboratory using the S. epi. in vivo model of 
peritoneal inflammation in WT and IL-6KO mice demonstrated the importance of non-
hematopoietic stromal cells of the peritoneal membrane in IL-6-mediated processes by showing 
that IL-6-trans-signalling and STAT3 activity in the peritoneal membrane may be responsible for 
the anti-bacterial activity of the infiltrating neutrophils. The study showed that upon S. epi. 
infection, sIL-6R is shed by resident macrophages and infiltrating neutrophils. Subsequently, 
these cells became unresponsive not only to IL-6 classic but also trans-signalling, and 
dependant on stromal cell trans-signalling and STAT3 activity for efficient phagocytic and 
respiratory burst activity by neutrophils (Hammond et al., manuscript in preparation). 
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IL-6 is a marker of disease progression, and a humanised anti-IL-6R antibody is now used to 
treat rheumatoid arthritis (Tanaka et al., 2012). However, blocking of IL-6 signalling has been 
associated with increased bacterial infections (Lang et al., 2012), an important issue to consider 
in prolonged/lifetime treatment therapies such as rheumatoid arthritis and other autoimmune 
diseases. The findings presented in this thesis by using IL-6KO mice are consistent with the IL-
6 blocking experiments reported previously, as they show that the lack of IL-6 reduces bacterial 
clearance substantially. Bacterial clearance is a major parameter to control in order to promote 
a timely resolution of inflammation and limit the damage of host tissue. Retention of leukocytes 
at sites of immunological challenges is also a risk factor of chronic inflammation and fibrosis. 
Well-designed in vivo models of peritoneal infection/inflammation are critical to a better 
understanding of the host’s response to bacterial challenge, which is vital to reduce the impact 
of the concomitant inflammation in the peritoneal cavity. The development, validation and use in 
this study of a mild-moderate mouse model of peritoneal infection using S. epi., S. aureus and 
E. coli, has allowed us to make key observations of clinical relevance to bacterial peritonitis. 
Notably, by collecting data on leukocyte profiling over time during infection, local and systemic 
bacterial dissemination/clearance rates, body temperature change profile and changes in the 
acute phase response, it was demonstrated that therapeutic modulation of the IL-6/sIL-6R 
signalling pathway could accelerate bacterial clearance as a result of its effect on leukocyte 
trafficking. The change in the spectrum of infecting organisms in PD patients correlates with the 
increased development of antibiotic resistance, which is driving the increased demand for novel 
therapeutic strategies to combat these types of infections. The new live in vivo model described 
here, specifically with the use of both Gram-negative and Gram-positive bacteria and also 
clinically relevant antibiotic resistant organisms, will help to evaluate whether modulating 
leukocyte trafficking and/or bacterial clearance through the use of molecules such as sTLR2 
and IL-6/sIL6R complex improves the resolution process and is a viable therapeutic option for 
all infections. The validation of this model should subsequently inform the development of 
therapeutic interventions to reduce inflammation, through a faster and more efficient resolution, 
and prevent progression to membrane and technique failure. 
 
IL-6 and sIL-6R possess the capacity to orchestrate both beneficial and detrimental outcomes. 
Plasma IL-6 levels are increased in numerous diseases, including CAPD, and considered to be 
a prognostic marker of poor outcomes (Pecoits-Filho et al., 2002). Sepsis is a complex 
syndrome, with a heterogeneous immune response (Remick et al., 2002). Elevated IL-6 levels 
in peritonitis mouse models of sepsis have been found associated with a higher mortality risk 
(Remick et al., 2002), although this correlation was demonstrated only for the early but not late 
sepsis mortality (Osuchowski et al., 2006). Therefore, IL-6 presence is often associated with 
detrimental outcomes, indeed, genetic polymorphism leading to increased IL-6 mRNA levels in 
the peritoneal membrane and IL-6 protein levels in dialysate and plasma are associated with 
higher membrane permeability and worse solute transport function (Gillerot et al., 2005). 
Despite high serum IL-6 concentration, studies have described an impaired IL-6/STAT3 
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signalling in sepsis that correlates with increased mortality - possibly due to an alteration of the 
gp130 signalling receptor phosphorylation status and/or inhibition of the JAK/STAT pathway 
(Abcejo et al., 2009; Ling et al., 2002). Serum sIL-6R levels are also increased during 
inflammation, as well as local levels in various autoimmune disorders and cancers, and 
correlate with poor survival (Kallen, 2002). Given its detrimental role in various diseases, 
blockade of IL-6 signalling with an anti-IL-6R antibody is now a common therapy, notably for 
rheumatoid arthritis, and has proven very effective (Serada et al., 2008; Takagi et al., 1998). In 
light of more recent research, and the differing activities of classic vs. trans- signalling, blocking 
of the latter pathway using soluble gp130 linked to the Fc portion of IgG (sgp130Fc) (Jostock et 
al., 2001) has shown promising results in preclinical animal models of chronic inflammatory 
diseases such as inflammatory bowel disease (IBD), rheumatoid arthritis (RA) and 
inflammation-associated cancer such as colon cancer, and is currently in phase I clinical trials 
for IBD and RA (Scheller et al., 2013). Separating clearly the role of classic IL-6 signalling vs. 
trans-signalling, however, remains a challenge. Through the design and use of the proteins 
Hyper-IL-6 (chimera IL-6/sIL-6R fusion protein) and soluble gp130Fc studies have 
demonstrated that IL-6 trans-signalling drives chronic inflammation and autoimmune disorders 
(Jones et al., 2011). Whether one of the two IL-6 signalling pathways is really detrimental 
remains to be determined. Some differences could be explained by the fact that different stages 
of the inflammatory process and disease progression - initiation, progression/resolution vs. 
chronic inflammation - are controlled by different cell-types, namely leukocytes/hematopoietic 
cells and hepatocytes, which express membrane-bound IL-6R, and non-hematopoietic cells, 
which express gp130 and are only activated via trans-signalling once the IL-6R has been shed 
by leukocytes. The immune activity of non-hematopoietic cells may not be as tightly regulated 
as in leukocytes, and a slight deregulation may trigger harmful signalling events. In addition, 
once sIL-6R has been shed, all cells in the environment may have the capacity to trigger IL-6-
mediated responses via trans-signalling, amplifying a potentially detrimental effect of IL-6 
signalling irrespective of the pathway classic or trans- signalling. Finally, the trans-signalling 
detrimental effect could be due to a deregulation of leukocyte activation status, primarily 
neutrophils, leading to an excessive sIL-6R shedding and a cascade of detrimental signalling 
events. Deciphering the role of the two different types of signalling, as well as cell-type activity, 
might be beneficial to inform future therapeutic options, and as knowledge increases, it might 
prove useful to block classic vs. trans- signalling at various stages of the disease. 
 
In HPMC, the simultaneous activation of the TLR2 and IL-6 signalling pathways - via NF-κB and 
STAT3 activation, respectively - showed an inhibitory effect on the NF-κB-driven secretion of 
the neutrophil chemoattractant CXCL8 and induction of the monocyte and T cell 
chemoattractant CCL2. These findings suggested an additional role of HPMC in response to 
Gram-positive infection, in the transition from the recruitment of leukocytes typically associated 
with innate immunity to those important in acquired immunity. This transition appears to 
facilitate the successful resolution of inflammation and the return to normal tissue homeostasis 
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without organ damage (DiTirro et al., 1998). The in vivo results using IL-6-deficient mice partly 
correlated with the in vitro findings, in particular regarding the role of IL-6 in controlling 
neutrophil recruitment, as IL-6 deficiency resulted in increased peritoneal neutrophil recruitment 
and CXCL1 levels. By contrast, in vivo, IL-6 deficiency also resulted in increased CCL2 levels 
and monocyte/lymphocyte recruitment, indicating a negative effect of IL-6 on mononuclear cells 
recruitment in vivo. CCL2 secretion and regulation - and its effect on mononuclear cell influx - in 
vivo, appear to be complex mechanisms and do not seem to be governed by IL-6 signalling 
exclusively. The use of whole bacteria (S. epi.) and the involvement of other peritoneal cells in 
addition to HPMC may have also contributed to the effect observed in vivo, as it is possible that 
microbial components other than those activating via TLR2 may have triggered signalling 
pathways in peritoneal cells that directly or indirectly modulate IL-6 signalling.  
 
sTLR2 also demonstrated a differing modulatory effect on neutrophil and mononuclear cell 
recruitment, as sTLR2 - via inhibition of CXCL8 secretion - reduced neutrophil influx, as shown 
in this study, whereas it had no effect on mononuclear cell recruitment, despite triggering a 
heightened CCL2 secretion, as shown by Raby et al. (Raby et al., 2009). Other chemokines - 
such as CCL3 and CCL5 - play an important role in inducing monocyte/macrophage infiltration 
to the site of infection and it would be of interest to study the effect of sTLR2 on their 
recruitment profiles. Another cytokine belonging to the IL-6 family affects the profile of leukocyte 
recruitment. Indeed, oncostatin M has been shown to limit monocytic cell infiltration by inhibiting 
CCL5 secretion by HPMC (Hams et al., 2008). In addition, human peritoneal fibroblasts have 
been shown to release CCL5 in response to inflammatory mediators present in the inflamed 
peritoneal cavity (Kawka et al., 2014). Alternatively, chemokine receptor expression might be 
affected, rather than the ligand. CCR1, CCR2 and CCR5 are CC chemokine receptors 
mediating the recruitment of blood monocytes towards infected tissues. It will be of interest to 
test whether the expression of these receptors is affected by sTLR2 and by IL-6/sIL-6R in 
TLR2-mediated responses, as TLR2 has been shown to negatively regulate these receptors 
(Fox et al., 2011). The chemokine network generated following an inflammatory insult will have 
compensatory roles, with the positive effect of one chemokine counteracted by other mediators. 
The results of the present study also suggest a differing regulation of the various chemokines 
expressed during an inflammatory episode between the various cell-types involved, resulting in 
an increased complexity when examining responses at the organ level. 
 
The modulatory effect of IL-6 and its STAT3 downstream signalling pathway on TLR2-mediated 
responses indicated by the findings of this study, has also been suggested in a number of 
studies and disease settings. In cancer, with tumorigenesis often reliant on/or involving a 
chronic inflammatory component, a common feature is the deregulated co-activation of STAT3 
and NF-κB (Mansell and Jenkins, 2013). Notably, one study on gastric cancer demonstrated 
that STAT3 activation directly increased TLR2 expression in gastric epithelial cells (Tye et al., 
2012). In this regard, it will be of interest to investigate the effect of IL-6/sIL-6R on TLR2 
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expression in HPMC as well as in the in vivo settings used in this study. Preliminary results of 
HPMC stimulation with Pam3Cys or SES in the presence or absence of the IL-6/sIL-6R complex 
showed that Pam3Cys-mediated and SES-mediated Tlr2 mRNA levels did not seem to be 
significantly affected by IL-6/sIL-6R. These results imply that the modulatory effect of IL-6 
signalling on TLR2-mediated responses may not be exerted through modulation of TLR2 
expression, but the data will need to be confirmed before a clear interpretation can be made. 
Another indication of the interplay between TLR2 and IL-6 signalling pathways is the 
observation that the production of a number of non-microbial TLR2 agonists is regulated by 
STAT3, such as the TLR2 agonist SAA (Hagihara et al., 2005). It will also be of interest to 
further study the regulation of this acute phase reactant in our in vivo settings. 
 
 
A number of issues and questions were raised by the present study that deserve to be 
addressed through future work: 
 
1. The results of the in vitro studies have indicated that SES responses are mediated 
primarily via TLR2. However, the extent of the TLR2 involvement and the possibility that 
additional signalling pathways are involved cannot be excluded at present. Stimulation of the 
astrocyte-like cell line U373, which expresses TLR1, TLR3, TLR4 and TLR5, but not TLR2 or 
CD14, gave an additional indication of the main role of TLR2 (Kurt-Jones et al., 2004). 
Following stimulation with increasing doses of LPS, Pam3Cys and SES, these cells showed a 
dose-dependent secretion of CXCL8 in response to LPS but not to Pam3Cys, and SES only 
triggered a response at the highest dose used. Preliminary in vivo experiments of i.p. injection 
of SES into C3H/HeJ mice, which are naturally deficient in TLR4 signalling (Poltorak et al., 
1998), showed a response to SES in terms of neutrophil recruitment over a 6h time period, 
further confirming the lack of involvement of TLR4 in SES responses. To further study the 
specificity of SES-induced responses it would be of interest to block specific signalling pathways 
using TLRs and NODs siRNAs in vitro, as well as TLR2KO mice in vivo. 
 
2. Following previous work on the role of sTLR2 and the elucidation of its mechanism of 
action (LeBouder et al., 2006; Raby et al., 2009), this study has further demonstrated in HPMC 
and in two in vivo models that sTLR2 is able to dampen inflammation by reducing NF-κB 
activation, neutrophil chemoattractant levels and the number of neutrophils infiltrating the 
peritoneal cavity. The lack of effect of sTLR2 on bacterial clearance has not been extensively 
investigated. As there is debate about the exact role of TLR2 in bacterial clearance, it will be of 
interest to evaluate the role of sTLR2 in IL-6KO animals, where there is an increased neutrophil 
influx and delayed bacterial clearance, and to determine sTLR2’s capacity to modulate a 
deregulated inflammatory response. 
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3. It will be of interest to examine the regulation of TLR expression further during in vivo 
inflammation. To this end, peritoneal inflammation using the established SES or S. epi. models 
may be induced in WT mice and several strain of knockin mice genetically modified in the 
gp130 signalling pathway. At specific time points, inflammatory mediator expression and 
leukocyte trafficking will be examined to define the immune activation process, and TLR2 
expression levels will be assessed in the peritoneal membrane. Preliminary experiments using 
the SES in vivo model indicate a reduction of TLR2 expression in the peritoneal membrane 
when STAT3 is over-expressed, suggesting a possible down-regulation of TLR2 expression by 
IL-6/STAT3 signalling. Changes in expression levels of SOCS3 - a STAT3-dependent inhibitor 
of IL-6 signalling - will also be monitored as SOCS3 has been described as being part of a 
negative feedback loop to regulate TLR signalling (Baetz et al., 2004; Rothlin et al., 2007). 
 
4. One of the main complications of PD therapy is the development of fibrosis of the 
peritoneal membrane (de Lima et al., 2013), leading to loss of peritoneal function. Fibrosis is 
linked to the duration of treatment and incidence of bacterial peritonitis (Davies et al., 1996; 
Williams et al., 2002). IL-6 signalling was shown to play a critical role in the development of 
fibrosis through STAT1 inhibition of homeostatic extracellular matrix turnover (Fielding et al., 
2014). The involvement of TLRs, and TLR2/4 in particular, in peritoneal fibrosis remains to be 
determined. To examine the influence of TLR signalling on the development of fibrosis, 
repeated rounds of inflammation will be induced in WT and TLR2/4KO mice. At defined time 
points up to 49 days, peritoneal lavages will be collected as well as membrane biopsies, 
specifically mesothelial cell layer obtained by laser dissection. Immuno-detection approaches 
and quantitative mRNA analysis will be used to assess changes in TLR and fibrotic markers 
expression, such as collagen, transforming growth factor β and SMAD7. Such changes will be 
correlated with alterations in leukocyte trafficking and inflammatory mediator expression. The 
thickness of the submesothelial compact zone will be measured, scored and compared in WT 
and TLR2/4KO mice. 
 
5. The anti-inflammatory capacity of sTLR2 and its presence in the PD effluent described in 
this study raise the question of whether sTLR2 levels in PDE correlate with treatment outcome 
and/or can be used as early and sensitive prognostic marker of infection in these patients. In 
this regard, it will be of substantial interest to monitor sTLR2 levels in the PDE of stable and 
infected patients. 
 
In conclusion, this study demonstrated that the interaction of Gram-positive bacteria with TLR2 
expressed on the mesothelium is an early feature of the induction and orchestration of the 
inflammatory response in the peritoneal cavity. A growing number of studies highlight the 
relevance of examining different pathways in relation to each other, as none acts in isolation, 
and what is observed results from a combination of interplays and cross-talks between various 
pathways. Understanding the regulatory processes governing the onset of inflammation and the 
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molecular mechanisms behind the altered responses observed in chronic diseases may inform 
the design of novel therapeutics against acute and chronic inflammatory conditions that will aim 
at reducing detrimental events while preserving microbial recognition and effective immune 
responses. Such therapeutics may prove useful in PD. 
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Chapter 4 
MATERIALS AND METHODS 
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4.1 Antibodies, reagents and equipment 
The antibodies used and their sources are listed in Table 4.1 and 4.8. All chemicals were 
reagent grade. The synthetic bacterial lipopeptides Pam3-Cys-Ser-(Lys)4 HCl (Pam3Cys) and 
Pam2-Cys-Phe-Glu-(Pro)3-Ala-(Thr)3 (Pam2Cys) were purchased from EMC Microcollections 
GmbH, (Tübingen, Germany). Ultra-pure LPS (from Escherichia coli O111:B4 strain), bacterial 
peptidoglycan and Flagellin (from Salmonella typhimurium) were purchased from Invitrogen™, 
Life Technologies (Paisley, UK). Human natural soluble CD14 (sCD14), purified from human 
milk as described previously (Labéta et al., 2000) and human recombinant sTLR2, produced 
and purified as described in Raby et al. (Raby et al., 2009), were prepared in our laboratories. 
sTLR2 corresponds to the full extracellular domain of human TLR2. Recombinant IL-1β, TNFα, 
IFNγ, IL-6, sIL-6R (proteolytic shedding form) and Oncostatin M were purchased from R&D 
Systems (Minneapolis, MN, USA). The unimolecular protein HYPER-DS-sIL-6R (HDS) is a 
genetically engineered sIL-6R-IL-6 fusion protein designed so that IL-6 is linked to the 
differentially spliced form (DS) of sIL-6R, was GMP-manufactured by Biovian Ldt. (Turku, 
Finland). DRAQ5 was from Biostatus Ltd. (Shepshed, UK). Fluorosave was from Merck 
Millipore (Nottingham, UK). Electrophoresis grade agarose (Ultrapure agarose) was from 
GIBCO/BRL (Paisley, UK). EDTA, DTT, recombinant ribonuclease inhibitor (RNAsin) and 
Klenow fragment (DNA polymerase I large) were from Promega Ltd (Southampton, UK). Ficoll 
Type 400, random hexamers and deoxynucleotides (dATP, dGTP, dCTP, dTTP) were from 
Amersham Biosciences UK Ltd (Chalfont St.Giles, UK). Nitrocellulose membrane (Hybond ECL) 
was from Amersham Pharmacia, UK Ltd., (Little Chalfont, UK). RNAse-free DNAse I, 
Superscript II reverse transcriptase and Superscript III 1st strand synthesis strand system were 
from Invitrogen™, Life Technologies. All cell culture media and reagents were purchased from 
Invitrogen™, Life Technologies, unless otherwise stated. 1X PCR buffer was from Applied 
Biosystems (Warrington, UK). The cell culture flasks (Falcon) were from Becton Dickinson 
(Oxford, UK). Human AB serum was from tcs biosciences Ltd (Buckingham, UK). RNase-free 
DNase Set and RNAEasy minicolumns were from Qiagen (Valencia, CA, USA). α[32P]-dTTP 
was from Perkin Elmer (Waltham, MA, USA). 6X DNA loading buffer and the centrifuge for 
cytospin were from Thermo Fisher Scientific (Waltham, MA, USA). X-ray films were from GE 
Healthcare (Chalfont St Giles, UK). Staphylococcus epidermidis (12228), Staphylococcus 
aureus (25923) and Escherichia coli (25922) were purchased from ATCC (ATCC, Teddington, 
UK). Heparin (5,000 units/ml) was from Sagent Pharmaceutical (Schaumburg, IL, USA). 
Modified Wright-Giemsa stain (Accustain), BAC-extract (Benzalkonium Chloride, 1 mg/ml), 
transferrin, insulin, hydrocortisone, Tri Reagent, 3M Whatman paper and Tyrode’s salt were 
purchased from (Sigma-Aldrich, Poole, UK). The ATP Bioluminescence Assay Kit CLS II was 
purchased from Roche Diagnostics (Burgess Hill, UK). Nutrient Broth No. 2, diagnostic 
sensitivity testing agar plate, agar slopes, 50% glycerol slopes on plastic beads, Mueller-Hinton 
Agar plates and Columbia Agar with 5% Horse blood were from Oxoid Limited (Basingstoke, 
UK). The tissue homogeniser (PowerGen125) was purchased from Fisher Scientific 
 
 
 
 
 Table 4.1 List of antibodies and immunoreagents 
 
Antibodies to 
 
Clone/code Isotype Source 
Human TLR2 T2.5 Mouse IgG1 eBioscience, CA, USA 
Human TLR2 TL2.1 Mouse IgG2a eBioscience 
Human TLR2 peptide 
N-terminus 20-mer 
peptide) 
TLR2p Rabbit IgGs 
Dr. M.O. Labéta, Institute of Infection 
& Immunity, School of Medicine, 
Cardiff University, UK {LeBouder, 
2003 #14} 
Human TLR4 HTA 125 Mouse IgG2a eBioscience 
Human TLR1 GD2.F4 Mouse IgG1 eBioscience 
Human TLR6 hPer6 Rat IgG2a eBioscience 
Human CD14 MY4 Mouse IgG2b Beckman Coulter, High Wycombe, UK 
Human CD14-PE M5E2 Mouse IgG2a BD Biosciences, Oxford, UK 
Human CA125-PE OC125 Mouse IgG1 Fujirebio Diagnostic Inc., Malvern, PA, USA 
Human gp130-PE 28126.111 Mouse IgG1 R&D Systems, Dorset, UK 
Human gp130 H-255 Rabbit IgGs Santa Cruz Biotechnology, Santa Cruz, CA, USA 
Rabbit IgGs - Goat IgGs Santa Cruz Biotechnology 
Mouse F4/80-FITC CI:A3-1 Rat IgG2b Serotec, Oxford, UK 
Mouse CD11b-APC M1/70 Rat IgG2b BD Pharmingen, Oxford, UK 
Mouse IgG-Alexa 568 - Goat IgGs 
Kindly provided by Prof V. O’Donnell, 
Institute of Infection & Immunity, 
School of Medicine, Cardiff University, 
UK 
Rabbit IgGs-HRP - Donkey IgG ECL system, Amersham 
Rat IgG-FITC 11-4811 Mouse IgG eBioscience 
Immunoreagents Clone/code Isotype Source 
Rat IgG (purified) eBR2a IgG2a eBioscience 
Mouse IgG (purified) 14-4714 IgG1 eBioscience 
Mouse IgG (purified) 14-4724 IgG2a eBioscience 
Mouse IgG (purified) 16-4732 IgG2b eBioscience 
Rat IgG (purified) LO-DNP-16 IgG2a Serotec 
Anti-Mouse IgG/RPE R0480 Goat F(ab’)2 Dako, Glostrup, Denmark 
Rat IgG-PE - Goat IgG Dako 
Normal rabbit serum - - Dako 
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(Loughborough, UK). The rectal probe thermometer (TES 1319 K type) was purchased from Vet 
Tech Solutions, (Congleton, UK). The Whitley Automated Spiral Plater (WASP II) and aColyte 3 
colony counter were purchased from Don Whitley Scientific Limited (Shipley, UK). The 
Beckman UV-DU64 spectrophotometer was from Beckman Instruments Ltd (High Wycombe, 
UK). The mini gel system was from Thermo Life Sciences Ltd (Basingstoke, UK). The 
ChemiDocTM Gel documentation system, the Bio-Rad Mini Protean II gel apparatus and the 
Bradford assay were from Bio-Rad Laboratories Ltd (Hercules, CA, USA). The inverted light 
microscope (Axiovert 25) was from Carl Zeiss Ltd (Cambridge, UK). The Coulter counter 
(Coulter Z2) was from Beckman Coulter (High Wycombe, UK). The NanoDrop-1000 
spectrophotometer was from Fisher Thermo (Wilmington, DE, USA) 
 
4.2 Cell and tissue culture 
4.2.1 HPMC isolation, growth conditions and sub-culture 
HPMC were isolated from consenting patients undergoing elective abdominal surgery by serial 
tryptic digestion of greater omental tissue obtained using an adapted version of Stylianou’s 
original method (Stylianou et al., 1990), as previously described (Topley et al., 1993a). Briefly, 
tissue sections were washed in sterile Dulbecco’s phosphate-buffered saline (PBS; 2.5 mM 
KH2PO4, 137 mM NaCl, 8 mM Na2HPO4 pH 7.4, then digested in 20 ml 0.1% (w/v) trypsin/ 
0.02% (w/v) EDTA, diluted in PBS and incubated 15 min at 37°C with continuous rotation. 
HPMC were harvested by centrifugation at 800 x g for 6 min at room temperature (RT). The 
omentum was transferred to a new tube for a second digestion step identical to the first one. 
Pelleted cells of each piece of omentum were suspended in 5 ml growth medium. Cells were 
cultured in Earle’s buffered 199 medium containing 10% (v/v) foetal calf serum (FCS) (Hyclone, 
Logan, UT, USA; < 0.06 U/ml endotoxin), supplemented with 2 mM L-Glutamine, 100 U/ml 
penicillin, 100 µg/ml streptomycin, 5 µg/ml transferrin, 5 µg/ml insulin and 0.4 µg/ml 
hydrocortisone (Li et al., 1998). Cell monolayers were grown in 25 cm2 cell culture flasks (T25) 
and incubated at 37°C in a 5% CO2 incubator until confluent, when the cells were passaged at a 
1:3 ratio. 
In order to remove potentially contaminating fibroblasts and macrophages from primary 
cultures, HPMC purity was enhanced by performing "differential sub-culture/adherence" (Lang 
and Topley, 1998). On reaching confluence, the primary culture cells in T25 flasks were 
transferred to 75 cm2 culture flasks (T75 Falcon). Growth medium was aspirated and cells in 
T25 flasks were washed in sterile PBS, followed by trypsinisation with 10% (v/v) trypsin/EDTA 
diluted in sterile PBS. Cell detachment was monitored by light microscopy following brief 
incubation at 37°C. Following detachment, 10 ml of growth medium was added to neutralise the 
trypsin. The cell suspension was transferred to a 30 ml tube and spun at 600 x g for 6 min at 
room temperature, the supernatant removed and the cell pellet resuspended in fresh growth 
medium, before transfer to a T75 culture flask and incubated at 37°C, 5% CO2. 
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The morphology of HPMC monolayer cultures was examined using an inverted light 
microscope. Confluent HPMC were typically polygonal in shape and displayed the classical 
“cobblestone” appearance, as shown on Figure 1.3 (Introduction). 
4.2.2 SV40-transformed HPMC 
SV40-transformed HPMC cell line (kindly provided by Dr. Jean-Phillipe Rougier, Department of 
Nephrology and Dialysis, Unité INSERM 64, Hôpital Tenon, Paris, France) (Rougier et al., 
1997), are derived from a primary HPMC culture transformed with a plasmid containing a 
modified SV40 virus sequence, containing a deletion in the late region and a 1 bp insertion, 
which disrupts the origin of replication site within the SV40 genome. These cells retain many of 
the characteristics of primary HPMC including morphology and the expression of Cytokeratins 8 
and 18 and Vimentin (Fischereder et al., 1997). They were used to test the bioactivity of SES 
preparations (section 4.12). SV40-transformed HPMC were cultured under the same conditions 
as HPMC in 10% FCS DMEM with 25 mM HEPES supplemented with 2 mM L-Glutamine, 100 
U/ml penicillin, 100 µg/ml streptomycin, 5 µg/ml transferrin, 5 µg/ml insulin and 0.4 µg/ml 
hydrocortisone. Cells were grown (incubated at 37°C, 5% CO2) in T25 culture flasks until 
confluent and passaged as previously described for HPMC (section 4.2.1). 
4.2.3 Isolation and culture of Peripheral Blood Mononuclear Cells 
Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll density-gradient 
centrifugation from whole blood of healthy volunteers. Briefly, blood was collected in tubes 
containing EDTA (0.5 M) as an anticoagulant and centrifuged at 400 x g (10 min, RT). The 
upper phase was discarded and the leukocytes were diluted in an equal volume of PBS and 
then 6 ml were carefully layered onto 5 ml of room temperature Ficoll-Paque PLUS (Ficoll 
PM400 and sodium diatrizoate with a density of 1.077 g/ml; Sigma-Aldrich) and centrifuged (400 
x g, 30 min, RT) without brake. PBMC sediment at the interface, whereas neutrophils pellet at 
the bottom. The interface between the upper layer of plasma and the Ficoll was carefully 
removed, transferred to a new tube and washed three times with PBS (first wash: 400 x g, 10 
min, RT; second and third washes: 300 x g, 8 min, RT). PBMC were resuspended in PBS at a 
concentration of 2 x 106 cells/ml in preparation for flow cytometry analysis (described in section 
4.5) or directly resuspended in Tri Reagent for RNA extraction (described in section 4.6). 
Alternatively, mononuclear cells were obtained by adherence (2h, 37°C) on cell culture flasks of 
PBMC that had been resuspended in RPMI-1640 medium supplemented with 2 mM L-
Glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin and 0.5% human AB serum. 
4.2.4 Culture of transfected Human Embryonic Kidney Cells 
Human Embryonic Kidney (HEK) 293 plasmid control transfected cells (HEK-pDR2) and HEK-
TLR2-transfected cells were generated in our laboratories as previously described (LeBouder et 
al., 2003). HEK-TLR4/MD2-transfected cells were kindly provided by Prof. Douglas T. 
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Golenbock (Department of Medicine, Division of Infectious Diseases and Immunology, 
University of Massachusetts Medical School, USA). HEK293-transfected cells were cultured in 
complete medium: DMEM containing 4500 mg/ml Glucose supplemented by 2 mM L-Glutamine 
and 10% FCS and specific additives as follows: 400 µg/ml hygromycin B (Calbiochem, San 
Diego, CA) for HEK-TLR2 (LeBouder et al., 2003) or 200 µg/ml Geneticin (G418) (Sigma 
Aldrich) for HEK-TLR4/MD2.  
 
4.3 Cell activation 
4.3.1 Activation of HPMC 
HPMC monolayers were cultured in T25 (for flow cytometry analysis), 6-well plates (for RNA 
analysis and protein extraction), or 24- and 48-well plates (for cytokine and chemokines 
secretion), until they reached confluence. Prior to experimentation, HPMC were growth arrested 
for 48h in serum free culture medium. All experiments were performed with confluent HPMC 
from the second passage, except when testing for TLR2 and TLR4 expression (Figure 2.1.3) 
when cells were used immediately following tryptic digestion, as described in section 2.1.1. 
Confluent growth-arrested HPMC were cultured (37°C for 24h) in triplicate in medium containing 
0.1% FCS (unless stated otherwise) in the presence or absence of the stimuli indicated in the 
figure legends and Results section. To test for cytokine and chemokine secretion, cell culture 
supernatants were harvested, centrifuged (300 x g, 5 min, RT) to remove cellular debris and the 
supernatant stored at -80°C until assayed using commercially available ELISA kits for human 
CXCL8, human CCL2, human CCL5 (BD OptEIA, BD Biosciences, Oxford, UK); TNFα and 
human IL-6 (DuoSet, R&D Systems) and human sIL-6R (DuoSet, R&D Systems; it does not 
distinguish between the two sIL-6R isoforms) according to the manufacturer’s instructions. For 
sTLR2 expression experiments (Figure 2.2.1A), the cell-free culture supernatants were 
analysed by Western blotting as described below in section 4.10. 
 
For Ab blocking experiments shown in Figure 2.1.13A, HPMC were pre-incubated (1h 30min) 
with an anti CD14-specific blocking mAb (MY4, IgG2b, 10 µg/ml) or its isotype-matched control, 
before adding SES and incubating for up to 24h.  
For cell activation experiments in the presence of sTLR2 shown in Figure 2.2.1C, sTLR2 (5 
µg/ml) was pre-incubated for 30 min at 37°C with Pam3Cys or SES in medium without serum 
before adding the stimulatory mixture to the cells for the time indicated in the figure. 
For cell activation shown in Figures 2.2.3 to 2.2.6, IL-6 and sIL-6R (at the concentrations 
indicated in the figure legend) were mixed and pre-incubated for 15 min at room temperature to 
allow complex formation, before incubation with the cells.  
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4.3.2 Activation of PBMC 
For the blocking experiments shown in Figure 2.1.13B, PBMC were seeded at 2 x 106 cells/ml 
and incubated for 2h before removing non-adherent cells by washing twice with PBS. PBMC 
were then pre-incubated or not with the anti CD14 blocking mAb (MY4, 10 µg/ml) or its isotype-
matched control for 1h at 37°C, and the stimulus was then added as indicated in the figure 
legend. Cells were cultured in phenol red free RPMI-1640 medium supplemented with 0.5% 
human AB serum and stimulated for 20h as indicated in the figure legend. CXCL8 levels in the 
cell-free culture supernatants were quantified by ELISA.  
4.3.3 Stimulation of transfected Human Embryonic Kidney Cells 
For the cell activation experiments described in Figure 2.1.9C, confluent cells were trypsinised 
and washed 5 times with PBS to eliminate serum sCD14 before stimulation with dilutions of 
SES or left untreated (medium alone). HEK-TLR2 were seeded in triplicate at 500,000 cells/well 
on 48-well plates, and directly stimulated in suspension for 15h. CXCL8 was quantified by 
ELISA in the cell-free culture supernatants. 
 
4.4 Detection of TLR expression by immunocytochemistry  
Non-stimulated and stimulated cells were trypsinised, washed with PBS and resuspended in 
PBS at a concentration of 1 x 106 cells/ml. Hundred microlitres of cell suspension were 
cytospined, and the cells were then fixed on slides with acetone for 5 min at -20°C, washed in 
PBS once (5 min, RT) and left in PBS overnight at 4°C. To reduce non-specific binding of Abs, 
the cells were incubated (1h, RT) with PBS containing 1% (w/v) BSA (bovine serum albumin 
fraction V) and 10% (v:v) normal rabbit serum before incubation (1h, RT) with either the 
appropriate Ab (T2.5, IgG1, 5 ug/ml) or an isotype matched control. Slides were washed three 
times over a 45 min period and were then incubated with Alexa 568-conjugated secondary Ab 
(kindly provided by Prof V. O’Donnell, Institute of Infection and Immunity, School of Medicine, 
Cardiff University, UK) for 30-45 min at 37°C in the dark. Slides were washed for a 45 min 
period changing buffer every 10-15 min, and cells were stained for 5 min at room temperature 
with DRAQ5, a marker of DNA content. Slides were washed once in PBS and once in water, 
dried and a drop of Fluorosave was added on the cells before placing a coverslip and sealing. 
Slides were kept in the dark and imaging was performed using an Axiovert 100 inverted 
microscope connected to a Bio-Rad MRC 1024ES laser scanning system (Bio-Rad 
Microscience, Hemel Hempstead, UK) and using a standard analysis software (Lasersharp 
2000, Bio-Rad Microscience). 
 
4.5 Flow cytometry analysis  
In preparation for flow cytometric analyses, HPMC were trypsinised or scraped from cell culture 
flasks. HPMC or PBMC were washed and resuspended in PBS at a density of 2 x 106 cells/ml. 
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Fifty microlitres of cell aliquots were distributed in wells of round bottom 96-well plates. Cells 
were incubated for 5 min at 4°C with 50 µl of blocking buffer (50% FACS buffer: PBS pH 7.3, 10 
mM EDTA, 1% BSA, 15 mM sodium azide; 25% normal rabbit serum and 25% human AB 
serum). For immuno-labelling, 50 µl of the indicated primary unconjugated Abs and their 
isotype-matched controls or primary fluorochrome-conjugated were added to the wells (1 µg 
mAb per 106 cells in 100 µl total) and incubated for 30 min at 4°C in the dark. Cells were 
washed twice in FACS buffer (1300 x g, 5 min, 5°C) and resuspended in 250 µl of FACS buffer. 
Where necessary, cells were incubated for a further 30 min at 4°C in the dark with appropriate 
fluorochrome-conjugated secondary Abs. The stained cells were analysed by using a 
FACSCalibur® flow cytometer (Becton Dickinson) using previously defined settings for HPMC 
(Hurst et al., 2002). Data were acquired from 10,000 to 20,000 events and staining compared 
against isotype control antibodies. Data were further analysed using the CellQuest Pro software 
(BD Bioscience) and expressed as mean fluorescence intensity values. 
 
4.6 RNA Analysis 
4.6.1 RNA isolation from HPMC and mouse peritoneal membrane 
Total cellular RNA was extracted using the TRI Reagent (Sigma Aldrich) and following a 
chloroform-isopropanol isolation protocol. HPMC monolayers were washed with PBS before 
adding 1 ml TRI Reagent and incubated for 5 min at room temperature. The resulting cell lysate 
was collected in a microcentrifuge tube, chloroform was added - 1:5 ratio (v/v) - and the 
samples were mixed by inversion and left on ice for 5 min to allow separation of two phases. 
The samples were then centrifuged (12,000 x g, 15 min, 4°C, no braking), the colourless upper 
phase - containing the RNA - was carefully removed, without disturbing the interface, and 
transferred to a new tube. RNA precipitation was achieved by adding an equal volume of 
isopropanol and incubating at -20°C 1h to overnight. RNA was pelleted by centrifugation at 
12,000 x g, 20 min at 4°C and the supernatant discarded. The pellet was then washed twice by 
adding 1.5 ml of 75% (v/v) ice-cold ethanol followed by brief vortexing and centrifugation at 
12,000 x g, 20 min at 4°C. The ethanol was removed and the RNA pellet allowed to air dry for 
approximately 1h before re-suspension in 10 µl of double distilled H2O. For RNA extraction from 
mouse peritoneal membrane, approximately 1 cm2 of membrane was homogenised in 2 ml TRI 
reagent, followed by the isolation protocol described previously. 
4.6.2 Nucleic acid quantification and RNA integrity assessment methods 
For RT-PCR experiments, the RNA concentration was determined by spectrophotometric 
analysis using a Beckman UV-DU64 spectrophotometer. In an appropriate cuvette, 1 µl of RNA 
or DNA was diluted in 54 µl of sterile water. The absorbance was read at 260 nm and 280 nm. A 
260/280 ratio above 1.8 was indicative of a sufficiently pure sample. The concentration was 
calculated using the following formula: 
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[RNA or DNA] (µg/ml)= Abs260 x Molar extinction coefficient x dilution factor 
Molar extinction coefficient for RNA = 40. Molar extinction coefficient for DNA = 50. Dilution 
factor = 55 
 
An Abs260 of between 0.1-1.0 was required to be in the linear range of the Beer-Lambert law, 
which states that a linear relationship exits between absorbance and the concentration of an 
absorbing substance, relying on both the distance light travels through the substance (path 
length) and the absorption coefficient of the substance. Samples were diluted where necessary 
and discarded if Abs260 was below 0.1. 
 
RNA integrity was determined by flat bed electrophoresis using a mini gel system with a 2% 
agarose gel composed of 1 g electrophoresis grade agarose, 50 ml of 1X TAE buffer (40 mM 
Tris-Acetate, 1 mM EDTA) and 5 µl ethidium bromide (5 mg/ml). One microgram of RNA was 
loaded into a single well of the mini gel together with 5 µl of loading buffer - 15% (v/v) Ficoll 
Type 400 in ddH2O, 0.25% (v/v) Orange G. RNA integrity was visualised under ultra violet light 
in the ChemiDocTM Gel documentation system. The quality of the RNA was assessed by 
observing the ethidium bromide staining pattern of 28S and 18S ribosomal RNA, with two 
clearly distinct bands indicative of good RNA integrity. 
For qRT-PCR experiments, RNA concentration and integrity was determined as described 
below in section 4.7.2. 
4.6.3 Reverse transcription 
Before performing RT-PCR reactions, the RNA was treated with RNAse-free DNAse I following 
the manufacturer’s instructions. Reverse transcription was then performed using the random 
hexamer method as described previously (Topley et al., 1993a). Briefly, 1 µg of total RNA in a 
total volume of 20 µl comprising 100 µM random hexamers, 5 mM mixed deoxynucleotides 
(dATP, dGTP, dCTP and dTTP), 1X PCR buffer (20 mM Tris-HCl, pH 8.4, 50 mM KCl, 
containing 1.5 mM MgCl2) and 10 mM DTT (Dithiothreitol; Invitrogen) was heated to 95oC for 5 
min to linearise the RNA. Following immediate cooling on ice, 40 units of recombinant 
ribonuclease inhibitor (RNAsin) and 200 units of Superscript II reverse transcriptase were 
added. The RNA was then reverse transcribed by heating to 20oC for 10 min to enable primer 
annealing to the linearised RNA, and to 42oC for 60 min to allow primer extension from the 
random hexamers by reverse transcription. The reaction was stopped by denaturation at 95oC 
for 5 minutes and 4oC for 2 min. Negative control reactions were performed by replacing the 
Superscript reverse transcriptase enzyme with distilled water. Two microlitres of the resulting 
complementary (c) DNA was used in each PCR reaction.  
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4.7 DNA Analysis 
4.7.1 Primer design and PCR 
All primer sequences were designed using the internet based Primer 3 software (Rozen and 
Skaletsky, 2000) (http://biotools.umassmed.edu/bioapps/primer3_www.cgi) and purchased from 
Invitrogen. Primers were designed to have a GC content of 50-60% and a TM  (annealing 
temperature) of approximately 60oC. Primer sequences are detailed in Table 4.2 for RT-PCR 
and Table 4.3 for qRT-PCR. All primers (lyophilised upon arrival) were reconstituted in ddH2O to 
give a stock concentration of approximately 100 µM. A working concentration of 10 µM was 
prepared for all primers. 
For each 50 µl PCR reaction, 2 µl of cDNA generated by reverse transcription (section 4.6.3) 
was used. Each reaction comprised 1X PCR Buffer containing 5 mM MgCl2, 0.2 mM dNTPs, 
1.25 U AmpliTaq Gold and 1 µM oligonucleotide primers (all from Invitrogen™, Life 
Technologies). Negative control reactions were performed by replacing the cDNA with 2 µl of 
ddH2O. PCR amplification was performed as described in Table 4.2.  
Five microlitres of PCR products were analysed by 2% agarose gel electrophoresis as 
described above in section 4.6.2. Typically, the gel was run at 90 volts for 45-60 min. The 
agarose gels were visualised/photographed using a ChemiDocTM Gel documentation system. 
4.7.2 Quantitative real-time PCR  
Human cells 
The quantity and quality of total RNA, isolated as described in section 4.6.1, was assessed with 
the NanoDrop-1000 spectrophotometer and on agarose gel as described in section 4.6.2. 
Reverse transcription was performed using 1µg of RNA with the High Capacity cDNA Reverse 
Transcription kit from Applied Biosystems and following the manufacturer’s protocol. cDNA was 
diluted 5 times before performing real-time PCR using Power SYBR green PCR master mix 
from Applied Biosystems and following the manufacturer’s protocol. The primers used for real-
time PCR are listed in Table 4.3 as well as the standard amplification process, using an Applied 
Biosystems ABI 7900 HT. 
 
Mouse peritoneal membrane  
Total RNA was isolated from snap-frozen mouse peritoneal membranes as described in section 
4.6.1. Fifty micrograms of total RNA was DNase-treated using an RNase-free DNase Set and 
washed using RNAEasy minicolumns. The DNase-treated RNA was quantified by 
spectrophotometry (Nanodrop) and its quality assessed with the Agilent Bioanalyzer 2100 using 
the RNA Nano LabChip kits and the Eukaryote total RNA assay (Agilent Technologies Inc, 
Santa Clara, CA, USA). One microgram of DNase-treated RNA was used to generate cDNA 
using the Superscript III 1st strand synthesis strand system. Two microlitres of cDNA (1:4 
dilution) was used in quantitative PCR reactions using 384-well plates, Taqman primer and 
  
 
 
 Table 4.2 Primer sequence and protocol used for RT-PCR 
 
 
 
 
 
 
 
 
Table 4.3 Primer sequence and protocol used for qRT-PCR in human cells 
 
 
 
 
Primer 
 
                                          Sequence (5’-3’) 
               Forward                                                        Reverse 
TLR2 
TLR4 
TLR6 
Actin 
TGGCCAGCAGGTTCAGGATG            TCGCAGCTCTCAGATTTACCC 
CCTCCAGGTTCTTGATTACAG           GTGCCGCCCCAGGACACT 
AGAACTCACCAGAGGTCCAACC       GAAGGCATATCCTTCGTCATGAG 
CGGCCAGCCAGGTCCAGA                GTGGGCATGGGTCAGAAGGATT 
PCR amplification: 32 cycles (TLR2, TLR4 and TLR6) or 22 cycles (Actin) at 94°C for 40s, 56°C for 40 s 
and 72°C for 90 s 
Human 
mRNA 
Sequence (5’-3’) 
Forward 
 
Reverse 
Accession 
number 
Tlr1 
Tlr2 
Tlr3 
Tlr4 
Tlr5 
Tlr6 
Tlr7 
Tlr8 
Tlr9 
Tlr10 
Gapdh 
CAATGCTGCTGTTCAGCTCTTC                        
AATCCTCCAATCAGGCTTCTCT                        
GAAAGGCTAGCAGTCATCCAAC                      
AGAACCTGGACCTGAGCTTTAATC                  
ACAAGATTCATACTCCTGATGCTACTG    
ATTGTTAAAAGCTTCCATTTTGTTTG     
TCTCATGCTCTGCTCTCTTCAAC    
GCTTGACTTACGTGGAAACAAACTAC     
TATTCATGGACGGCAACTGTTATT        
CGATTCCACGCATTTATTTCATAC   
CCTCTGACTTCAACAGCGACAC     
GCCCAATATGCCTTTGTTATCC 
TGTAGGTCACTGTTGCTAATGTAGGT 
GTCAGCAACTTCATGGCTAACA 
GAGGTGGCTTAGGCTCTGATATG 
CCAGGAAAGCTGGGCAACTA 
CTAAGACTTTGGTTTTCAGCGGTAG 
TTGTCTCTTCAGTGTCCACATTGGAAA 
AACTTAAATCGAGGTGCTTCAGACTAC 
TACTTGAGTGACAGGTGGGTGAG 
TAGCTTTCATAAAGGCAAATCAAGATAG 
TGTCATACCAGGAAATGAGCTTGA 
NM_003263.3 
NM_003264.3 
NM_003265.2 
NM_138554.2 
NM_003268.3 
NM_006068.2 
NM_016562.3 
NM_016610.2 
NM_017442.2 
NM_001017388.1 
NM_002046.3 
PCR amplification: 
3 stages: Stage 1, 1 cycle, 95°C for 10 min, Stage 2, 40 cycles, 95°C for 15 s, 60°C for 1 s, 
Stage 3, 1 cycle, 95°C for 15 s, 60°C for 15 s, 95°C for 15 s 
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probe sets for Eukarytotic 18s RNA (only for Fig 2.1.17), GAPDH and murine TLR2 and 
Taqman Universal PCR master mix  (all from Applied Biosytems) and the Applied Biosystems 
ABI 7900 HT machine using a standard program as detailed in Table 4.4. 
 
Analysis of real-time PCR 
GAPDH was used as endogenous reference for normalisation. Baseline and threshold for Ct 
values were determined using the Sequence Detection System 2.3 software provided by 
Applied Biosystems. Results are expressed as relative induction to the housekeeping gene 
GAPDH (2-ΔCt) or using the 2-ΔΔCt Method (Livak and Schmittgen, 2001). 
 
4.8 NF-κB reporter assay 
For experiments shown on Figure 2.1.10, HEK-TLR2 and HEK-TLR4/MD2 cells were seeded at 
1 x 105 cells/well in 24-well plates the day before transfection. Twenty-four hours later, 
approximately 2 x 105 cells/well were transfected, using 2 µl of Lipofectamine™ per well and 2 µl 
of Plus Reagent™ per µg of construct (Lipofectamine transfection reagent, Invitrogen™, Life 
Technologies), with 0.25 µg of a construct directing expression of the firefly luciferase reporter 
under the control of the NK-κB promoter (pNF-κBLuc; Stratagene, La Jolla, CA) and 0.05 µg of 
a construct directing expression of Renilla luciferase (pRL-SV40; Promega, Southampton, UK). 
Forty-eight hours post-transfection, the cells were stimulated for 16h at 37°C with SES at the 
dilutions indicated in the figure legend. Luciferase activity was measured using the Dual-
Luciferase® reporter assay system (Promega), according to the manufacturer’s instructions. 
 
4.9 Preparation of nuclear extracts 
4.9.1 HPMC nuclear extracts 
Following stimulation, cells were washed and scraped into ice-cold PBS and pelleted by 
centrifugation (4500 x g, 1 min, 4oC). The cells were resuspended in ice-cold buffer A (detailed 
in Table 4.5) and lysed on ice for 10 min. After vortexing, samples were centrifuged (13,000 x g, 
5 min, 4oC), the supernatant - cytosolic extract - was transferred to a new tube and the pellet 
resuspended in buffer B (detailed in Table 4.5) and incubated on ice for 20 min with vortexing 
every 5 min, for high salt extraction of nuclear proteins. Cell debris were removed by 
centrifugation (13,000 x g, 5 min, 4oC), and the supernatant - nuclear extract - was stored at -
80oC before measuring protein concentrations using a Bradford assay following the 
manufacturer’s instructions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.4 Primer sequence and protocol used for qRT-PCR in mouse peritoneal membranes 
Mouse mRNA Taqman Assay ID Company 
Tlr2 
Cxcl1 
Gapdh 
Eukarytotic 18S 
Mm00442346_m1 
Mm00433858_g1 
43522339E 
VIC-labeled, 4310893E 
                Applied Biosytems 
                Applied Biosytems 
                Applied Biosytems 
                Applied Biosytems 
PCR amplification: 3 stages: Stage 1, 1 cycle, 50°C for 2 min; Stage 2, 1 cycle, 95°C for 10 min; Stage 
3, 40 cycles, 95°C for 15 s, 60°C for 1 min 
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4.9.2 Nuclear extracts from murine peritoneal membrane 
Nuclear proteins were extracted from snap-frozen peritoneal membrane sections taken during in 
vivo experiments. Membrane sections were kept frozen on dry ice, placed in a mortar containing 
liquid nitrogen and ground to a fine powder with a pestle. The tissue extracts were collected, 
resuspended in buffer A (Table 4.5), lysed on ice for 30 min and vortexed for 10 s. Samples 
were centrifuged (13,000 x g, 5 min, 4oC), the supernatant - cytosolic extract - collected and the 
pellet resuspended in buffer B (Table 4.5) and incubated on ice for 30 min with regular 
vortexing. Cell debris were removed by centrifugation (13,000 x g, 5 min, 4oC), the supernatant 
- nuclear extract - was stored at -80oC and protein concentrations were determined as for 
HPMC nuclear extracts (above section. 4.9.1). 
 
4.10 Electrophoretic Mobility Shift Assay (EMSA) 
4.10.1 Annealing of primers and radio-labelling of oligonucleotide probes 
All work involving radioactive material was performed behind Perspex shield. Double stranded 
oligonucleotide primers (sequences detailed in Table 4.6) were labelled using an end-labelling 
technique. Reverse complementary oligonucleotide sequences were annealed in order to create 
overhanging 5' single stranded sequences (identified by lower case in 5'-3' sequences listed in 
Table 4.6). Primers were annealed at a concentration of 100 ng/µl in the presence of 100 mM 
NaCl at 95oC for 10 min. The annealed probe was cooled slowly overnight at room temperature 
and stored at -20oC. The labeling reaction was prepared as follows: oligonucleotide probe (25 
ng), dNTP mix (dATP, dCTP, dGTP; 2.5 mM each), 10X Klenow buffer (500 mM Tris-HCl, pH 
7.2, 100 mM MgSO4, 1 mM DTT), NaCl (100 mM) made up to 46 µl with ddH2O. Binding of 30 
µCi of α[32P]-dTTP was catalysed by 2 units of Klenow fragment (DNA polymerase I large). The 
50-µl reaction was incubated at room temperature for 1h, and the reaction was stopped by 
addition of EDTA (10 mM, pH 8) and STE buffer (100 mM NaCl, 10 mM Tris-HCl, 1 mM EDTA, 
pH 8). Probes were purified from any free contaminating radioactivity using size exclusion 
columns (GE Healthcare) and stored at -20oC. 
4.10.2 Analysis of DNA-protein complexes by electrophoresis 
All samples were run on vertical 8% (w/v) polyacrylamide gels (cast and run on Hoeffer Sturdier 
gel apparatus), the composition of which is described in Table 4.7. Wells were washed with 
0.5X TBE (Tris-Boric Acid EDTA running buffer, detailed in Table 4.7). 
The EMSA technique allows evaluating the formation of protein/DNA complexes by showing 
restricted electrophoretic mobility. A binding reaction was thus prepared, consisting of 1X 
binding buffer (10 mM HEPES, pH 7.9, 50 mM KCl, 10% glycerol, 0.2 mg/ml acetylated BSA, 1 
mM DTT, 0.2 mM PMSF), poly dI/dC (1 mg/ml), nuclear extracts (2 µg HPMC or 10 µg 
peritoneal membrane extract) and ddH2O. After 10 min incubation at room temperature to allow 
           Table 4.5 Buffer composition for nuclear protein extraction 
 
 
 
            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
           Table 4.6 Oligonucleotide sequence of primers  
 
 
 
 
 
 
 
 
 
 
 
           Table 4.7 EMSA gel composition  
 
 
 
 
 
 
 
 
 
Cytolasmic protein buffer A Nuclear  protein buffer B Source 
10 mM HEPES, pH 8 
1.5 mM MgCl2 
10 mM KCl 
0.01% (v/v) NP40 
 
Addition of protease and 
phospphatase inhibitors: 
0.8 µM PMSF 
40 µM Na3VO4 
0.2 mM NaF 
2 µM DTT 
0.025% protease inhibitor cocktail*  
 20 mM HEPES, pH 8 
1.5 mM MgCl2 
420 mM NaCl 
0.2 mM EDTA, pH 8 
25% (v/v) Glycerol 
Addition of protease and 
phospphatase inhibitors: 
0.8 µM PMSF 
40 µM Na3VO4 
0.2 mM NaF 
2 µM DTT 
0.025% protease inhibitor cocktail* 
Sigma-Aldrich 
*Protease inhibitor cocktail containing 4-(2-aminoethyl) benzenesulfonyl fluoride (AEBSF), pepstatin A, E64, 
bestatin, leupeptin and aprotinin. 
Transcription factor Orientation Sequence* 
NF-κB 
Forward 
Reverse 
5’-gaTCCATGGGGAATTCCCC-3’ 
5’-gaGGGGAATTCCCCATGGA-3’ 
SIE (M67)-STAT 
Forward 
Reverse 
5’-cgaCATTTCCCGTAAATCG-3’ 
5’-cgaCGATTTACGGGAAATG-3’ 
* Transcription factor binding motifs are shown in bold type 
Composition Amount Source 
dH2O 
40% Acrylamide/Bis Acrylamide (29:1) 
5X TBE* 
50% glycerol 
10% ammonium persulphate  
TEMED 
44.25 ml 
15  ml 
7.5  ml 
7.5  ml 
0.75  ml 
60 µl 
Bio-Rad 
*5X TBE: (0.45 M Tris-HCl, 0.45 M Boric acid, 0.01 M EDTA, pH8) 
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blocking of non-specific binding sites, the radiolabelled oligonucleotide probe containing a 
binding motif for a transcription factor - NF-κB or SIE (M67) - was added. Samples were 
incubated with the probe for a further 20 min when the binding reaction was stopped by adding 
6X DNA loading buffer, prior to loading onto the gel. Gels were run at 180 volts for 3h 30 min 
and transferred to 3M Whatman paper and dried on a vacuum drier at -80oC for 2h. Dried gels 
were exposed to X-ray film overnight to several days at -80oC, and developed by 
autoradiography. 
 
Quantification of band intensities was performed for each individual time point or stimulation 
condition by gel scanning followed by analysis using the ImageJ software (ImageJ, NIH, USA). 
For HPMC stimulations, changes in stimuli-mediated transcription factor activation were 
expressed as a ratio over non-stimulated cells. For in vivo experiments, changes of transcription 
factor activation following specific stimulations as detailed in figure legends were expressed 
relative to PBS-injected WT mice. 
4.10.3 Analysis of transcription factor subunits 
The composition of individual transcription factors subunits in protein/DNA complexes was 
determined by “supershift” assays using specific rabbit polyclonal antibodies against the NF-κB 
subunits p65, p50, RelB, p52 and cRel or STAT subunits STAT1, STAT3 and STAT5 as 
detailed in Table 4.8. If the subunit is present, antibody binding to the protein bound to the 
probe will either directly block DNA binding - loss of DNA binding observed with STAT1 Ab 
(Figure 2.3.8) - or result in the formation of a larger complex which migrates slower during gel 
electrophoresis - the supershift. The binding reaction was prepared as described above in 
section 4.10.2. Following the 10 min blocking step, nuclear extracts were incubated (20 min, 
RT) with specific Abs before adding the radio-labelled probe and processing as described in 
section 4.10.2. 
 
4.11 SDS-PAGE and Western blotting 
PD fluids were collected from stable and infected patients and centrifuged (2 x 1000 x g, 15 min, 
4°C) to remove the cells. SDS-PAGE was carried out using the Bio-Rad Mini Protean II gel 
apparatus. To detect sTLR2, samples were diluted 1:20 with Laemmi reducing sample buffer 
(2% SDS, 100 mM DTT, 50 mM Tris-HCl, pH 6.8, 10% glycerol and 0.1% bromophenol blue) 
and boiled for 4 min prior to 10% SDS-PAGE. Forty microlitres were run on the gel, and pre-
stained molecular weight markers (Bio-Rad) were run in parallel. Electrophoresis was carried 
out using SDS running buffer (25 mM Tris base, 192 mM glycine, 0.1% SDS). Gels were briefly 
washed twice in PBS before Western blotting. 
Following electrophoresis and in preparation for Western blot, the gels were incubated at room 
temperature with transfer buffer (48 mM Tris base, 39 mM glycine, 20% (v/v) methanol) for a 
total of 20 min with three changes of buffer. Extra thick filter paper (Bio-Rad) and the 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          Table 4.8 Antibodies used for supershift analysis  
 
Transcription factor Subunit Clone* Isotype 
NF-κB 
p50 
p52 
p65 
cRel 
RelB 
NL2 
C5 
A 
N-466 
C-19 
Rabbit IgG 
Mouse IgG2a 
Rabbit Ig G 
Rabbit Ig G 
Rabbit Ig G 
SIE (M67) 
STAT1 
STAT3 
STAT5 
M-22 
C-20 
C-17 
Rabbit Ig G  
Rabbit Ig G 
Rabbit Ig G 
*All antibodies were from Santa-Cruz Biotechnology and used at a concentration of 20 ng/ml 
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nitrocellulose membrane used for transfer were kept in transfer buffer for 20 min before transfer. 
Electrotransfer was conducted in a semi-dry transfer cell apparatus (Transblot SD, Bio-Rad) for 
30 min at 13 volts. Following transfer, the membranes were blocked for 1h at room temperature 
with blocking buffer consisting of PBS/0.1% Tween-20 (PBS-T) in 2% milk. The membranes 
were then washed (1 x 15 min and 2 x 5 min) and incubated with the TLR2-specific rabbit 
polyclonal Ab TLR2p (1/3000 dilution in 2% milk) overnight at 4°C with gentle rocking. Following 
washing (as above), the membranes were incubated for 1h at room temperature with an anti 
rabbit IgGs Ab-horseradish peroxidase-conjugated. Subsequently, the membrane was washed 
(PBS-T, 1 x 15 min and 4 x 5 min, RT) before detection by enhanced chemiluminescence (ECL 
system, Amersham) following the manufacturer’s instructions. 
 
4.12 Preparation of S. epi. cell-free supernatant (SES) 
A lyophilized cell-free supernatant (SES) was prepared from S. epi. - isolated from a CAPD 
patient  with peritonitis (Mackenzie et al., 1990) - as previously described (Hurst et al., 2001). 
Briefly, a colony of S. epi. grew to stationary phase in Nutrient Broth No. 2 at 37°C in a shaking 
incubator overnight. Bacteria were centrifuged at 1800 x g, 20 min at 20°C and the pellet 
resuspended in Tyrode’s salt solution without gelatin (1.8 mM CaCl2•2H2O, 1 mM MgCl2•6H2O, 
2.6 mM KCl, 137 mM NaCl, 0.42 mM NaH2PO4, 5.5 mM D-glucose, with 12 mM NaHCO3), 
diluted to an absorbance of 0.5 at 560 nm, and incubated at 37°C for 24h. Bacterial 
suspensions were centrifuged (5000 x g, 30 min, 20°C) and the supernatant was filtered prior to 
dialysis against distilled water. Ten millilitres aliquots were freeze-dried and the lyophilised 
powder was stored at -80°C. SES preparations were free of live bacteria as assessed by the 
lack of bacterial growth on diagnostic sensitivity testing agar plate. SES was reconstituted in cell 
culture media (in vitro experiments) or sterile PBS (in vivo experiments) and filtered (0.2 µm). 
For cell activation, one aliquot of SES was resuspended in 2.5 ml of the appropriate medium 
(neat SES). For in vivo experiments and i.p. injections, one aliquot of SES was resuspended in 
0.75 ml of sterile PBS and 0.5 ml of this neat SES was injected in each mouse. 
To evaluate the bioactivity of SES, CXCL8 secretion in response to SES was quantified using 
SV40-transformed HPMC, grown as described in sections 4.2.2. Adherent monolayers were 
growth arrested for 48h and stimulated for 24h with serial dilutions of SES. Supernatants were 
collected, rendered cell free by centrifugation and CXCL8 levels were quantified by ELISA. To 
maintain experimental reproducibility, SES was only used when CXCL8 secretion by SV40 
HPMC exceeded 2500 ± 500 pg/ml.  
 
4.13 In vivo experiments 
Experiments were performed using groups of mixed genders, 8 to 12 week-old inbred WT 
C57BL6/J (Charles River Ltd, Margate, UK and Harlan, Shardlow, UK) and IL-6KO mice with 
the same genetic background, which were bred in house. Procedures were conducted following 
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Home Office approval under project license number PPL 30/2269. Peritoneal inflammation was 
induced by i.p. inoculation of 500 µl of SES in the presence or absence of sTLR2 (in WT mice), 
or HDS (in IL-6KO mice), as indicated in the figure legends. Control animals were i.p. injected 
with 500 µl PBS. At the indicated time points, the mice were sacrificed and the peritoneal cavity 
was lavaged with 2 ml of PBS and kept on ice until further processing. Total leukocyte numbers 
were determined using a Coulter counter, slides for differential cell counting were prepared by 
cytospin and stained with Wright-Giemsa. Leukocyte subsets - neutrophils, macrophages and 
lymphocytes - were counted according to cell morphology as visualised by light microscopy. For 
results shown on Fig 2.4.4, leukocyte numbers were quantified by flow cytometry analysis by 
double staining with FITC-conjugated anti-mouse F4/80 mAb (monocytes/macrophages) and an 
APC-conjugated anti-mouse CD11b mAb (monocytes/macrophages and granulocytes). Levels 
of CXCL1, CCL2, IL-6 and sIL-6R in cell-free peritoneal lavage samples were quantified by 
ELISA (DuoSet, R&D Systems). Sections of peritoneal membrane were collected and snap-
frozen in liquid nitrogen and stored at -80oC until processing for analysis of RNA expression by 
qRT-PCR (described in section 4.6), or transcription factor activation by EMSA (described in 
sections 4.9. and 4.10).  
 
The detailed description of the development of, and experiments performed using the in vivo 
model of S. epi. infection are detailed in the Results section (section 2.4) and in figure legends. 
In addition, for Serum Amyloid A (SAA) determinations, immediately after the mice were 
sacrificed blood samples were collected by cardiac puncture using heparin-coated syringes and 
centrifuged at 900 x g for 10 min at 4oC. Plasma was collected and stored at -80oC until SAA 
was quantified by ELISA (Biosource, UK). 
 
4.14 Statistical Analysis 
Data presented are expressed as means (±SD or ±SEM, as indicated in the figures) and 
statistical analyses were performed using a two-tailed Student’s t test. A p value of less than 
0.05 was considered significantly different.  
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